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The  precise  neurochemical  effects  of  antidepressants  that  underlie  their 
efficacy  remain  unclear.  Many  antidepressants  modulate  noradrenaline 
transmission  in  vivo.  However,  the  selective  serotonin  reuptake  inhibitors 
(SSRIs)  and  NK1  receptor  antagonists  target  5-HT  and  substance  P 
transmission,  respectively.  Whether  effects  on  noradrenaline  neurones 
contribute to the efficacy of these drugs has been largely neglected. This study 
investigates modulation of central  NA transmission  by an  SSRI  (fluoxetine) in 
rats and by NK1  receptor ablation in mice.  NK1  ‘knockout’ mice are used as a 
model  for  lifelong  inhibition  of  the  NK1  receptor.  Changes  in  noradrenaline 
transmission  were  determined  using  in  vivo  microdialysis  to  sample  the 
extracellular  noradrenaline  concentration  (efflux).  Noradrenaline-related 
behavioural  effects  of  these  treatments  were  determined  using  a  modified 
light/dark exploration test.
Systemic fluoxetine increased noradrenaline efflux in two brain regions (frontal 
cortex  and  hypothalamus).  The  effect  was  inconsistent,  echoing  the  5-HT 
response  to  SSRIs.  Fluoxetine  reduced  noradrenaline  efflux  after  partial 
lesioning of noradrenergic axon terminals (by DSP-4), suggesting an inhibitory 
action  upstream  of  these  terminals.  Locally  infused  (retrodialysis)  fluoxetine 
augmented noradrenaline efflux in the terminal field. Whereas 50pM fluoxetine 
elevated  efflux  in  both  regions,  5pM  infusion  increased  efflux  in  the  frontal 
cortex only.  This effect was 5-HT-dependent (i.e. 5-HT synthesis inhibition with 
pCPA  blocked  the  response).  However,  this  increase  was  not  secondary  to 
inhibition  of  5-HT  reuptake  (since  the  more  potent  and  selective  SSRI, 
citalopram,  did  not  change  noradrenaline  efflux).  Thus,  fluoxetine  has 
opposing effects on noradrenaline efflux, probably at cell bodies and terminals. 
The balance of processes could underlie its variable effects.
Fluoxetine  reduced  locomotor  activity  of  DSP-4-pretreated  rats  in  the  novel 
compartment of the exploration  box,  suggesting a noradrenaline-related effect 
on  behaviour.  A  5-HT-related  effect  of  fluoxetine  was  also  found  (reduced 
locomotor activity in the dark compartment), since this was abolished by pCPA.
2Thus,  both  noradrenaline  and  5-HT-related  behavioural  effects  of  fluoxetine 
were found.
Basal  noradrenaline  efflux  was  two-fold  greater  in  NK1  knockout  mice, 
indicating  elevated  noradrenaline  transmission.  Noradrenaline  uptake  was 
normal,  since the uptake inhibitor DMI  increased  efflux equally in both strains. 
However,  the  a2-autoreceptor  antagonist,  atipamezole,  (which  increases 
noradrenaline cell firing and  release) had  no effect on efflux in knockout mice. 
Also,  NK1  receptor ablation  produced  the  same  behavioural  changes  in  the 
light/dark box (/.e increased ‘locomotor activity in light’, reduced ‘time to return’) 
as seen with the  0 2-adrenoceptor antagonists (atipamezole and  yohimbine)  in 
normal  mice.  These  noradrenaline-related  behaviours  unchanged  by  either 
drug  in  knockout  mice.  This  loss  of sensitivity  is  consistent with  diminished 
a2-autoreceptor function in NK1  knockout mice.
Collectively,  these  studies  demonstrate  that  both  an  established  SSRI 
(fluoxetine) and a novel antidepressant target, (NK1  receptor) modulate central 
noradrenaline  transmission  in  vivo.  The  results  support  a  common  role  for 
noradrenaline in antidepressant drug therapy.
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Chapter 1 
Introduction
1.1.  Depression
Depression  is  a  common  and  debilitating  psychiatric  illness.  Its  symptoms 
include  low  mood  (dysthymia),  loss  of  interest  or  pleasure  in  activities 
(anhedonia),  sleep  disturbances,  reduced  or  increased  appetite,  reduced 
movement  or  agitation,  fatigue,  delusions,  feelings  of worthlessness  or  guilt, 
inability to concentrate and thoughts of death or suicide, (DSM  IV, 2000).  Not 
only do these symptoms produce a highly distressing condition for the patient, 
they  often  lead  to  behavioural  impairment.  Depressed  patients  are  at  an 
increased  risk  of premature  mortality as  up  to  15%  of  individuals  with  major 
depressive disorder commit suicide.
Depression is a chronic, relapsing disorder with 17% of the population suffering 
from  the  illness,  (Lepine  et  al,  1997).  The  World  Health  Organization 
recognizes depression as the fourth leading contributor to the global burden of 
disease,  (Murray  &  Lopez,  1996).  Given  its  debilitating  nature  and  its 
prevalence, depression presents a significant economic burden.  One estimate 
of the total  cost of depression  to the  US  economy  is  $83.1  billion  each  year 
(Greenberg et al, 2003).
The most common  approach to the treatment of depression  is  antidepressant 
drug  therapy.  Although  the  precise  mechanisms  underlying  their therapeutic 
effects are, as yet, unknown all antidepressant drugs share a common property 
in  that  they  increase  central  noradrenaline  (NA)  and/or  5-hydroxytryptamine 
(5-HT) transmission on chronic administration.  These neurotransmitters belong 
to a group known as monoamines, which also includes dopamine.  The role of 
dopamine in the action of antidepressant drugs is less well established.  In any 
case,  the  possible  adverse  consequences  of  increasing  central  dopamine 
transmission  with  respect  to  dependence  liability  make  this  an  undesirable 
therapeutic  target.  Therefore,  discussion  of  the  monoamines  here  will  be 
confined to NA and 5-HT.
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1.2.  Central NA system
Central  noradrenergic neurones were first described  in the CNS by Dahlstrom 
&  Fuxe  (1964),  using  the  Falck-Hillarp  formaldehyde  vapour  fluorescence 
technique.  Noradrenergic  cell  bodies  are  located  in  pontine  and  brainstem 
regions  (Figure  1.1).  Based  on  cell  body  location,  efferent target  areas  and 
axon  morphology,  noradrenergic nuclei  are divided  into two principle systems: 
the  locus  coerulus  (LC;  corresponding  to  cell  groups  A6  and  A4  of  the 
classification of Dahlstrom and Fuxe) and lateral tegmental system (A1- A3, A5, 
A7; Moore & Bloom,  1979). The LC is the largest noradrenergic nucleus of the 
brain,  located  along  the  lateral  margin  of the  pontine  fourth  ventricle.  This 
nucleus  contains  approximately  1400  cells  bilaterally,  about  45%  of 
noradrenergic cells in the rat brain, (Swanson,  1975).  In addition to fluorescent 
histochemical  techniques,  details  of  noradrenergic  innervation  have  been 
derived from axon tracing  methods  in combination with  immunohistochemistry 
and  autoradiography.  The most striking feature of this system  is the extent to 
which a relatively small number of cells distribute terminals widely through the 
entire  CNS.  Efferents from  the  LC  project caudally to  all  levels  of the spinal 
cord,  dorsally to the  cerebellum  and  rostrally to the  thalamus,  hypothalamus, 
amygdala,  hippocampus,  olfactory system,  and  entire neocortex,  (Foote et al, 
1983).
The lateral tegmental system is composed of medullary and  pontine groups of 
noradrenergic  neurones.  Axons  arising  from  these  cell  groups  differ  from 
coerulofugal  axons,  with  larger  varicosities  of  more  irregular  size  and 
distribution.  Efferents  innervate the spinal  cord,  basal  forebrain,  septal  area, 
amygdala  and  thalamus.  Lateral  tegmental  neurones  do  not  project  to  the 
neocortex or hippocampus, their principle target being the hypothalamus.  This 
receives a dense noradrenergic innervation from the lateral tegmental system, 
in  addition  to  a  minor  contribution  from  the  LC,  which  sends  fibres  to  the 
periventricular,  paraventricular, dorsomedial and supraoptic nuclei only (Moore 
& Bloom, 1979).
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Figure 1.1. Ascending noradrenergic innervation of the rat brain.  Adapted from Stanford (1999)
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1.3.  Central 5-HT system
The 5-HT innervation of the CNS  is similar to the noradrenergic innervation  in 
that  a  relatively  small  number  of  cell  bodies,  located  in  the  midbrain,  send 
extensive projections throughout the entire  CNS.  5-HT-containing cell  bodies 
and  projections  in the brain were first described  by Dahlstrom  &  Fuxe (1964). 
Also like noradrenergic neurones, the majority or 5-HT neuronal cell bodies are 
located  in  two  brainstem  nuclei,  with  separate  but  overlapping  terminal 
projection  areas.  Ascending axons arise from  the dorsal  raphe  nuclei  (DRN, 
B4, B6 and B7 according to the classification of Dahlstrom & Fuxe), the largest 
5-HT-containing cell group, containing 50-60% of 5-HT neurones in the human 
CNS (Jacobs & Azmitia,  1992).  Cells in this nucleus innervate the substantia 
nigra,  striatum,  septum,  olfactory  cortex,  thalamus,  hippocampus  and 
neocortex.  The  median  raphe  nuclei  (MRN,  B5  and  B8)  form  the  second 
largest  cluster  of  5-HT  neurones  in  the  CNS.  Its  projections  have  larger 
diameter axons, with a greater number of varicosities, than those of the DRN. 
Projections from the MRN terminate in the hippocampus, entorhinal cortex and 
amygdala.  Nucleus  B9  (supralemniscal  nucleus)  is  the  most  lateral  of 
serotonergic  nuclei.  Additional  5-HT  cell  clusters  are  located  caudally,  e.g. 
nucleus  raphe  pallidus  (B1),  raphe  obscurus  (B2)  and  raphe  magnus  (B3). 
Figure 1.2.
1.4.  Monoamine systems and depression.
A substantial  body of evidence  now links  central  NA and  5-HT systems with 
depression  and  its  treatment  with  antidepressant  drugs  (for  reviews  see 
Slattery et al,  2004;  Elhwuegi,  2004;  Ressler &  Nemeroff,  2000;  Montgomery, 
1997).  Magnetic resonance  imagining studies  have found that the volume of 
several  structures  innervated  by  these  neurones  is  reduced  in  depressed 
patients. Atrophy of the amygdala (Sheline et al,  1998), frontal cortex (Bremner 
et al, 2002),  hippocampus (Sheline et al,  1996) and  basal ganglia (Krishnan et 
al,  1992)  have  been  reported.  Abnormalities  of  NA  metabolites  excretion  in 
depressed  patients  (Maas  et  al,  1968),  NA  and  5-HT-depleting  treatment- 
induction of relapse in depressed patients (Delgado et al,  1991,  1993) suggest 
that  dysregulation  of  monoamine  transmission  are  a  feature  of  depression. 
However,  most evidence for involvement of monoamines in depression comes 
from the apparent mode of action of antidepressant drugs.
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Figure 1.2. Ascending 5-HT innervation of the rat brain.  Adapted from Stanford, (1999)
C
h
a
p
t
e
r
 
1
:
 
I
n
t
r
o
d
u
c
t
i
o
nChapter 1: Introduction
1.5.  Monoamine systems and antidepressant drugs
The  monoamine  oxidase  inhibitor,  iproniazid,  was  originally  used  in  the 
treatment  of  tuberculosis  (Segal  &  Chakravarty,  1954).  Some  patients 
receiving  this  drug  displayed  increased  locomotor  activity  and  euphoria 
(Deverteuil & Lehmann, 1958).  Monoamine oxidase is the enzyme responsible 
for metabolism of NA and 5-HT in axon terminals and other tissues.  Inhibition 
of this  enzyme  increases the amount of monoamine stored  in vesicles  in  the 
nerve terminal and so, indirectly, its impulse-evoked release.  Many other drugs 
with this mode of action have proven efficacious in the treatment of depression. 
Collectively they are known as the monoamine oxidase inhibitors (MAOIs), e.g. 
pargyline, phenelzine, tranylcypromine.
At  the  same  time,  the  dibenzazepine,  imipramine,  (derived  from  the 
antihistamine  promazine),  was  found  to  be  useful  in  treating  depressed 
patients, (Kuhn,  1958).  This drug is an inhibitor of NA and 5-HT reuptake into 
axon  terminals  (Hertting  et  al,  1961).  The  reuptake  process  is  a  principle 
mechanism  by which  monoamine synaptic transmission  is  inactivated.  Once 
released  into the extracellular space,  NA and  5-HT  are taken  back into axon 
terminals  via  their  respective  trans-membrane  Na+ /CI‘-dependent  carrier 
proteins  (‘transporters’,  Nelson,  1998).  Inhibition  of  this  transport  process 
prolongs the increase in synaptic concentration after release of the respective 
monoamine.  Most  antidepressant  drugs  are  believed  to  operate  via  this 
mechanism.  Other compounds structurally related to imipramine have proven 
clinically  effective  and  collectively  these  are  known  at  the  tricyclic 
antidepressants,  (TCAs),  e.g.  desipramine,  amitriptyline,  nortriptyline, 
chlomipramine.
Both  the  MAOIs  and  TCAs  proved  effective treatments  for depression.  This 
raised the profile of NA and 5-HT in the etiology of the disorder and  led to the 
‘monoamine theory’ of depression, (Schildkraut,  1965).  This proposed that the 
disorder itself is due to reduced  central  monoamine transmission which, when 
corrected  for  by  antidepressant  drugs,  leads  to  clinical  improvement.  The 
theory was  supported  by the  mood-altering  properties  of the antihypertensive 
drug  reserpine,  which  depletes  the  brain  of  monoamines  and  can  induce  a 
depressed  state  in  humans  (Freis,  1954).  However,  some  findings  are
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inconsistent with the original theory:  most notably the time course of action of 
antidepressant therapy.  Despite inhibiting monoamine reuptake or metabolism 
on acute application, several weeks of antidepressant treatment are necessary 
for  clinical  improvement.  A  landmark  finding  was  the  down-regulation  of 
(3-adrenoceptors  after  long-term  treatment  with  antidepressants  (Vetulani  & 
Sulser,  1975; Banerjee et al,  1977).  This occurs after chronic treatment with a 
variety of antidepressant strategies.  Thus,  MAO  inhibition  (Sellinger-Barnette 
et al,  1980) tricyclic antidepressants (Bergstrom  & Kellar,  1979) and  repeated 
electroconvulsive shock (ECS,  Stanford & Nutt,  1982) lead to down-regulation 
of (3-adrenoceptors.  Since this effect takes place over a time-scale equivalent 
to  the  ‘therapeutic  lag’  of  antidepressant  therapy,  it was  hypothesized  to  be 
central  to  the  therapeutic  efficacy  of  these  drugs.  However,  subsequent 
studied  demonstrated  that  some  SSRIs  do  not  cause  (3-adrenoceptor  down- 
regulation.  Since this  is  not a  common feature  of all  antidepressant drugs,  it 
cannot be the mechanism by which they exert their effects.
The  original  monoamine  hypothesis  has  been  revised  to  account  for  the 
delayed  onset of therapeutic efficacy of antidepressant drugs.  Neurochemical 
changes  observed  after chronic administration  of antidepressant demonstrate 
adaptive  changes  in  a  wide  range  of  receptor  populations  that  normally 
regulate  the  firing  and  release  rate  of  5-HT  and  NA.  Down-regulation  of 
presynaptic a2-adrenoceptors,  (Charney et al,  1981; Thomas et al,  1998;  Guo 
et al,  1998; Mateo et al, 2001) 5-HTiB /id receptors, (Pineyro & Blier,  1996) and 
somatodendritic 5-HTiA  autoreceptors (Blier & de Montigny,  1980;  Invernizzi et 
al,  1994)  occurs  after  several  weeks  of  antidepressant  therapy.  These 
adaptations  lead  to  greater  efflux  of  NA  and  5-HT  and  these  long-term 
adaptations  are  thought  to  account  for  the  delayed  onset  of  antidepressant 
efficacy.
Despite  their  efficacy  as  antidepressants,  both  MAOIs  and  TCAs  are  by  no 
means  a  ‘cure’ for depression.  Both  classes of drug  produce side-effects that 
can  limit their use.  MAOIs,  particularly irreversible  inhibitors,  can  cause fatal 
hypertensive reactions when co-administered with dietary tyramine.  TCAs are 
ligands at histamine (Hi),  NA (ai) and muscarinic (Mi) acetylcholine receptors, 
as  well  as  fast-conducting  Na+  channels  in  cardiac tissue.  In  the  periphery,
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TCAs  produce antimuscarinic effects at postganglionic  parasympathetic nerve 
terminals  and  elevate  noradrenergic  transmission  at  sympathetic  nerve 
terminals.  In  combination,  these  actions  can  lead  to  a  fatal  hypertension. 
Sympathomimetic  effects,  as  well  as  nonspecific  effects  at  ai  (dizziness, 
urinary retention),  Hi  (sedation) and  Mi  receptors  (blurred  vision,  dry mouth), 
have  an  adverse  impact on  patient compliance.  Both  MAOIs  and  TCAs  are 
toxic  in  overdose,  a  serious  problem  when  treating  a  group  of  patients  at 
increased  risk  of  suicide.  These  adverse  effects  led  to  a  search  for 
antidepressants  with  an  improved  side  effect  profile  and  development  of the 
selective serotonin reuptake inhibitors (SSRIs).
1.6.  SSRIs
The  SSRIs  are  a  structurally  unrelated  group  of compounds,  which  all  inhibit 
reuptake of 5-HT, with varying degrees of selectivity and  potency.  The SSRIs 
currently  used  in  the  treatment  of  depression  are  fluoxetine,  paroxetine, 
citalopram, sertraline and fluvoxamine.  They were developed specifically not to 
have marked affinity for NA, histamine or acetylcholine receptors in an attempt 
to  improve  on  the  side  effect  profile  of  their  predecessors.  Although  of 
comparable  therapeutic  efficacy with  MAOIs  and  TCAs,  SSRIs  are  relatively 
non-toxic  in  overdose  (Barbey  &  Roose,  1998).  This,  together  with  their 
improved  side  effect  profile  means  that  the  SSRIs  are  now  the  ‘first  line’  of 
antidepressant therapy.  SSRIs are now one of the most commonly prescribed 
classes of antidepressant drugs.
Despite  the  improvement  in  side  effects  and  toxicity  with  SSRIs,  these 
compounds  also  produce  unwanted  side  effects.  These  include  sexual 
dysfunction,  nausea,  headache,  restlessness and  increased anxiety during the 
early stages  of treatment.  Increased  risk of self-harm  during  initial  treatment 
may  also  be  a  problem,  although  this  remains  controversial  (Gunnell  et  al, 
2005).  These adverse effects, together with the large population of depressed 
patients  who  show  no  improvement  after  treatment  with  any  class  of 
antidepressant (approximately 30%), means there is still an unmet clinical need 
in the treatment of depression. Therefore,  clinical and  preclinical  research into 
the mechanism of antidepressant drugs is still necessary.
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Since  the  use  of  SSRIs  has  proliferated  several  classes  of  antidepressants 
have emerged and found use in the treatment of depression.  For example, the 
mixed  “serotonin-noradrenaline  reuptake  inhibitors”  (SNRIs)  duloxetine, 
venlafaxine  and  milnacipran.  These  compounds  inhibit  reuptake  of  both 
noradrenaline and 5-HT, and so share a similar mechanism to that of the TCAs 
(see  above).  SNRIs  have  similar efficacy to  that  of TCAs  (Schweizer  et  al, 
1994) with  possibly even  greater efficacy than  that of SSRIs (Goldstein  et al, 
2004;  Clerc et al,  1994).  SNRIs  lack  affinity for adrenergic,  histaminergic or 
muscarinic receptors,  and  this  is  reflected  by their improved  tolerability when 
compared  with  TCAs  (Schweizer  et  al,  1994;  Van  Amergongen  et  al,  2002; 
Kasper etal, 1996).
The  “Noradrenaline  and  Specific  Serotonin  Receptor  Antagonists”  (NaSSAs, 
e.g.  mianserin,  mirtazapine)  increase  transmission  of  noradrenaline  by 
inhibiting presynaptic ci2-adrenoceptor-mediated  inhibition  of NA cell firing and 
release  rate,  which  may  explain  the  antidepressant  efficacy  of these  drugs. 
Simultaneous  antagonism  of 5-HT2C and  5-HT3  receptors  could  underlie the 
reduced  rate  of  5-HT  related  adverse  effects  that  has  been  reported  for 
mirtazapine compared with TCAs (Smith et al, 1990).
Another novel antidepressant is the “Noradrenaline Reuptake Inhibitor” (NARI) 
reboxetine.  This compound selectively inhibits reuptake of noradrenaline, free 
from effects on 5-HT reuptake.  It has comparable efficacy to TCAs and SSRIs. 
In particular, reboxetine may have even greater efficacy that other drugs in the 
treatment  of  severe  from  of  the  illness,  and  has  been  shown  to  have  a 
beneficial effect on social functioning of depressed patients.  The emergence of 
a  NA-selective  antidepressant  demonstrates  the  central  role  this  transmitter 
plays in the action of most, if not all antidepressant drugs.
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1.7.  NK1 receptor antagonists as putative, novel antidepressants
Neurokinin  1  (NK1)  receptors  are  the  primary  target  for  the  peptide 
neurotransmitter  substance  P.  Along  with  neurokinin  A  and  neurokinin  B, 
substance P belongs to a family of peptides known as tachykinins (/.e, peptides 
that  share  the  sequence  Phe-X-Gly-Leu-Met-NH2).  In  addition  to  the  NK1 
receptor two  other tachykinin  receptors  have  been  identified that  mediate the 
postsynaptic  effects  of  these  peptides  (NK2  and  NK3  receptors).  NK2 
receptors  show  the  greatest  efficacy  for  neurokinin  A  and  NK3  receptors 
neurokinin  B.  However,  the selectivity of the receptors for each  neurokinin  is 
low since each is able to illicit full-agonist responses at each receptor type (see 
Maggi,  1995).  Tachykinin-mediated transmission  is complicated further by the 
biological  activity  of  metabolite  fragments  that  may  differ  in  their  rate  of 
clearance  from the extracellular space (Michael-Titus et al, 2002).
Substance P is released from primary afferent fibres in superficial layers of the 
spinal  cord  during  noxious  thermal,  chemical  or  mechanical  stimulation 
(Duggan et al,  1988).  Binding sites for substance P are also localized in limbic 
areas, such as the hippocampus, striatum, olfactory bulb, central nucleus of the 
amygdala,  thalamus  and  superior  colliculus,  (Dam  &  Quirion,  1986).  Non­
peptide  NK1  receptor antagonist drugs were developed  in the hope that they 
would be useful analgesics.  However, drugs that act at the NK1  receptor have 
effects  other  than  analgesia,  (see  below).  In  particular,  a  double  blind, 
placebo-controlled  study  demonstrated  that  the  NK1  receptor  antagonist 
MK-869 was of similar efficacy in reducing symptoms in depressed  patients as 
the SSRI, paroxetine, (Kramer et al,  1998).  Moreover, MK-869 produced fewer 
adverse  effects  than  paroxetine.  Taken  alone,  this  study  demonstrated  that 
NK1  receptor antagonists might be effective and well-tolerated antidepressants. 
This was particularly interesting since they represent the first class of putative 
antidepressants  that  apparently  do  not  target  monoamine  metabolism  or 
reuptake  as  their  primary  mode  of  action.  However,  development  of  this 
compound  in  the  treatment  of  depression  was  abandoned  since  subsequent 
data failed to demonstrate of efficacy.
Other  NK1  receptor  antagonists  are  in  the  development  pipeline. 
GlaxoSmithKline  (GSK)  are  conducting  Phase  I  trials  of the  NK1  antagonist
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GW823296  for  depression  and  anxiety.  Combination  treatment  of  the  NK1 
antagonist  Vestipitant  with  the  SSRI  paroxetine  is  in  Phase  II  development. 
Also, Pfizer have an NK1 antagonist (CP-122,721) undergoing Phase II trials.
NK1  receptor  antagonists  may  have  therapeutic  potential  for  additional 
indications.  Currently,  GSK  are  testing  the  NK1  antagonist  Casopitant, 
(679769)  for  symptoms  of  depression  and  anxiety,  urinary  incontinence  and 
chemotherapy-induced nausea and emesis.
In  addition  to  NK1  receptor ligands,  NK2  and  NK3  receptor antagonists  may 
prove  useful  in  the  treatment  of  depression  and  anxiety  states  and  some 
additional  indications.  The  NK2  antagonist  Saredutant,  (SR48968,  Sanofi 
Aventis)  is  currently  in  Phase  III  testing  for  depression/anxiety.  Their 
compound  SAR-102279  is  at  the  preclinical  stage  of  testing  for  the  same 
indication.  The  mixed  NK2/NK3 antagonist,  SSR-241586  is  at the  preclinical 
stage  of development for depression  and  anxiety.  This  compound  may also 
have  therapeutic  potential  for  irritable  bowel  syndrome  (IBS)  and  chronic 
obstructive pulmonary disorder.  NK2 receptor antagonist have been suggested 
as possible treatments for IBS, also (see Lecci et al, 2004).  The NK3 receptor 
antagonist, Talnetant (SB223412) is at the Phase  III  stage of development for 
IBS and urinary incontinence.
There is evidence that NK3 antagonists  may  prove useful  in  the treatment of 
positive symptoms of psychosis  (see Spooren  et al,  2005).  Two  compounds 
are currently in development for this  indication (GSK’s Talnetant and  Sanofi’s 
SSR-146977).
The fact that neurokinin receptors antagonists are being developed for a broad 
range  of  seemingly  unrelated  clinical  states  is  reflective  of their  widespread 
distribution  and  principle  role  as  chemical  mediators  in  a  range  of  tissues. 
Also,  the overlap  regarding clinical  indications that each  selective antagonists 
may treat reflects coexpression of tachykinins (and the ability of neurokinins to 
act at multiple tachykinin receptors (Maggi et al, 1995; Drew et al, 2005)
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1.7.1  Antidepressant-like  properties  of  NK1  receptor  antagonist- 
preciinical evidence.
Preclinical experiments using NK1  receptor antagonists have used a variety of 
tests and several rodent species.  This is because antagonists with high affinity 
for  the  rat  and  mouse  NK1  receptor  have  low  affinity  for  the  human  NK1 
receptor  (Gitter  et  al,  1991).  Species  variations  in  the  receptor  amino  acid 
sequence  produce  differences  in  antagonist  binding  affinities  (Fong  et  al, 
1992).  Also,  drugs  that  have  high  affinity for  rat  and  mouse  NK1  receptors 
have poor brain  penetration and short half-lives (Rupniak et al,  1997).  These 
problems  may  be  overcome  in  two  ways:  by  using  species  that  have  NK1 
receptor pharmacology similar to humans, (e.g. guinea pig, gerbil,  hamster) or 
by using NK1  receptor knockout mice (see below).
NK1 receptor antagonist drugs
Several  studies  demonstrate  antidepressant-like  effects  of  NK1  receptor 
antagonist.  For example,  acute treatment with either fluoxetine or imipramine 
blocks the vocalization of gerbils induced by i.c.v.  infusion of the NK1  receptor 
agonist,  GR73632.  This  response  is  also  prevented  by  the  NK1  receptor 
antagonist,  L760735,  (Kramer  et  al,  1998).  Fluoxetine,  phenelzine  and 
imipramine all prevent ultrasonic vocalization of guinea pig pups in response to 
transient  maternal  separation.  This  behaviour  is  also  blocked  by  the  NK1 
receptor antagonists  L760735 (Kramer et al,  1998) or RP67580 (Santarelli  et 
al,  2001).  Thus,  blockade of the NK1  receptor inhibits behavioural  responses 
to  aversive  stimuli  in  the  same  way  as  conventional  antidepressants. 
Moreover,  NK1  receptor  antagonists  and  conventional  antidepressants  have 
the same effect on behaviours such as the mouse forced swim test (Rupniak et 
al,  2001;  Zocchi  et al,  2003),  hamster  resident  intruder (Rupniak  et al,  2001) 
and mouse marble burying  (Millan et al, 2002).  The modulation of behaviours 
sensitive  to  antidepressant  drugs  by  NK1  receptor  antagonist  indicates  their 
potential for use as antidepressant therapy.
NK1 receptor knockout mice
Although studies are limited, NK1  ablation produces the same pattern of results 
as NK1  receptor antagonist drugs.  Thus,  NK1  receptor knockout mice behave 
like  normal  mice  that  have  been  treated  with  an  established  antidepressant.
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For  example,  NK1  receptor  knockout  mice  struggle  for  longer  in  the  forced 
swim  and  tail  suspension  tests  (Rupniak  et  al,  2001),  exhibit  less  ultrasonic 
vocalization on transient maternal separation (Santarelli et al, 2001) as well as 
increased latency to initiate aggression in the resident intruder test, (Rupniak et 
al, 2001).  These studies demonstrated that the NK1  receptor knockout mouse 
is a valid preclinical model of treatment with NK1  receptor antagonist drugs.
1.8.  SSRIs and NK1 antagonists- free from effects on NA transmission?
The  increased  use  of  SSRIs  over  older classes  of antidepressants  led  to  a 
more  prominent  role  for  5-HT  in  theories  of  the  etiology  and  treatment  of 
depression.  The clinical efficacy of SSRIs was not believed to involve an action 
at  NA  transmission,  since  they  were  thought  to  be  free  from  effect  on  this 
transmitter  in  vitro  (see Wong  et al,  1995).  Likewise,  despite  evidence  for 
substance P activating  noradrenergic cell firing (Guyenet & Aghajanian,  1977; 
Cheeseman  et  al,  1983)  the  NK1  receptor  antagonists  had  no  established 
effects  on  noradrenergic  transmission,  (Kramer  et  al,  1998).  However, 
evidence is emerging that,  like other established  antidepressants,  both  SSRIs 
and NK1  antagonist modulate NA transmission in vivo.
1.9.  Augmented N  A transmission by SSRIs
Evidence  has  accumulated  over  the  last  decade  for  augmentation  of  NA 
transmission in vivo by SSRIs.  The majority of studies have employed  in vivo 
microdialysis  in  freely-moving  rats.  Table  1.1  summarizes  the  results  from 
microdialysis  studies  showing  the  effect of acute  SSRI  administration  on  NA 
'efflux’.  Efflux is defined as the fraction of extracellular transmitter that collects 
in  the  perfusate  of  a  microdialysis  probe.  An  increase  in  the  extracellular 
concentration of NA will  be followed  by an  increase in  its  probe concentration 
(‘efflux’).  These studies  examined  the effects  of systemic and  locally applied 
SSRIs in several brain regions receiving a noradrenergic innervation.  Overall, 
they  can  be  divided  into  studies  where  increased  efflux  has  been  seen  and 
those where it has not (Table 1.1  A and B, respectively).  In general, increased 
NA efflux after acute SSRI treatment has been reported most commonly in the 
frontal  cortex,  with  one  report  in  the  hypothalamus  but  not,  so  far,  in  the 
hippocampus or nucleus accumbens.
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A)  Increased NA efflux reported.
SSRI REGION ROUTE DOSE REFERENCE
FC IP 10,20 Jordan e ta l, 1994
FC SC 10 Bymaster et al, 2002
FC sc 10 Gobert et al ,1997
FC IP 30 Hatanaka et al, 2000
FC IP 40 Zocchi et al, 2003
FLUOX FC sc 1,3,10 Koch et al, 2004
FC sc 10 Zhang et al 2000
FC LI 5,50pM Hughes & Stanford, 1996,1998
FC LI 100 Jordan e ta l, 1994
HYP IP 10 Perry & Fuller, 1997
VTA LI 10-1000pM Chen & Reith, 1994
FLUVOX
FC
FC
IP
LI
12
10pM
Shachar et al,  1997 
Jordan et al 1994
FC IP 4,8 David et al, 2003
CITAL FC LI 50pM Hughes & Stanford, 1998
LC LI 100pM Mateo et al, 2000
PAROX
FC
FC
IP
SC
1,4,8
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David et al, 2003 
Beyer et al, 2002
SERT FC SC 10 Zhang et al, 2000
Table  1.1(A).  Summary of microdialysis  studies  of the  effect of acute  SSRI 
administration  on  NA efflux.  Doses are  in  mg/kg,  except local  infusion  probe 
concentrations,  which  are  given  in  pM.  FC=  frontal  cortex,  HIPP= 
hippocampus,  HYP=  hypothalamus,  LC=  locus  coerulus,  NAC=  nucleus 
accumbens,  VTA=  ventral  tegmental  area.  IP=  intraperitoneal,  SC= 
subcutaneous, Ll= local infusion (via microdialysis probe).
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B)  No change in NA efflux reported
DRUG REGION ROUTE DOSE REFERENCE
FC SC 5 Li et al, 2002
FC sc 30 Beyer et al, 2002
FLUOX HIPP IP 10 Page & Abercrombie, 1997
HYP sc 10 Li etal, 2002
NAC sc 10 Li etal2002
FC IP 1-20 Jordan et al, 1994
FLUVOX FC sc 10,20 Bymaster et al, 2002
FC IP 1 David et al, 2003
CITAL
FC sc 10 Bymaster et al, 2002
FC IP 30 Hatanaka et al, 2000
VTA LI 100pM Chen & Reith, 1994
FC sc 3 Bymaster et al, 2002
PAROX FC sc 1,3,10 Beyer et al 2002
HIPP sc 5 Hajos-Korcsok et al, 2000
FC sc 10 Bymaster et al, 2002
SERT FC IP 10 Thomas etal, 1998
HIPP IP 10 Thomas et al, 1998
Table  1.1(B).  Summary  of  microdialysis  studies  of  the  effect  of  acute  SSRI 
administration  on  NA  efflux.  Doses  are  in  mg/kg,  except  local  infusion  probe 
concentrations,  which  are  given  in  pM.  FC=  frontal  cortex,  HIPP= 
hippocampus,  HYP=  hypothalamus,  LC=  locus  coerulus,  NAC=  nucleus 
accumbens,  VTA=  ventral  tegmental  area.  I.P.=  intraperitoneal,  S.C.= 
subcutaneous, L.l.= local infusion (via microdialysis probe).
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There  could  be  several  different  mechanisms  by  which  SSRIs  modulate  NA 
transmission in vivo (see below).  Precisely which or how many of these factors 
contribute to the action of SSRIs on NA transmission remains undetermined.
1.9.1.  Effects of SSRIs on NA reuptake
SSRIs  inhibit  NA  uptake  in  vitro,  albeit  at  higher  concentrations  than  those 
required  for inhibition  of 5-HT  uptake (for review see  Stanford,  1996).  Most 
studies of SSRI inhibition of the 5-HT and NA transporters measure inhibition of 
uptake of tritiated  monoamines in synaptosomal or brain  slice preparations in 
vitro.  Richelson & Pfenning, (1984) reported K$ for inhibition of [3H]-NA uptake 
into synaptosomes from rat occipital cortex.  Fluoxetine inhibits NA uptake with 
a K\ value of 0.28pM.  KjS for fluvoxamine and  citalopram  induced  inhibition  of 
[3H]-NA uptake were 0.5pM and 4.0pM respectively.  Using a different measure 
of potency (IC50 which  is valid only for ‘within’  study comparisons),  Koe et al, 
(1983)  reported  inhibition  of  NA  uptake  to  hypothalamus  synaptosomes  for 
sertraline (1.2pM) fluvoxamine, (1.9pM) and fluoxetine (0.74pM).
Most studies have compared uptake of individual monoamines in different brain 
regions, (e.g. NA uptake in the hypothalamus with 5-HT uptake in the striatum). 
However,  uptake  of  monoamines  varies  between  different  brain  regions, 
(Snyder & Coyle, 1969).  For example, Wong et al, (1975) determined inhibition 
of 5-HT uptake by fluoxetine in synaptosomes prepared from different regions 
of the rat brain.  The cerebral  cortex and  brain  stem were most affected,  (70 
and 50% reduction  respectively), with only 23% inhibition in the diencephalon, 
19%  in  the  corpus  striatum  and  no  effect  in  the  cerebellum.  Therefore,  the 
selectivity  ratios of SSRIs for inhibition  of uptake of 5-HT and  NA  in  different 
brain regions is misleading.
The effects of fluoxetine on NA/5-HT uptake have been compared in the same 
brain region.  Its selectivity for inhibition of 5-HT uptake over that of NA is only 
2-fold  in  slices  of  frontal  cortical  tissue  (Harms,  1983)  and  20-fold  in  the 
hypothalamus,  (Thomas  et  al,  1987).  Hughes  &  Stanford  (1996)  reported 
marked  inhibition  of  [3H]-NA  uptake  into  cortical  synaptosomes  by  5.0pM 
fluoxetine. Comparison of the effects of fluoxetine with desipramine, (regarded 
as  a  selective  NA  reuptake  inhibitor)  in  brain  slices  (Harms,  1983)  or
32Chapter 1: Introduction
synaptosomes (Hughes & Stanford, 1996) reported roughly similar potencies of 
both these drugs for inhibition of NA transport.
Most relevant to effects on NA transmission is the potency of a particular SSRI. 
In other words,  regardless of effects on  5-HT uptake, to what extent do these 
drugs  modulate  NA  transmission  by  a  direct  inhibition  of  its  transport? 
Estimates  of  potency  of  inhibition  of  [3H]-NA  uptake  by fluoxetine  vary from
0.1 pM  -  9.5pM  (Bolden-Watson  &  Richelson,  1993;  Richelson  &  Pfenning, 
1984;  Thomas  et  al,  1987;  Wong  et  al,  1975).  Estimates  of  plasma 
concentration  of  fluoxetine  after  chronic  dosing  in  humans  are  0.5-1.5pM 
(Amsterdam  et  al,  1997;  Baumann  P,  1996).  Therefore,  in  vitro  studies 
demonstrate direct inhibition of the NA transporter at clinically relevant doses of 
fluoxetine.
In vivo studies suggest that SSRIs do inhibit NA transport.  Gobert, et al (2000) 
reported  increased  NA efflux  in  the frontal  cortex  of freely  moving  rats  given 
systemic  fluoxetine.  The  authors  suggested  this  effect  was  due  to  direct 
inhibition  of NA uptake by fluoxetine,  since  it was  not modified  by a  range of 
5-HT receptor antagonists and  unlikely, therefore, to be due to 5-HT-mediated 
effects (see below).
However, several studies have found no evidence for inhibition of NA reuptake 
by fluoxetine.  Acute  and  5-day administration  of fluoxetine  did  not decrease 
[3H]-NA  uptake  into  rat  heart  tissue,  ex  vivo,  (Wong  et  al,  1975).  Also, 
systemically administered fluoxetine did not decrease ex vivo binding of the NA 
reuptake inhibitor [3H]-nisoxetine in  rat cerebral cortex (Bymaster et al,  2002). 
A  relatively  low  concentration  of  fluoxetine  (0.5pM)  did  not  reduce  [3H]-NA 
uptake into synaptosomes from  rat cortical  tissue (Hughes & Stanford,  1996). 
Fuller  et  al,  (1975)  used  the  neurotoxins  a-ethyl-3-hydroxy-4- 
methylphenethylamine (H75/12) and  6-hydroxydopamine (6-OHDA) to deplete 
intracellular stores of NA and 5-HT. These agents enter monoamine neurones 
via their respective transporters.  Fluoxetine inhibited  uptake of the  neurotoxin 
via the 5-HT transporter and prevented depletion of 5-HT.  However, fluoxetine 
treatment did  not prevent the depletion of NA by either of these agents.  This
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inability to prevent the effects of these drugs on NA concentration was taken to 
indicate that fluoxetine does not block uptake via the NA transporter in vivo.
1.9.2.  SSRI receptor actions
SSRIs  have  relatively  high  affinity  for  several  neurotransmitter  receptor 
subtypes,  (see  Stanford,  1999  for  review).  SSRIs  could  modulate  NA 
transmission  by  directly  activating  these  receptors.  Cusack  et  al  (1994) 
reported  equilibrium  dissociation  constants  (KdS)  for  a  variety  of 
antidepressants at a number of different receptor classes.  Fluoxetine binds to 
5 -HT2A  receptors with  a  Ka value of 280nM.  Fluoxetine also  binds  to  5 -HT2C  
receptors (Jenck et al,  1993). These authors reported 5-HT2c receptor binding 
in the pig myenteric plexus for a variety of antidepressants.  The rank order of 
affinities of the SSRIs that were studied was fluoxetine> citalopram> sertraline> 
fluvoxamine.  Palvimaki, et al, (1999) reported 5-HT2c receptor occupancy with 
fluoxetine,  with  10-fold  greater  selectivity  over  5-HT2A  receptors.  Using  a 
phosphoinositide assay, they demonstrated 5-HT2C  receptor antagonist actions 
of fluoxetine.  The  stereoisomer  R-fluoxetine  binds  to  the  5-HT2A  and  5-HT2C  
receptor (Koch et al,  2002).  Functional  GTP-y-S  binding studies indicate that 
R-fluoxetine acts as an antagonist at both these receptor subtypes.  Given that 
5-HT  has  a  tonic,  inhibitory  action  on  NA  neurones  (see  section  1.12.), 
antagonism  at  5-HT2c  receptors  would  increase  noradrenergic  cell  firing  and 
release.  Indeed,  systemic administration  of 5-HT2c antagonists  increases  NA 
efflux in the frontal cortex (Millan et al,  1998).  This effect of fluoxetine has been 
proposed  to  explain  its  effects  on  NA  transmission,  (Millan  et  al,  1998; 
Bymaster et al, 2002) and antidepressant its action (Palvimaki et al, 1999, Koch 
et al 2002).
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1.9.3.  Secondary effects of SSRIs on NA transmission via effects on 5-HT 
transmission.
Interactions between central 5-HT and NA systems are well documented.  One 
way SSRIs  could  augment  NA efflux  is  by the  secondary  effects of elevated 
extracellular. 5-HT can modulate noradrenaline transmission by effects both at 
the somatodendritic and terminal  level.  SSRI will  affect both these processes 
by increasing the extracellular concentration of 5-HT.
5-HT effects at noradrenergic ceii bodies
Immunocytochemistry and autoradiography studies demonstrate a dense 5-HT 
innervation of noradrenergic neurones in the  LC of the rat (Pickel  et al,  1977, 
Leger & Decarries,  1978).  Also, 5-HT synthesis inhibition with pCPA increases 
synthesis of NA (McRae-Degueurce et al, 1985) and LC firing rate (Ferron et al, 
1988).  These  studies  demonstrate  an  inhibitory  effect  of  5-HT  on  NA 
transmission.
Electrophysiological  and  microdialysis  studies  in  anaesthetized  rats  confirm 
that 5-HT has an inhibitory effect on  LC neurones (for review see Millan et al, 
2000).  For  example,  systemic  administration  of  5-HT  agonists,  such  as 
quipazine,  the  5-HT2  receptor  agonists,  1-(4-bromo-2,  5-dimethoxyphenyl)-2- 
aminopropane  (DOB;  Gorea  &  Adrien,  1988)  and  2,5-dimethoxy-4- 
methylamphetamine  (DOM;  Rasmussen  &  Aghajanian,  1986)  decrease  the 
discharge frequency of LC  neurones  in  the  rat.  The  effect of these drugs  is 
prevented  by  the  5-HT2A  antagonist,  ritanserin.  Quipazine  and  the  5-HT2 
agonist,  1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)  also  decrease 
NA efflux in the hippocampus (Done & Sharp,  1992).  Again, these effects are 
prevented  by ritanserin, which also increases LC neuronal activity (Clement et 
al, 1992).
These  studies  show that  5-HT  inhibits  noradrenergic  neurones  in  the  LC  via 
5-HT^ receptor activation.  However, this is not a direct effect on noradrenergic 
cells since direct application of 5-HT2 receptor agonists to the LC does not alter 
the firing-rate of noradrenergic neurones, (Gorea et al,  1991).  An indirect effect 
via excitation of an inhibitory GABAergic input is more likely, since the inhibitory 
effects  of  systemic  5-HT2  receptor  agonists  are  blocked  by  the  GABA
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antagonist,  bicuculine  (Chiang  &  Aston-Jones,  1993)  or  by  lesions  of  the 
prepositus  hypoglossal  nucleus,  (Gorea  et al,  1991).  This  nucleus  provides 
GABAergic  afferents  to  the  LC  ((Ennis  &  Aston-Jones,  1989).  Therefore, 
increased  extracellular  5-HT  after  SSRI  administration  could  inhibit 
noradrenergic neurones via this multi-synaptic pathway (Figure 1.3).
5-H T
5-HT2A
N A
Figure  1.3.  Schematic  diagram  describing  possible  interaction  between 
noradrenaline and 5-HT neurones. 5-HT= 5-HT-releasing neurones of the DRN; 
NA=noradrenaline-releasing  neurones  of the  LC;  GABA=  GABAeric  neurones 
of  the  prepositus  hypoglossal  nucleus  V   =  excitatory  effect;  =  inhibitory 
effect.  See section 1.12.
Systemic  administration  of  SSRIs  preferentially  activates  presynaptic  5-HT1 A  
autoreceptors  in  the  DRN  that  reduce  5-HT  cell  firing  and  release  (Hervas  & 
Artigas,  1998).  This effect could  increase  NA efflux by removing the 5-HT2A - 
mediated inhibition of noradrenergic cell firing and  release (see above).  Using 
the  push-pull  cannula  technique,  Kaehler  et al,  (1999)  demonstrated  a  long- 
lasting  reduction of 5-HT overflow in the  LC after microinjection  of the 5-HT1 A  
receptor agonist 8-OHDPAT  to  the  DRN.  Systemic  administration  of  5-HT1 A  
agonists, (MKC-242, 8-OHDPAT, buspirone, MDL73005EF, S15535) increases
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NA efflux in the frontal cortex, hippocampus and hypothalamus of rats (Suzuki 
et al,  1995; Millan et al,  1997; Hajos-Korcsok & Sharp,  1996;  Hajos-Korcsok et 
al,  1999). 8-OHDPAT and buspirone also increase Fos-like immunoreactivity in 
the LC (Hajos-Korcsok & Sharp,  1999), while 8-OHDPAT increases the firing of 
LC  noradrenergic  neurones  (Lejeune  &  Millan,  2000).  Since  SSRI 
administration  preferentially  activates  5-HTiA   receptors  on  the  cell  bodies  on 
5-HT  neurones,  they  could  increase  NA  efflux  by  diminishing  the  inhibitory 
effects of 5-HT transmission as 5-HT2A receptors.
5-HT effects at noradrenergic axon terminals
Despite  fewer  studies  in  this  area,  SSRIs  could  also  increase  NA  efflux  at 
noradrenergic  axon  terminals  by  activating  5-HT  heteroceptors.  Paroxetine, 
exogenous  5-HT,  the  5 -HT2A/2C  agonist,  DOI  and  the 5-HT3 agonist 2-methyl- 
5-HT  enhance electrically-evoked  NA  release from  slices  of rat frontal  cortex 
and  hypothalamus,  (Mongeau  et  al,  1994).  However,  administration  of  the 
2-methyl-5-HT  decreases  K+-evoked  noradrenaline  release  in  slices  of  the 
hypothalamus  (Blandina  et  al,  1991)  and  hippocampus  (Matsumoto  et  al, 
1995).
Importantly,  when fluoxetine is  administered  locally to the frontal  cortex  via a 
microdialysis  probe,  it  consistently  increases  NA  efflux,  (Jordan  et  al,  1994; 
Hughes  &  Stanford,  1998;  see  Chapter  4).  Whether  this  is  due  to  direct 
inhibition  of  NA  reuptake  (see  above)  or  secondary  to  its  effect  on  5-HT 
remains unresolved.  Experiments described in Chapter 4 address this issue.
If the effects of SSRIs on NA efflux are secondary to their effects on 5-HT, they 
will be attenuated or blocked by a reduction in 5-HT transmission.  This can be 
achieved  using the 5-HT synthesis  inhibitor, para-chlorophenylalanine,  (pCPA, 
Koe & Weissman,  1966).  This amino acid is a potent and selective inhibitor of 
tryptophan  hydroxylase (Jequier et al,  1967),  the rate-limiting enzyme in  5-HT 
biosynthesis.  However,  if  pCPA  does  not  abolish  fluoxetine’s  effect  on  NA 
efflux,  this  would  support  a  direct  effect  of  fluoxetine  on  noradrenergic 
neurones,  possibly  due  to  inhibition  of  the  noradrenaline  transporter  (see 
above).
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1.9.4.  Selectivity of monoamine transporters
The effects of SSRIs in vivo will depend on the substrate selectivity of the 5-HT 
transporter.  For  example,  if  NA  is  also  taken  into  neurones  via  the  5-HT 
transporter, inhibition of this would elevate the extracellular the concentration of 
both  5-HT  and  NA.  However,  the  5-HT  transporter  appears  to  be  highly 
selective.  Thus,  uptake  of  [3H]-5-HT  in  the  rat  lung  was  unchanged  by  NA 
(10pM)  administration  (Paczkowski  et  ai,  1996).  However,  a  higher 
concentration  of  5-HT  (50pM)  caused  a  56%  inhibition  of  NA  uptake, 
suggesting that 5-HT competes with NA transport at high concentrations.  If this 
is  also  the case  in  the  brain,  the  increase  in  extracellular  5-HT  produced  by 
SSRIs could cause a competitive reduction in  NA uptake, which could  explain 
the increase in its extracellular concentration.
1.10.  Effect of NK1 antagonists on NA and 5-HT
Since  all  established  antidepressants  target  the  noradrenergic  and/or  5-HT 
systems,  it is vital to determine whether NK1  antagonists act independently of 
these  systems  or  if,  in  fact,  they also  modulate  monoamine function.  When 
originally proposed  as  antidepressants  (Kramer et al,  1998)  NK1  antagonists 
were  suggested  to  function  independently  of  monoamines  and  hence, 
represent  an  entirely  new  approach  to  the  drug  treatment  of  depression. 
However, substance P affects monoamine function (see below) and preliminary 
evidence  suggests  that  NK1  antagonists  may  have  similar  effects  on 
monoamine transmission  as conventional  antidepressants.  There are several 
mechanisms that could explain these interactions.
Millan  et  al,  (2001)  examined  the  effects  of  NK1  receptor  antagonist 
administration on NA and 5-HT efflux in the frontal cortex and hypothalamus of 
freely  moving  rats.  The  NK1  receptor  antagonist  GR205.171  increased  NA 
efflux in both brain regions, but had no apparent effect on 5-HT efflux.  A lack of 
effect of this drug on 5-HT efflux was also reported in the frontal cortex of freely 
moving  mice  (Guiard  et  al,  2004).  DRN  cell  firing  in  anaesthetized  rats  is 
similarly  unchanged  by  the  NK1  antagonists  WIN  51,708  or  CP-96,345 
(Haddjeri & Blier, 2000).
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Despite this lack of effect of NK1  receptor antagonists on  5-HT efflux and cell 
firing,  several  studies  report changes  in  5-HT  regulation  after inhibition  of the 
NK1  receptor,  either  using  antagonist  drugs,  or  receptor  knockout  mice  (see 
below).  The  NK1  receptor antagonist,  RP67580,  increased  the firing-rate  of 
5-HT  neurones  in  the  DRN  of  anaesthetized  mice  (Santarelli  et  al,  2001). 
Spontaneous DRN cell firing was also greater in  NK1  receptor knockout mice. 
This  study  also  demonstrated  reduced  5-HTiA   receptor  function  in  NK1 
knockout  mice,  since  the  decrease  in  5-HT  cell  firing  and  body temperature 
after  administration  of  the  5-HTia  receptor  agonist,  8-OHDPAT,  were 
diminished in these animals.
Down-regulation  of  5-HTia  autoreceptors  is  a  common  effect  of  chronic 
treatment with many antidepressants and is thought to be central to their long­
term  effects  on  5-HT  transmission  and  therapeutic  efficacy  (Blier  & 
DeMontigny,  1983;  Artigas  et al,  1996).  The  above  study  demonstrates  that 
loss of NK1  receptor function leads to changes in 5-HT regulation in a manner 
common  to  that  of conventional  antidepressants.  Confirmation  of decreased 
5-HTia receptor function was provided  by a study by Froger et al, (2001): they 
reported  reduced  DRN  5-HT1A   receptor  labeling  by  [3H]-WAY100,635, 
decreased  DRN  5-HT1A   receptor mRNA,  a  reduced  hypothermic  response  to 
the  5-HT1A   agonist  8-OHDPAT  and  reduced  efficacy  of  the  5-HTia  agonist, 
ipsapirone,  to  diminish  5-HT  cell  firing  in  NK1  receptor  knockout  mice. 
Nevertheless,  NK1  knockout mice had  no difference in spontaneous DRN cell 
firing or basal efflux of 5-HT in the frontal cortex.
Despite  evidence  for  modulation  of  5-HT  transmission  by  NK1  receptor 
antagonists,  or  in  NK1  receptor  knockout  mice,  a  direct  effect  on  5-HT 
neurones is unlikely.  NK1  receptors are located on few if any 5-HT cell bodies 
of the  DRN.  Thus,  Froger et al,  (2001),  using  double  labeling with  antibodies 
raised against 5-HT and the NK1  receptor, found no co-expression of these by 
neurones  of the  DRN.  Likewise,  Santarelli  et al,  (2001),  found  little  overlap 
between 5-HT neurones and NK1  receptors in the DRN.  Therefore, the effects 
of NK1  receptors antagonists on 5-HT transmission, and those reported in NK1 
receptor knockout mice, may be due to indirect effects.
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In contrast to its relationship with 5-HT, there is anatomical evidence of a direct 
substance  P-  NA interaction.  Substance  P-containing fibres form  axodendritic 
synapses with  noradrenergic  neurones  of the  LC,  (Pickel  et al,  1979).  Using 
double  immunolabelling  in  the  rat,  Chen  et  al  (2000)  found  that  100%  of 
tyrosine  hydroxylase  labeled  neurones  in  the  LC  complex  co-express  NK1 
receptors.  Localization of NK1  receptors on noradrenergic neurones in the LC 
has  also  been  reported  in  mice,  (Santarelli  et al,  2001).  Functional  evidence 
also  suggests  substance  P-mediated  effects  on  NA  transmission.  Thus, 
application  of substance  P in  vivo,  (Guyenet & Aghajanian,  1977),  or in  vitro 
slice  preparations,  (Cheeseman  et  al,  1983)  increases  LC  cell  firing-rate. 
Paradoxically, systemic administration of an NK1  antagonist also increases NA 
efflux  in  the  frontal  cortex  of  freely  moving  rats  (Millan  et  al,  2001)  and 
increases the number of LC c-fos-immunoreactive cells in response to restraint 
stress  (Hahn  &  Bannon,  1998).  Since  NK1  receptor  activation  depolarizes 
neuronal  membranes,  the  fact  that  both  agonists  and  antagonists  at  this 
receptor increase the firing-rate of LC neurones seems problematic.  This could 
reflect populations of NK1  receptors, both on LC neurones themselves, and on 
inhibtory  afferents  to  the  LC.  Thus,  inhibition  of  NK1  receptors  located  on 
GABAergic afferents to the LC from the prepositus hypoglossal nucleus would 
produce a disinhibition of noradrenergic neurones.
Down-regulation  of  a2-adrenoceptors  is  a  common  feature  of  long-term 
treatment with antidepressant drugs of several different classes (see Invernizzi 
&  Garattini,  2004).  NK1  antagonists  attenuate  the  suppressant  effect  of 
a2-adrenoceptor activation on LC firing-rate, suggesting a common mechanism 
of  action  of  NK1  antagonist  and  conventional  antidepressants,  (Haddjeri  & 
Blier,  2000).  However,  despite  increased  burst  firing  of  guinea  pig  LC 
neurones  following  chronic treatment with  the  NK1  antagonist,  L760.735,  no 
down-regulation  of a2-adrenoceptors was found,  (Maubach  et al,  2002).  The 
impact of NK1  receptor ablation  on  NA transmission  has  not been studied  so 
far (see below).
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1.11.  Approach
NA is  central  to our understanding  of depression  and  its treatment,  since the 
original monoamine theory of Schildkraut to the development of new treatments 
that selectively target this transmitter,  {e.g. the selective NA reuptake inhibitor, 
reboxetine).  Given  the  large  proportion  of depressed  patients  who  show  no 
improvement after antidepressant treatment, an increased understanding of the 
neurochemical  effects  of  these  drugs  is  necessary.  Unlike  all  other 
antidepressants,  effects  on  the  noradrenergic  system  are  not  considered 
central  to  the  effects  of  SSRIs.  Likewise,  a  role  for  NA  has  yet  to  be 
established  in  the  action  of  the  putative,  novel  NK1  receptor  antagonists. 
However,  there is growing evidence that these drugs modulate NA function in 
vivo.  The  aim  of  experiments  in  this  thesis  was  to  determine  the  effects  of 
acute  SSRI  treatment  (fluoxetine)  and  NK1  receptor  blockade  (using  NK1 
receptor knockout mice) on NA transmission in vivo.  A dual approach is used, 
recruiting  both  in  vivo  neurochemical  measurement  of  NA  efflux  using 
microdialysis  and  scoring  of  behaviours  sensitive  to  changes  in  NA 
transmission in a modified light/dark exploration test.
The effects of fluoxetine were studied  in rats.  Previously microdialysis studies, 
and  experiments  presented  here,  suggest that fluoxetine augments  NA efflux 
(see  above).  However,  often  this  effect  is  not  replicated.  In  addition, 
fluoxetine’s  effects  on  NA  efflux  vary  across  brain  regions.  As  yet,  it  is 
unknown  whether  this  variation  represents  differences  in  NA  regulation 
between  brain  regions,  or simply the greater number of studies  performed  in 
the frontal cortex. The aim here was to examine the effect of fluoxetine on  NA 
efflux  by  comparing  its  effects  in  two  brain  regions  receiving  noradrenergic 
innervation from different brainstem sources (frontal cortex and hypothalamus). 
Since 5-HT can augment NA transmission, the ability of fluoxetine to increase 
NA efflux could  be secondary to its effects on  5-HT.  This was determined  by 
administering  fluoxetine  to  rats  pretreated  with  the  5-HT  synthesis  inhibitor 
para-chlorophenylalanine (pCPA).
Because of the lack of availability of compounds with high affinity for the rat and 
mouse  receptor  NK1  receptor,  a  strain  of  NK1  receptor  knockout  mice  was 
used.  Receptor knockout models  represent ‘lifelong’  inhibition of that receptor,
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since it is absent throughout life.  This may be advantageous when studying a 
receptor  related  to  antidepressant  therapy,  since  long-term  treatment  with 
antidepressant is required for clinical efficacy.
Knockout mice are generated  by genetic modification of embryonic stem cells. 
These cells are transfected with a DNA vector- a portion of DNA that is identical 
to  the  allele  of  interest  (e.g.  NK1  receptor),  but  altered  to  render  it  non­
functional.  When these cells divide, a proportion of them have the parent allele 
replaced by that containing the non-functional vector.  When these transfected 
cells  are  introduced  to  a  blastocyst  and  incubated  in  a  foster  mother,  the 
resultant offspring contain the targeted  allele in  cells of their germline.  These 
offspring are backcrossed with  normal  mice to generate heterozygotes for the 
non-functional,  ‘null’  allele.  Inbreeding  of  heterozygotes  generates  offspring 
that are homozygous for the null allele, with no functional copy of the targeted 
gene, i.e. ‘knockouts’.
NK1  receptor knockout mice offer a model of lifelong inhibition of the receptor. 
By genetically ablating  the  NK1  receptor,  the  lack  of  high  affinity,  poor  brain 
penetrance and short half-life of antagonist drugs are obviated.  However,  loss 
of  function  of  a  receptor  could  produce  compensatory  adaptations  during 
development, which could lead to functional changes not seen after long-term 
administration of an antagonist.  Ultimately,  both approaches offer advantages 
and both have limitations.
In  summary,  experiments  here  use  the  same  line  of  NK1  receptor  knockout 
mice  as  that  used  in  the  study  by  Froger  et  al,  (2001,  see  above),  which 
demonstrated  diminished  5-H Tia  receptor function  in  the  knockout  mice.  It  is 
unknown how NK1  receptor ablation modulates 5-HT transmission since these 
receptors are not found on 5-HT neurones (see above).  One possibility is via 
effects on NA transmission.  So far, the impact of NK1  receptor ablation on this 
transmitter has not been explored.
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1.12.  Aims
The aim of experiments in this thesis was to determine the effects of fluoxetine 
and NK1  receptor ablation on NA transmission in vivo.  Since drugs that belong 
to these classes (i.e.  SSRIs,  NK1  receptor antagonists) are not considered to 
target  NA as their primary mode of action,  demonstration  that they modulate 
this  transmitter  in  vivo  will  add  to  the  growing  body  of  evidence  that  NA  is 
implicated in the mechanism of all antidepressant drugs.
43Chapter 2: Methods
Chapter 2 
Materials and methods
2.1.  Introduction
The  techniques  used  in  this  study  were  chosen  to  measure  changes  in  NA 
transmission elicited by drug administration or genetic ablation.  Neurochemical 
changes  in  NA  efflux  were  monitored  using  in  vivo  microdialysis,  a  now 
widespread in vivo sampling technique that is used to study many endogenous 
substances.  The  effects  of  these  treatments  on  NA  function  were  also 
measured  using  a  behavioural  assay:  a  modified  version  of  the  light/dark 
exploration box. Both techniques are discussed here.
2.1.1.  In vivo sampling techniques
Technologies that enable measurement of neurotransmitters in vivo have been 
developed  over  the  past  40  years.  This  became  possible  when  assay 
procedures  of  suitable  sensitivity  were  developed.  Several  techniques  are 
employed, both in freely-moving and anaesthetized animals.  A brief description 
of each of these follows.
The Cortical cup
The  cortical  cup  (Macintosh  &  Oborin,  1953) enables  recovery of substances 
from the surface of the cerebral cortex for subsequent ex vivo analysis.  A small 
cylinder (0.2 -  1   cm2) is placed in tight contact with the surface of the cerebral 
cortex.  The  cylinder  is  filled  with  artificial  CSF,  into  which  neurotransmitters 
diffuse from  the  surface  of the  brain.  The fluid  is  exchanged  periodically and 
analyzed  for  neurotransmitter  content.  The  cortical  cup  can  be  applied  in 
anaesthetized or conscious animals.  The technique has been used to study the 
relationship  between  behavioural  changes  and  neurotransmitter  release 
(Rasmusson  &  Szerb,  1976).  However,  applications  of  the  cortical  cup  are 
limited  as  it  only  allows  measurement  of  neurotransmitter  release  from  the 
neurones at the upper layers of the cortex.
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The Push-pull cannula
The push-pull cannula (Gaddum,  1961; Stadler et al,  1975) is composed of two 
concentric  hollow  fibres  or  steel  cannula,  the  inner  for  delivery  of  perfusion 
medium,  the  outer  for  collection  of  the  fluid  (outer  diameter  >2  mm). 
Neurotransmitters and  other substances are taken up  by the flow of fluid from 
the cannula for subsequent analysis.  The  push-pull  cannula was  a  significant 
advancement over the cortical cup, since neurotransmitters could be measured 
from discrete locations within the brain.  Drugs can be included in the perfusion 
medium  and  applied  directly  to  the  site  of  interest  (Dietl  et  al  1981).  The 
response of local neurones to direct electrical stimulation can also be studied by 
using the outer tube of the cannula  as  a  monopolar electrode (Philippu  et al, 
1973). However, the push-pull cannula causes extensive tissue damage due to 
the flow of artificial CSF in direct contact with nervous tissue. Since the ends of 
the  inlet  and  outlet tubing  are  exposed,  they  can  become  blocked  by tissue 
debris.
In vivo voltammetry
In  vivo voltammetry (for  reviews see:  Adams,  1978;  Stamford,  1989)  enables 
measurement  of  monoamine  concentration  in  vivo,  by  exploiting  the 
electrochemical  properties of these neurotransmitters.  The voltammetry probe 
is a fine diameter (8 -  300 pm) carbon fibre microelectrode that causes minimal 
tissue  damage  when  inserted  into  small  structures  of  the  brain.  A  positive 
potential is applied to the electrode, which oxidizes monoamines at its surface. 
The  current  produced  by  the  release  of  electrons  is  amplified  and  detected. 
This current is directly proportional to the number of neurotransmitter molecules 
oxidized,  in  accordance  to  Faraday’s  Law.  ‘Fast-cyclic’  voltammetry  allows 
almost real time measurement of changes in the extracellular concentration  of 
neurotransmitters  and,  therefore,  has the greatest temporal  resolution  of all  in 
vivo  sample  techniques.  However,  since  there  is  no  separation  of the  ECF 
solutes prior to detection of transmitters,  problems of selectivity can arise.  The 
oxidation  potentials  of  monoamines  and  their metabolites  (and  certain  drugs) 
are very similar.  This is the main drawback of the technique.
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2.2.  In vivo microdialysis
Dialysis  is  defined  as  any  process  by  which  solutes  of  different  kinds  are 
selectively  removed from  a  liquid  as  a  consequence of their capacity to  pass 
through  a semi-permeable membrane. The first use of in  vivo dialysis was  by 
Bito et al,  (1966).  They implanted  semi-permeable membrane sacs filled with 
6% dextran  in  saline to the cerebral cortex of dogs.  10 weeks  later,  the sacs 
were  removed  and  their contents  analyzed  for amino  acid  content  and  other 
electrolytes.  Using this method, the composition of the brain  extracellular fluid 
was compared with that of blood plasma and subcutaneous tissue.  This group 
later attempted  to  take  repeated  samples  from  in  vivo  dialysis  fluid  by  using 
dialysis sacs fitted with polythene tubes.
Delgado et al (1972) developed the ‘dialytrode’.  This was a push-pull cannula 
with a small  membrane sac fitted over the exposed  ends of an inlet and outlet 
tubing.  This created a closed environment through which Ringer’s solution was 
passed. Amino acids and other molecules passed into the membrane sac.  As 
well  as  causing  less  damage  to  the  surrounding  tissue,  the  addition  of  a 
membrane protects recovered neurotransmitters from enzymatic degradation.
Modern microdialysis involves  insertion of a  probe (250-300  pM  diameter) into 
the brain region or tissue of interest.  The end of the probe is a small cylinder of 
semi-permeable  membrane  (Ungerstedt  &  Pycock,  1974).  The  membrane 
allows diffusion of small molecules and water.  It is fitted with an inlet and outlet 
and  continuously perfused with  a  medium  devoid  of the substance of interest. 
This creates a concentration gradient between the ECF and the ‘perfusate’ that 
results  in  movement  of  small  molecules  across  the  membrane  and  into  the 
probe,  where  they  are  extracted  for  subsequent  analysis.  In  this  way,  a 
microdialysis  probe  acts  as  an  artificial  capillary:  the  amount  of  transmitter 
recovered is proportional to its concentration in the ECF.
2.2.1.  Probe design
Several different probe designs have been developed.  The ‘transcranial’ probe 
(Imperato  &  DiChiara,  1984)  is  composed  of  a  length  of  dialysis  membrane 
passing  through  the  brain  transversely.  This  design  has  the  advantage  of
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offering  a  large  surface  area  for  exchange  of  molecules  to  occur,  but  is 
obviously limited in terms of spatial resolution.
The  ‘loop’  probe  (Hernandez,  et al,  1983;  Abercrombie  et  al,  1988)  is  made 
from  a  length  of membrane,  bent into a vertical  loop at the end  of the probe. 
Again this  increases the surface area over which dialysis occurs,  but can also 
increase damage to the area being studied.
The ‘concentric’ probe design has the inlet tubing placed inside the outlet, with a 
small  diameter,  hollow  fibre  of  dialysis  membrane  at  the  end  (Tossman  & 
Ungerstedt, 1986).
All experiments described in this thesis use the ‘side by side’  probe (Sandberg 
et al,  1986).  This is similar to the concentric probe design, but has the inlet and 
outlet tubing next to one another with a small diameter hollow membrane fibre 
at the tip.
2.2.2.  Neurotransmitter ‘efflux’
Brain  tissue  has  three  fluid  compartments:  the  intracellular  fluid,  the 
extracellular fluid and the vascular fluid.  When neurotransmitters are released, 
they diffuse into the extracellular space. At the same time, neurotransmitters are 
cleared from the ECF by reuptake and enzymatic degradation.  What dialysis is 
sampling,  therefore,  is  the  net result of these  processes.  It  is  not  measuring 
release per se,  but  rather the  concentration  of substances  that  pass  into  the 
extracellular  fluid,  which  is  determined  by  the  balance  of  release  and 
reuptake/degradation.  The  term  ‘efflux’  is  used  to  describe  the  amount  of 
transmitter that reaches the probe.
2.2.3.  Probe ‘recovery’
Since  the  perfusion  medium  in  the  probe  is  not  static,  the  concentration  of 
substances within the probe will  not equal that in the surrounding tissue.  The 
‘recovery’  of  a  microdialysis  probe  is  defined  as  the  ratio  between  the 
concentration of a substance in the perfusate and the concentration of the same 
substance  in  the  solution  outside  the  probe:  this  is  normally  expressed  as  a 
percentage (Zetterstrom  et al,  1982).  Recovery can  be  calculated  In  vitro  by
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perfusing the probe at a constant flow rate in a solution of known concentration 
of the substance of interest.  The recovery is calculated from the concentration 
of substance in the perfusate relative to that in the external solution.  However, 
extrapolation from an in vitro model to the situation in vivo is not straightforward. 
Passage of substances in brain tissue in  not the same as in aqueous solution, 
since  mass  transport  is  confined  to  the  extracellular space,  which  comprises 
only 20% of the total brain volume (Levin et al 1970).
For  experiments  described  in  this  thesis,  the  concentration  of  NA  in  the 
perfusate was not corrected for probe recovery, since the objective was not to 
quantify the absolute concentration of NA in the ECF.  The aim was to monitor 
changes  in  NA  efflux  relative  to  spontaneous,  ‘basal’  efflux.  However,  both 
approaches  require a  constant  probe  recovery.  Several  factors  are  known  to 
influence the recovery of transmitters  by microdialysis.  Therefore,  these must 
be carefully controlled.
The main factors that determine probe recovery are:
•  membrane surface area
•  perfusion (‘flow’) rate
•  composition of the perfusion medium
•  membrane material
Membrane surface area
The larger the surface area of the dialysis membrane, the greater area available 
for  exchange  of  molecules  to  occur.  Therefore,  the  greater  the  recovery 
(Sandberg  &  Lindstom,  1983;  Tossman  &  Ungerstedt,  1986).  Increasing  the 
membrane  area  is  normally  achieved  by  increasing  the  length  of  membrane 
fitted  to the end of the probe.  However, the greater the membrane length,  the 
lower the spatial resolution and greater the tissue damage.
Perfusion (‘flow’) rate
The flow rate of the perfusion medium will determine the concentration gradient 
between  inside and  outside  the  probe,  i.e.  lower flow  rates  will  allow greater 
recovery  and  a  lower  concentration  gradient.  Increasing  the  flow  rate  will
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increase the concentration gradient, but also reduce the relative recovery, since 
the volume of perfusate flowing per unit time will be increased in relation to the 
amount of substance recovered.  High flow rates should be avoided since they 
can  produce  hydrostatic  pressure within  the  membrane,  expelling  fluid  to the 
ECF and causing tissue damage.  A flow rate in the region of 2 pl/min is typical.
Composition of perfusion medium (‘perfusate’)
The perfusion medium  is a critical consideration for microdialysis experiments. 
Differences in composition  between the medium used and the ECF will lead to 
additional  concentration  gradients  between  the  two  compartments  that  could 
affect the recovery of the substance of interest.  Also, removal of ions from the 
ECF, or addition of ions from the perfusate to the ECF can disrupt the electrical 
activity of neuronal cell membranes and the in vivo release of neurotransmitters. 
K+ and  Ca2+  ions are  particularly important in  this  respect (Abercrombie et al, 
1988;  Westerink  et  al,  1988).  A  perfusion  medium  with  a  K+  concentration 
greater than that of the ECF will  raise the  ECF  K+  concentration as  it crosses 
the membrane down its concentration gradient.  Elevated ECF K+  concentration 
leads  to  depolarization  of  neurones,  increasing  neurotransmitter  release. 
Conversely,  if Ca2+ concentration  is  lower in  the  perfusion  medium  that  ECF, 
these  ions  will  be  removed  from  the  area  surrounding  the  probe.  Since 
neurotransmitter  release  is  a  Ca2+  dependent  process,  this  will  reduce 
neurotransmitter release (Dailey & Stanford, 1995).
The  perfusion  medium  used  for  microdialysis  in  this  thesis  was  a  modified 
Ringer’s solution  containing 4 mM  KCI,  145  mM  NaCI  and  1.3  mM  CaCb,  pH
6.8.  Continuous  perfusion  with  this  medium  produces  a  stable  spontaneous 
efflux of NA, which is within the limits of detection of the assay (see below).
Membrane material
Most  non-commercial  microdialysis  probes  are  made  with  renal  dialysis 
membrane.  A variety of materials is available.  Each must be porous enough to 
allow passage of water and  substances  of interest,  but impermeable to  larger 
molecules  to  prevent  passage  of  unwanted  components  of  the  ECF,  which 
could  potentially  contaminate  the  detection  assay.  Typically,  the  molecular
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weight cut-off varies between  10-50 KDa.  A vital property of dialysis membrane 
is  biocompatability,  i.e.  the  membrane  should  not  interact physiologically with 
living tissue, cause immune responses or have toxic effects.  In this thesis, two 
types  of membrane fibre were  used.  For experiments  using  rats,  a synthetic 
AN69,  acrylonitrile  and  sodium  methallyl  sulfonate  copolymer  (Hospal 
industries)  was  used.  For  experiments  using  mice,  a  smaller  diameter, 
regenerated  cellulose  membrane  (cuprophan)  was  used,  to  minimize  tissue 
damage.  Since  no comparisons  were  made  between  data from  microdialysis 
experiments using rats and mice, the use of different membrane materials is of 
no consequence.  What is critical is that all properties of the microdialysis probe 
are consistent within studies where comparisons are made.
2.3  In vivo Microdialysis procedure
2.3.1  Construction of probes
The  microdialysis  probes  used  in  this  study  were  custom-made  in  the 
laboratory.
Probes for use in rats
Two 4cm lengths of silica tubing (i.d. 75jnm, o.d.  150pm, SGE) are inserted to a 
2cm  length  of  stainless  steel  cannula  (i.d. 380pm,  o.d.  500pm,  Goodfellow). 
These are glued in place with epoxy resin.  Two 0.5cm lengths of stainless steel 
tubing  are  placed  over the fixed  ends  of the silica,  which  act as  the inlet and 
outlet channels.  The lengths of stainless steel are fixed  in  position with epoxy 
resin.  Two 5cm lengths of Portex fine bore tubing (i.d. 280pm, o.d. 610pm) are 
fitted  over the  silica  and  glued  in  place.  A  length  of dialysis  membrane  (i.d. 
240 pm, o.d. 300 pM; molecular weight cut-off 40KDa;  Filtral  12, AN69;  Hospal 
Industries) is placed over the end of the silica and glued inside the steel cannula 
to leave a length of exposed membrane.  This is trimmed to 2.5 cm and the end 
sealed with epoxy resin.  The length of membrane exposed is 2 cm.  Figure 2.1 
shows the main stages of probe construction.
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Figure 2.1.  Diagram showing the main stages of microdialysis probe construction.  Arrows depict direction of perfusion 
medium flow.  Details of construction are given in section 2.3.1. Drawings are not to scale.
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Probes for use in mice
Probes for use in mouse dialysis were made using the same method as used in 
rats but with one modification.  This was to minimize damage to neuronal tissue, 
given the smaller dimensions of the mouse brain. The membrane material used 
was  Cuprophan  (i.d.  180  pm,  o.d.  250pm;  molecular  weight  cut-off  10KDa; 
Medicell International Ltd), with an active membrane length of 1.5mm.
2.3.2.  Surgery and implantation of probes 
Experiments using awake (freely-moving) rats
Adult,  male  Sprague-Dawley  rats  (230-320g)  were  anaesthetized  using  5% 
halothane (in 95% oxygen, 5% carbon dioxide, ‘carbogen’; 2 l/min).  They were 
placed  in  a  stereotaxic frame  (Kopf instruments) with  the  head  held  in  place 
using  ear  and  incisor  bars.  Anaesthesia  was  maintained  at  2.0  -  2.5% 
halothane,  1   l/min.  The  skull  was  shaved  and  the  scalp  coated  in  iodine 
solution  and  a  layer  of  2%  xylocaine  ointment.  Body  temperature  was 
monitored  using  a  rectal  thermometer  and  maintained  with  a  thermostatic 
heating  pad.  A  small  rostro-caudal  incision  was  made  in  the  scalp  and  the 
underlying connecting tissue removed to expose the surface of the skull.  The 
position  of  bregma  was  taken  and  co-ordinates  for  frontal  cortex  and 
hypothalamus  calculated  in  accordance  with  the  atlas  of  Paxinos  &  Watson 
(1998).  Co-ordinates from bregma were (mm): frontal cortex; AP +3.5, ML ± 1.5 
mm; hypothalamus; AP -1.8 mm, ML ± 0.4 mm.  Two small trephine holes were 
drilled in the skull and the underlying dura mater pierced to prevent damage to 
the  probe.  A  small  screw  was  fixed  into  the  frontal  skull  surface  for  extra 
purchase  of  the  dental  cement  used  to  hold  the  probes  in  place.  The 
hypothalamus  probe  was  lowered  first  (-9.2  mm  from  dura)  and  glued  to  the 
skull  surface  and  screw  using  dental  acrylic.  The  frontal  probe  was  then 
lowered (-4.0 mm from dura) and the minimum amount of dental acrylic required 
to provide rigid support for both probes was added.  The ends of the inlet and 
outlet  tubing  were  sealed  with  bone  wax.  Animals  were  removed  from  the 
frame  and  placed  in  an  incubator  for  recovery.  Once  they  had  regained 
consciousness and were sitting upright, they were put back in their homecages 
(1  per cage) overnight, with free access to food and water.
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Experiments using anaesthetized mice
Adult,  male  NK1  wild  type and  NK1  knockout C57BL/6 x  SvEv mice (25-30g) 
were  anaesthetized  with  5%  halothane  in  70%  nitrogen,  30%  oxygen  mixture 
(1.5 l/min).  They were placed in a stereotaxic frame (Kopf instruments) with the 
head  fixed  in  place  with  a  mouse  adapter.  Anaesthesia  was  maintained 
throughout  at  approximately  1.5%  halothane.  An  incision  was  made  in  the 
scalp to expose the surface of the skull.  The position of bregma was taken and 
probe placement determined relative to bregma using the atlas of Paxinos and 
Watson  (2001).  Co-ordinates  for the frontal  cortex were  (mm):  AP  +2.1,  ML 
±1.0.  A small trephine hole was drilled in the skull and the dura mater pierced 
to prevent damage to the dialysis membrane on entry.  The probe was fitted to 
the holder of the stereotaxic frame and  slowly lowered  into position, (-2.0 mm 
from the surface of the dura).
2.4.  The  detection  assay-  High  Performance  Liquid  Chromatography 
with Electrochemical Detection, (HPLC-ED)
2.4.1.  HPLC
Given the low concentrations of neurotransmitters collected using microdialysis, 
a highly sensitive assay must be available for the technique to be useful.  The 
development  of  liquid  chromatography for  separation  of  catecholamines  was 
developed  over 20  years  ago  (Kissinger et al,  1975;  Refshauge  et al.  1974). 
This  is  used  to  separate  the  components  of  the  dialysate  prior  to  their 
measurement  with  electrochemical  detection.  Separation  is  achieved  by 
exploiting differences in the relative affinities of the constituent compounds to a 
solid,  non-polar  phase  (the  ‘stationary  phase’)  and  a  polar,  liquid  phase  (the 
‘mobile phase’).
In  this  type  of  ‘reversed  phase’  chromatography,  the  stationary  phase  is  a 
hydrocarbon-bonded  surface,  usually  octadecyl  silyl  (ODS)  bonded  to  silica. 
This  particulate  phase  is  densely  packed  within  a  length  of  stainless  steel 
housing  (the  ‘column’).  The  mobile  phase  is  a  pH  buffered  water/methanol 
mixture.  Samples  are  introduced  to  the  flow  of  mobile  phase  and  passed 
through  the  stationary  phase  at  a  constant  flow  rate.  The  most  polar 
components of the sample will elute first, having lowest affinity for the non-polar 
stationary phase.  By adjusting the pH of the buffer, the polarity of compounds
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within the sample can  be adjusted, therefore determining their retention to the 
stationary phase.  Individual  compounds are identified  by their ‘retention  time’
i.e. the time taken to pass through the column and onto the electrochemical cell.
2.4.2.  Electrochemical detection
After passing through the column, the mobile phase undergoes oxidation at an 
electrochemical  cell.  Electrochemical  detection  of  NA  is  possible  since  this 
molecule  is  readily  oxidized.  A  positive  potential  is  applied  to  the  working 
electrode of the cell in contact with the mobile phase.  The release of electrons 
creates  a  current,  which  is  amplified  and  detected.  The  amount  of  current 
produced  is directly proportional to the  number of molecules  of NA present in 
the sample, in accordance with Faraday’s Law.
The  optimum  oxidizing  potential  for  detection  of  NA  was  determined 
systematically.  A  standard  solution  of  NA  was  used  to  determine  the  peak 
heights  produced  by  a  range  of  applied  potentials.  Figure  2.2  shows  the 
resulting  ‘voltammagram’.  A  potential  of  +180mV  was  chosen  as,  at  this 
potential,  NA oxidation  is saturated.  Lower potentials will  result in  incomplete 
oxidation  of NA (and  reduced sensitivity of the system).  Higher potentials are 
unnecessary and will lead to oxidation of additional component of the perfusate, 
producing unwanted noise or peaks on the chromatogram, making separation of 
the NA more difficult.
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Figure  2.2.  Voltammagram  demonstrating  optimum  oxidation  potential  of  NA. 
X-axis  shows  the  oxidation  potential  applied  to  the  working  electrode  of  the 
electrochemical  cell;  Y-axis  shows  the  resulting  peak  height  produced  on  the 
chromatogram.  A standard  NA solution  of  100fmol/50pl  was  used to generate 
all  peaks.  Dotted  line  shows  the  optimum  potential  (+180mV).  See  section
2.4.2.
In addition to measuring the content of NA in microdialysis samples, HPLC-ECD 
was  also  used  to  measure  the  content  of  NA,  5-HT  and  dopamine  in  brain 
tissue.  This  was  to  establish  the  extent  of  monoamine-depleting  chemical 
lesions in experiments using DSP-4 and pCPA pretreatment in rats (Chapters 3-
5).  Some differences exist between the  HPLC-ECD procedures used for these 
tasks,  reflecting  the  approximately  1000-fold  lower  concentration  of  NA  in 
dialysis samples, compared to homogenized brain tissue.
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2.4.3.  Components of the assay system- microdialysis experiments
The HPLC-ECD system consisted of:
•  Shimadzu LC 6A isocratic dual piston pump ESA 582, delivering the mobile 
phase at 1.3 ml/min.
•  Pulse dampener (ESA)
•  50pl  stainless  steel  injection  loop  (Anachem) attached to a  Rheodyn  7125 
injection port.
•  Aquapore guard column (7pM  particle size,  30 x 4.6 mm,  Brownlee,  Perkin 
Elmer),
•  Column  (Hypersil  ODS;  5pM;  250  x  4.6  mm;  Thermo  Hypersil  Ltd.,  UK), 
maintained  at  26  °C  by  a  column  heater  (Jones  Chromatography,  model 
7955).
•  An  analytical  cell:  ESA  5014  electrochemical  cell,  with  two  electrodes  in 
series;  a  conditioning  electrode set at -280mV and  a  measuring  electrode 
set at +180mV.
•  An ESA model 5100A coulometric detector.
•  As Spectraphysics Chromjet integrator.
The  mobile  phase  consisted  of  HPLC  grade  water  with  12%  methanol 
containing  2  mM  octanesulphonic  acid  (OSA),  0.1  M  sodium  dihydrogen 
orthophosphate  (Na^PO^  anhydrous),  0.67mM  ethylenediaminetetraacetic 
acid (EDTA, disodium salt).  The pH of the mobile phase was adjusted to 3.75 
using hydrochloric acid.
2.4.4  Measurement of brain tissue monoamine content.
To determine the effect of pretreatment with either DSP-4 or pCPA, the frontal 
cortex  and  hypothalamus  were  dissected  from  the  rest  of  the  brain  post­
mortem.  These  were  homogenized  in  1 0 pl/mg  perchloric  acid  (HCI04)  and 
centrifuged  at  13  000 x  g for 5  min.  The  supernatant was  injected  manually 
onto a  Hypersil  ODS (5pm  particle size,  250 x 4.6 mm,  Thermo  Hypersil  Ltd., 
UK) HPLC column using a 50 pi stainless steel injection loop (Anachem) and a 
Rheodyn  7125  injection  port.  The system  was fitted  with  an Aquapore guard 
column (7pm,  30 x 4.6 mm,  Brownlee,  Perkin  Elmer) between the sample loop 
and  the  main  column.  Electrochemical  detection  of  NA,  dopamine  and  5-HT
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was  achieved  using  a  BAS  LC4B  detector  and  an  amperometric  cell,  with  a 
Ag/AgCI  reference  electrode  and  a  working  electrode  set  to  an  oxidizing 
potential  of  +750  mV.  The  mobile  phase  consisted  of  water  and  10.5% 
methanol  with  0.1  M  sodium  dihydrogen  orthophosphate  buffer  (Na2HP04i 
anhydrous),  2.8  mM  octanesulphonic  acid  (OSA,  sodium  salt)  and  0.7  pM 
ethylenediaminetetraacetic acid  (EDTA,  disodium salt).  The  mobile  phase was 
adjusted to pH 4 using orthophosphoric acid.
Chromatogram peaks were converted to monoamine concentration (ng/50pl) by 
reference  to  standard  solutions  of  known  monoamine  concentration  (Figure 
2.3).  This was expressed and ng/g of wet tissue.
NA
DA
5-HT
Monoamine calibration curve
200
Cone ng/50ul
Figure  2.3.  Monoamine  calibration  curve.  Standard  solutions  of  NA,  DA  and 
5-HT  were  used  to  calibrate  sample  peak  heights  to  fmoles.  This  was  then 
converted to ng/g of wet tissue.
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2.5.  In vivo microdialysis- experimental procedure
Chapters  3  &  4  describe  experiments  using  in  vivo  microdialysis  in  freely 
moving  rats.  Chapter  6   describes  microdialysis  experiments  performed  on 
anaesthetized  mice.  The  methods  sections  of  the  individual  chapters  give 
details  of  the  precise  drug  treatments  and  experiments  performed.  The 
following descriptions  are of procedures common to all the experiments  using 
microdialysis.
2.5.1.  Freely-moving rats
The morning after surgery, (see 2.3.2) rats were moved (in their homecages) to 
the  experiment  room.  The  sealed  ends  of  the  inlet  and  outlet  tubing  were 
trimmed  and  the  inlet  connected  via  polythene  tubing  to  a  2  ml  syringe 
containing  Ringer’s solution.  The  probes were  perfused  at 2.0  pl/min  using  a 
multi-channel  perfusion  pump  (KD  Scientific).  The  outlet  of the  probes  was 
connected via  2 0  cm  of fine-bore tubing (1 .2   pl/ 1 0 0  mm, to tapered  polythene 
tubes (Hughes & Hughes Ltd.).
Samples were taken  at 20  min  intervals (i.e.  40  jil) and  analyzed  immediately 
for  content  of  NA.  At  least  3  baseline  measurements  (i.e.  1   h)  were  taken 
before administration of drugs.  Drugs given systemically were administered in a 
dissolved in Ringer’s solution.  At the end of the experiment, animals were killed 
by halothane overdose and cervical dislocation. The probes were removed and 
inspected  for  any  damage  or  leaks.  Only  data  from  experiments  where  the 
probes were removed intact were used in the final analysis.
2.5.2.  Anaesthetized mice
Microdialysis probes were perfused at  1.5 pl/min with fractions collected  every 
20  min  (i.e.  30pl  samples).  The  first  three  samples  were  discarded  as  the 
perfusate  equilibrated  with  its  surroundings.  At  least  3  basal  samples  were 
taken before administration of any drugs.  Drugs (given  i.p.) were dissolved  in 
saline and given in a volume of 10ml/kg.  Local  infusion of drugs via the probe 
was  achieved  by switching the  probes’  perfusion  medium  to  Ringer’s  solution 
containing the drug.  At the end of the experiment mice were killed by cervical 
dislocation.  The probes were removed and inspected for any damage or leaks.
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Only data from  experiments where the probes were removed  intact were used 
in the final analysis.
2.6.  Analysis of behaviour
In addition to effects of fluoxetine and NK1  receptor ablation on NA efflux, their 
effects on behaviour were also determined.  The aim was to determine whether 
any of the behavioural effects of either fluoxetine or NK1  receptor ablation could 
be attributed to effects on NA transmission.  A modified version of the light/dark 
exploration  box  was  used.  This  procedure  was  chosen  since  its  principle 
component  is  exposure  to  a  novel,  brightly-lit  arena.  Exposure  to  such 
environments  is  paralleled  by  increased  NA  transmission,  (Aston-Jones  & 
Bloom, 1981; Dailey & Stanford, 1995; McQuade et al, 1999; Mason etal, 1998; 
Rajkowski  et al,  1994).  Moreover,  drugs  that target  central  NA transmission 
(Mason  et  al,  1998;  Haller  et  al,  1997;  Berridge  &  Dunn,  1986;  Stone  et al, 
2004), as well as NA -depleting lesions (Mason & Fibiger 1977; Delina-Stula et 
al,  1984;  Berridge &  Dunn  1990;  Harro  et al,  1995)  modulate the behavioural 
response of rodents to novel environments (see Chapters 5 & 7)
The rationale was to identify behaviours that were modulated by manipulation of 
central NA transmission (using DSP-4 pretreatment in rats and a2-adrenoceptor 
antagonists in mice) then to determine whether these behaviours were sensitive 
to fluoxetine or NK1  receptor ablations.
2.6.1.  The light/dark exploration box
The light/dark exploration test apparatus consists of a  box partitioned  into two 
compartments joined  by  a  small  door (Figure  2.4).  The  larger  compartment 
(normally two  thirds)  is  a  brightly-lit  area,  while  the  remaining  one  third  is  in 
darkness. Rodents find the larger, brighter area more aversive than the smaller, 
dark area.  This is borne out by the finding that when placed in the box, animals 
spend more time in the dark area.  A random behaviour predicts that they would 
spend only on third of the time in the dark area, (reflecting its relative size).
Box design can differ among groups with some using light/dark components of 
equal  size (Griebel  et al,  1994),  while  others  use separate  boxes joined  by a 
connecting tube (Belzung et al,  1987) or a black box in the corner of an open
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field  (Merlo-Pich  et al,  1986).  Other factors which  can  affect behaviour in  the 
test are strain differences (Griebel et al, 2000), prior test experience (Holmes et 
al, 2001), the time of day (Costall et al,  1989) and age of the animals (Hascoet 
etal, 1999)
A  variety  of  parameters  are  measured  in  the  light/dark  exploration  test.  For 
example,  latency to leave the light area after initial  placement there,  number of 
transitions between areas, total time spent in the lit area,  locomotor activity in 
both  areas  and  exploratory  rearing.  Also,  stretch  attend  postures  and 
thigmotaxis  (wall  hugging)  have  been  recorded  in  the  mouse  (Holmes  et  al, 
2001).  Traditionally, the aim of scoring these behaviours is to identify those that 
are sensitive to the anxiolytic effects of drugs.  This has meant that most studies 
measure  a  limited  number of behaviours,  such  as the  total  time  in  the  novel 
arena,  or  the  number  of  transitions  between  arenas,  both  of  which  are 
increased  by  benzodiazepines  and  barbiturates  (Crawley  &  Goodwin,  1980; 
Crawley, 1981).
For  experiments  described  here,  the  light/dark  exploration  box  is  used  in  a 
novel way e.g. is it not used as a screen for ‘anxiolytic’ activity.  Since behaviour 
in this test is paralleled by changes in central NA transmission (see above) it is 
employed  as  an  assay  to  determine  whether  any  behavioural  effects  of 
fluoxetine or NK1  receptor ablation could be due to effects on this transmitter.
For  this  reason,  a  relatively  large  number  or  behavioural  parameters  were 
recorded,  in  addition  to those  normally taken  in  studies  using  the  exploration 
box.  This  approach  was  used  to  increase  the  likelihood  of  identifying  any 
behaviours sensitive to manipulation of central NA transmission, since these will 
not necessarily equate with those that are sensitive to classical anxiolytic drugs.
60Chapter 2: Methods
35
A
35
B
23.3
Figure  2.4.  The  light/dark  exploration  box  (aerial  perspective).  A=  light 
compartment;  B=  dark compartment.  Dimensions  (cm)  shown  are for the  box 
used  with  rats.  See  section  2.7  for  a  description  of  box  dimensions  and 
experimental procedure for the light/dark exploration test in rats and mice.
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A description  of each  of the  behavioural  parameters  is  given  below.  Where 
applicable, these were recorded in both the light and dark compartments.  Time 
measurements were in seconds, unless stated otherwise.
1)  Locomotor activity
Defined  as  the  number  of  line  crosses  made  in  each  compartment.  The 
criterion for one line cross was passing over a line with all four paws.
2)  Number of rears
‘Rears’  were  defined  as  the  animals  lifting  onto  its  back  paws,  with  both 
forepaws off the floor on the box.
3)  Number of grooms
Grooming  behaviour was  recorded  when  the  animal  groomed  any  part  of  its 
body.
4)  Time spent grooming
This was the total time the animal was engaged in grooming (see above).
5)  Number of stretch attend postures  (SAP)
Stretch attend  postures were defined  as  a flat body-  posture with  all four feet 
stationary  and  the  animal  stretching  forwards.  This  behaviour  is  part  of the 
typical behaviour sequelae of rats and  mice when  exploring novel surroundings.
6)  Time to leave light zone
Time to leave was the time taken for the animal to leave the light compartment 
after initially being  placed  there.  The animal  was  considered  to  have  left the 
light compartment when all four paws where in the dark compartment.
7)  Time to return to light zone
Time to return was the time between the animal leaving the light compartment 
when initially placed there, and its first return to the light compartment.  A return 
(both for this behaviour and the total number of returns) was defined as an entry 
into the light compartment with the entire head and ears.
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8)  Number of returns to light
This  was  the  total  number  of  times  the  animal  passed  from  the  dark 
compartment to the light compartment (see above).
9)  Time spent in light zone
This was the total time spent in the light, novel arena.
10)  TZ activity/m  in in light zone
Test Zone  activity/minute’  was  the  number of  line  crosses  per  minute  in  the 
light, novel compartment.
2.7.  Light/dark exploration box-experimental procedure:
2.7.1  Experiments using rats
The rat exploration box (Figure 2.4; length 58.3 cm; width 35 cm; depth 35 cm) 
had a small ‘dark zone’ (length 23.3 cm; 30 lux) and a larger ‘light zone’ (length 
35 cm; 2000 lux).  The walls and floor of the dark zone were black and the walls 
and  floor of the  light zone transparent  Plexiglas  (McQuade  et al,  1999).  The 
floors of both zones were divided into 12cm2 squares (i.e.  6  in the dark zone; 9 
in the light zone) to allow scoring of locomotor activity.  A door (height 12 cm, 
width  8   cm)  separated  the  two  zones,  with  a  removable  partition  to  restrict 
movement between the zones.
Experiments were performed either in the morning (AM group, 09:00-13:30h) or 
the  afternoon,  (14:00-18:30h).  A  modified  light/dark  exploration  box  protocol 
was used.  This involved  an extended  period of testing (120 min) to provide a 
time frame similar to that of the microdialysis experiments of Chapters 3 and 4. 
On the day of testing,  rats were placed  in the dark zone of the exploration box 
with  the  partition  closed.  After a  1   h  habituation  period,  either fluoxetine  or 
vehicle was administered.  Subjects were put back in the dark zone for a further 
90  min.  They were  then  transferred  to  the  novel  compartment  and  the door 
between both compartments was removed.  Subjects were placed in the centre 
of the  novel  compartment,  facing  away from  the  entrance  to  the  dark  arena. 
Behaviour was  recorded  on  VHS  film  for 2  h  for subsequent scoring.  (See 
Figure 2.5.)
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Figure 2.5.  Representation of timing of light/dark exploration box testing using 
rats.  A =  rat placed  in  dark zone of box with  door closed  for 60  min.  B=  rat 
receives fluoxetine or vehicle injection, placed back in dark zone for a further 90 
min.  C= rat transferred to novel, brightly lit zone for 120 min while behaviour in 
both zones recorded for scoring.  Animal had free access to both compartments 
during this period.  D= end of experiment.
2.7.2.  Experiments using mice
Adult, male C57BL/6 mice were used.  The exploration box (length 45 cm; width 
20 cm; depth 25 cm) had a small ‘dark zone’ (length  15 cm; 4 lux) and a larger 
‘light zone’ (length  30 cm;  20 lux).  The walls and floor of the dark zone were 
black  and  the walls  and  floor of the  light zone were white.  The floors  of both 
zones were divided  into 5 x 5 cm  squares (i.e.  12  in  the dark zone;  24 in the 
light zone) to allow scoring of locomotor activity.  A door (height 10.5 cm, width 
6.5  cm)  separated  the  two  zones,  with  a  removable  partition  to  restrict 
movement between the zones.
Mice were placed in the dark zone of the box with the partition in place for 1   h. 
They then  received  either  drug  or vehicle  and  were  placed  back  in  the  dark 
zone for a further 30  min (see  Figure 2.6).  The door separating the light and 
dark zones was  removed  and  mice were transferred  to the centre of the  light 
zone,  facing  away from  the  door.  Their behaviour  recorded  on  VHS  film  for 
later analysis.  At the end of each experiment the mice were removed and killed 
by C02 overdose and cervical dislocation.
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Figure 2.6.  Representation of timing of light dark exploration box testing using 
mice.  A = mouse placed  in dark zone of box with door closed for 60 min.  B= 
mouse receives drug or vehicle injection, placed back in dark zone for a further 
30  min.  C=  mouse  transferred  to  novel,  brightly  lit  zone  for  30  min  while 
behaviour  in  both  zones  recorded  for scoring.  Mice  had  free  access  to  both 
compartments during this period.  D= end of experiment
2.8.  Selective monoamine lesions
Experiment  using  fluoxetine  in  rats  involved  the  use  of monoamine-depleting, 
drug-induced  lesions  (Chapters  3,  4 &  5).  These  depletions were  induced  to 
determine the contribution of NA and 5-HT transmission to the in vivo effects of 
fluoxetine.  Two agents were used: DSP-4 to deplete tissue stores of NA: pCPA 
to deplete tissue stores of 5-HT.  A description of these agents is given below.
2.8.1.  Depletion of NA stores using DSP-4.
The p-chloroalkylamine N-(2-chloroethly)-N-ethyl-2-bromobenzylamine (DSP-4) 
is  a  neurotoxic  compound  that  selectively  destroys  noradrenergic  axon 
terminals.  A single administration of DSP-4 causes a rapid and extensive loss 
of NA terminals in the brain and  periphery (Ross,  1976;  Ross &  Renyi,  1976). 
DSP-4  crosses  the  blood-brain  barrier  and  can  therefore  be  administered  by 
intra-peritoneal  injection.  This  is  an  advantage  over  existing  noradrenergic 
toxins,  such  as  6 -hydroxydopamine,  which  must  be  administered  by  i.c.v. 
infusion.  DSP-4  is  taken  into  NA  neurone  terminals  via  the  NA  transporter 
(Fritschy et al, 1990; Hallman & Jonsson, 1984).
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Once inside the  neurone,  the toxin forms  irreversible covalent bonds with  cell 
proteins  leading  to  degeneration  of  the  axon  terminal  (Dudley  et  al,  1990). 
DSP-4 is typically given in doses of 40-60mg/kg, with larger doses bringing an 
increased  risk of mortality due to loss of noradrenergic axons that control  vital 
functions such as feeding, temperature control and respiration.
2.8.1.1.  Selectivity of lesion
DSP-4  acts  preferentially  on  terminals  originating  from  the  LC.  Loss  of  NA 
axons  after  DSP-4  is  largely  confined  to  areas  innervated  by  neurones 
projecting from this nucleus, (Fritschy & Grzanna,  1989).  Thus, areas such as 
the hypothalamus are less affected by DSP-4.  DSP-4 inhibits uptake of [3H]-NA 
into  cortical  synaptosomes  more  potently  (Ki  ~  180nM)  than  uptake  into 
hypothalamic  synaptosomes  (Ki  ~  460nM),  (Zaczek  et  al  1990).  This  may 
explain  why  LC  efferents  are  more  susceptible  to  the  effects  of  DSP-4. 
Nevertheless,  noradrenergic  terminals  in  the  hypothalamus  are  affected  at 
higher concentrations of DSP-4 (Heal et al, 1993).
Effects of DSP-4 on other cell types are minimal.  Some lesioning of 5-HT axon 
terminals has been  reported,  (Jonsson et al,  1981),  but these are negligible in 
comparison  with  NA  neurones.  Ross  &  Renyi  (1976)  demonstrated  that  high 
doses  of DSP-4 (100mg/kg)  have  no  effect on  uptake  of [3H]-DA  in  slices  of 
striatum or [3H]-5-HT uptake in slices of midbrain.  Also, Harro et al (1992), who 
found  no  changes  in  [14C]-5-HT  or  [14C]-DA  uptake  in  the  frontal  cortex, 
hippocampus,  or striatum.  Some  authors  however,  use  5-HT  uptake  inhibitor 
(Heal  et al,  1993),  to  protect  5-HT  neurones  from  the  effects  of  DSP-4.  No 
significant destruction of DA neurones  has  been  reported.  This  selectivity for 
NA neurones is a definite advantage of DSP-4 over 6 -hydroxydopamine, which 
also affects DA axons.
2.8.1.2.  Assessment of NA lesion
Many different measures are used to assess the extent of NA depletion caused 
by DSP-4.  For example, immunohistochemical staining for NA itself, (Fritschy & 
Grzanna,  1991), for the enzyme marker of noradrenergic neurones, dopamine- 
p-hydroylase  (DpH)  (Fritschy  &  Grzanna,  1991;  Schuerger  et  al  1995), 
measuring  brain  region  tissue  content of NA  by  HPLC,  (Jonsson  et al,  1981;
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Berridge  &  Dunn,  1990;  Finnegan  et  al,  1990;  Cornwell-Jones  et  al,  1992; 
Lategan et al,  1992; Riekkinen et al,  1992;  Heal et al,  1993; Mishra et al,  1994; 
Wiecezorek  &  Romaniuk,  1994;  Wolfman  et al,  1994;  Zagrodzka  et al,  1994; 
Abe et al,  1997; Al-Zahrani  et a/,1997;  Fontana et al,  1999;  Harro et al,  1999; 
Puolivali et al, 2000; Shirokawa et al, 2000; Prieto & Giralt, 2001),  fluorescence 
histochemistry of NA fibres, (Jonsson et al,  1981;), [3H]-NA uptake in vitro brain 
slices or synaptosomes, (Jonsson et al,  1981; Daoust et al,  1990), NA turnover, 
(Logue et al,  1985),  PHj-desipramine binding, (Hallman & Jonsson,  1984) and 
NA efflux by in vivo microdialysis, (Kask et a/,1997;  Hughes & Stanford,  1996, 
1998).  Other less common measurements are weight loss, (Harro et al,  1995) 
and  loss of post-decapitation  reflex,  (Delini-Stula et al,  1984).  The consensus 
reached  from  these  approaches  is  that  DSP-4  causes  a  rapid  and  marked 
destruction of NA axon terminals.
2.8.1.3.  Staining of noradrenergic fibres
Loss  of NA staining  is  observed  within  several  hours after DSP-4 and  loss  of 
DpH staining  is  maximal at 4-5 days (Fritschy et al,  1990).  This  suggests that 
DSP-4 causes axons to loose transmitter rapidly before destroying them. Some 
large,  swollen  axons  remain  visible  after anti-NA and  anti-DpH  staining,  even 
after  the  majority  of  stained  fibres  are  lost.  This  suggests  lesioning  of  the 
terminal field  and therefore accumulation  of these  markers  in  proximal  axons. 
After 7-14 days,  these damaged  axons also degenerate,  leaving  only residual 
axons of normal  appearance.  DpH staining  has shown that noradrenergic cell 
bodies  in  the  LC  are  also  lost  6   months  after  exposure  to  50mg/kg  DSP-4, 
reaching an average of 57% after one year, (Fritschy & Grzanna,  1992).
Regeneration of lesioned axons has  been demonstrated  (Fritschy & Grzanna, 
1992).  Normal  staining  density of  DpH  in  the forebrain  is  restored  one  year 
after DSP-4 administration,  by regeneration  of LC  axons,  despite 50-70%  cell 
loss  in  the  nucleus.  The  regeneration  demonstrates the  homeostatic ability of 
these cells.
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2.8.1.4. Tissue Content of NA
Many  studies  have  measured  brain  tissue  content  of  NA  using  HPLC  with 
electrochemical detection after DSP-4 exposure.  In general, these demonstrate 
a  marked  reduction  in  NA.  Jonsson  et al,  (1981) showed that this effect was 
rapid,  occurring  with  6   h  after exposure,  with  most pronounced  effects  in  the 
cerebral cortex and spinal cord. A marked reduction is seen in the cerebellum, 
also.  Measurements  of  tissue  content  of  NA  provide  an  excellent  means  to 
verify the  extent  of  DSP-4  lesion.  However,  they do  not  provide  information 
about changes in noradrenergic transmission.
2.8.1.5.  Receptor changes
As  one  would  expect,  DSP-4  leads  to  changes  in  noradrenergic  receptor 
populations.  Changes indicative of reduced NA tone are most common, i.e. up- 
regulation  of  postsynaptic  a-  and  p-receptors.  However,  these  changes  are 
generally  dependent  on  the  time  after  lesion.  Binding  studies  also  use 
radioligands,  which  may  or  may  not  be  of  desired  specificity.  For  example, 
Using  [3H]-dihydroalprenalol and  [3H]-WB4101  as ligands for p- and a-receptor 
binding  respectfully,  Jonsson  et al,  (1981)  reported  that  14  days  after  DSP-4 
administration  there  was  an  up-regulation  of  p-adrenoceptor  binding  to 
membranes  derived  from  homogenates  of  rat  cerebral  cortex.  After  16  h,  a 
significant decrease  in  a-adrenoceptor binding was observed.  After 4 and  14 
days  a  small,  insignificant  increase  in  a-receptor  binding  was  observed.  The 
initial decrease in binding was attributed to binding of DSP-4 to a-receptors.
Heal et al, (1993) looked at a2-adrenoceptor binding after DSP-4 administration. 
At 3 days after exposure to the toxin,  a2-adrenoceptor binding was reduced  in 
the cortex,  hippocampus, cerebellum and hypothalamus.  This loss of binding 
was  supposedly  due  to  a  loss  of  presynaptic  a2-adrenoceptors  following 
destruction  of  the  axon  terminals.  Fifteen  days  after  the  lesion  however, 
a2-adrenoceptor binding showed some recovery.
Wolfmann et al, (1994) looked at changes in ai, a2 and p-adrenoceptor binding 
at various times after DSP-4 administration.  They found that cortical ai and a2- 
receptor  binding  was  significantly  increased  7days  after  a  lesion,  but  had
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returned  to  control  values  by  90  and  365  days.  In  contrast,  p-adrenoceptor 
binding was increase at 7 days and 1  year after DSP-4 exposure.
All  experiments  were  carried  out  5  days  after  treatment  with  DSP-4  as  this 
corresponds to the optimum  loss of NA axons terminals  (as shown  by loss of 
DpH  staining,  Fritschy  et  al,  1990),  with  the  no  corresponding  sprouting  of 
surviving terminals.
2.8.1.6.  Protocol of DSP-4 administration
DSP-4 was  dissolved  in  0.9%  saline.  Subjects  received  40mg/kg  (in  1  ml/kg 
solution i.p.) 5 days prior to testing (either microdialysis or exploration box).  For 
dialysis  experiments,  surgery  was  performed  on  day  4  after  DSP-4 
pretreatment.
2.8.2.  Depletion of 5-HT tissue content by pCPA.
2.8.2.1  Mode of action
para-Chlorophenylalanine (pCPA) is an amino acid that potently and selectively 
depletes the brain of 5-HT.  Its effects were first demonstrated in mice, rats and 
dogs (Koe & Weissman,  1966).  Unlike  DSP-4, pCPA is not a  neurotoxin  and 
does  not  destroy  5-HT  axon  terminals  or  cell  bodies.  pCPA  depletes  5-HT 
stores  by  inhibiting  the  enzyme tryptophan  hydroxylase  (Jequier  et al,  1967). 
Tryptophan  hydroxylase  catalyses  the  rate-limiting  step  in  5-HT  biosynthesis, 
converting  the  amino  acid  5-hydroxytryptohan  (5-HTP)  to  the  amine 
5-hydroxtryptamine  (5-HT).  In  vitro,  pCPA  is  a  competitive  inhibitor  of 
tryptophan  hydroxylase.  However,  in  vivo,  pCPA  blocks  the  enzyme 
irreversibly.
pCPA crosses the blood brain barrier and so can be administered systemically. 
4 h after treatment with pCPA,  both competitive and  non-competitive inhibition 
of tryptophan hydroxylase occurs in vivo.  After 2 days, however, the effects are 
irreversible  (Jequier  et  al,  1967).  This  relatively  slow  time  course  of  pCPA 
suggests that an active metabolite is  responsible for its effects.  This could  be 
para-chlorophenylpyruvic acid, which is also an effective 5-HT depletor.  Within 
2 weeks, the effects of pCPA are completely reversed (Koe,  1971). This is due
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to  synthesis  of  new  tryptophan  hydroxylase  enzyme,  its  transport  to  axon 
terminals and restoration of 5-HT synthesis.
2.8.2.2.  Effects on 5-HT transmission
In  addition  to  reducing  the  brain  content,  pCPA  lowers  the  extracellular 
concentration of 5-HT in vivo, as demonstrated  by microdialysis.  O’Connell et 
al,  (1991)  demonstrated  reduced  5-HT  efflux  in  the  frontal  cortex  of  rats 
pretreated  with  a  single  dose  of pCPA (150  mg/kg).  This treatment  reduced 
tissue stores  and  dialysis  concentration  of 5-HT  by around  50%.  The  rise  in 
5-HT efflux following perfusion with a high concentration (100pM) of K+  was also 
diminished suggesting that pCPA reduces impulse-dependent release of 5-HT. 
Pozzi et al, (1999),  reported  reduced tissue stores of 5-HT in the rat prefrontal 
cortex  (87%) after a single oral dose of pPCA (300mg).  This treatment had no 
effect  on  NA  or  dopamine.  These  animals  also  had  a  44%  reduction  in  the 
extracellular concentration of 5-HT.
An  important  finding  with  respect  to  the  present  experiments  is  that  pCPA 
completely prevents the increase in 5-HT efflux produced by systemic fluoxetine 
or citalopram (Pozzi et al, 1999).  The increase in 5-HT efflux after local infusion 
of  both  these  drugs  in  the  frontal  cortex  was  also  attenuated  by  pCPA.  A 
diminished  effect  of fluoxetine  on  5-HT  efflux  was  also  found  by  Yan  et  al, 
(1994).  These  studies  support  the  case  for  using  pCPA  to  determine  the 
contribution of 5-HT transmission on the effects of fluoxetine, both on NA efflux 
and on behaviour.  Since pCPA reduces 5-HT transmission in vivo, this should 
diminish any 5-HT dependent effects of fluoxetine.
2.8.2.3.  Selectivity of depletion
pCPA is  considered  to  be  relatively selective for depletion  of brain  5-HT,  with 
minimal  effects  on  content of NA (Koe  &  Weissman,  1966).  Although  pCPA 
inhibits tyrosine hydroxylase in vitro (with  40 times  lower potency than the NA 
synthesis inhibitor, a-methyltyrosine), this effect is not seen in vivo, after 3 daily 
administrations of 100mg/kg (Koe & Weissman, 1966).
However,  more  recent  work  suggests  that  pCPA  could  have  effects  on  NA 
transmission.  Thus,  Reader  et  al,  (1986)  reported  depletion  of  NA  content
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(-24%)  in  the  cerebral  cortex  of  rats  after  2  daily  treatments  of  pCPA 
(400mg/kg). Geranton et al, (2004) found that NA content in the hypothalamus, 
but  not  the  frontal  cortex,  was  reduced  by  pCPA.  Increased  tyrosine 
hydroxylase activity in the LC of pCPA pretreated rats has also been reported, 
(McRae-Degrueurce  et al,  1982).  An  increase  in  tyrosine  hydroxylase  activity 
indicates elevated synthesis of NA.  This will occur if there is increased demand 
on  NA transmission.  In  support of this,  the  spontaneous firing  activity of  LC 
noradrenergic neurones is also elevated by pCPA (Reader et al,  1986;  Ferron, 
1988).
However,  these  effects  on  NA  transmission  are  not  always  replicated,  since 
Shiekhattar & Aston-Jones, (1993) found no difference in LC firing rate in pCPA 
and  saline  pretreated  rats.  Also,  pCPA  pretreatment  has  no  effect  on 
spontaneous efflux of NA (Geranton et al, 2004;  Mateo et al, 2000; Chapters 3 
& 4), but markedly reduces 5-HT efflux (see above).
2.8.2.4.  Protocol of pCPA administration.
Early  studies  show  that,  for  several  hours  after  pCPA  pretreatment,  brain 
catecholamine  content  is  also  reduced  (Koe  et al,  1971).  However,  after  2-3 
days, effects of tryptophan hydroxylase predominate, with a marked depletion of 
5-HT  stores  (Koe,  1971).  Administration  of  large  does  of  pCPA  can  be 
debilitating,  due  to  effects  in  peripheral  organs.  Therefore,  repeated 
administration  of  smaller  doses  is  desirable.  Experiments  here  used  two 
administrations  of  (250mg/kg)  pCPA:  one  at  48  h  and  one  at  24  h  prior  to 
experimenting.  This protocol will allow enough time for a maximum depletion of 
5-HT biosynthesis, (see above) and minimize adverse effects outside the brain.
2.9.  Statistical analysis
2.9.1.  Analysis of Microdialysis data
Statistical analysis was performed on raw data routinely.  For each experimental 
treatment  group,  the  mean  and  standard  error  of the  mean  were  calculated. 
Net changes  in  NA efflux were  also  calculated.  Thus,  the  mean  of the  last 
three ‘basal’ samples was subtracted from all samples in the time course.  This 
normalizes treatment groups with respect to basal efflux, facilitating drug-effect 
comparisons.
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Analysis  of  all  microdialysis  data  was  performed  using  two-way  analysis  of 
variance (ANOVA) with repeated measure using SPSS version  12.  ‘Time’ was 
used as the ‘within subject’ factor.  The ‘between subjects’ factor depended on 
the  particular  experiment,  details  of which  are  given  in  the  results  chapters. 
Where  necessary,  the  Greenhouse-Geisser  correction  was  applied  to 
compensate  for  violation  of  the  variance-covariance  matrix,  a  condition 
necessary for use of repeated measures ANOVA.
When  comparing  NA efflux after local  infusion of drugs with  basal  efflux,  data 
were  divided  into  time  ‘bins’.  Each  time  bin  was  of  three  consecutive  time 
points,  corresponding  to  either  basal  efflux,  or the  last  three  samples  during 
local drug infusion.  Bin was included as a second ‘within subjects’ factor.
2.9.2.  Analysis of Behavioural data.
Behavioural  data  were  analyzed  for  significance,  using  two-way  or  one-way 
ANOVA.  The methods section of Chapters 5 & 7 give details of the treatment 
groups and comparisons made.  In general, where a main effect was revealed 
by  two-way  ANOVA,  this  would  be  followed  by  one-way  ANOVA.  In  all 
behavioural  experiments,  there were four treatment groups.  Post-Hoc  multiple 
comparisons  using  the  LSD  test  were  performed  to  explore  any  difference 
between individual treatment groups.
Levene’s test of homogeneity of variance was performed routinely.  Where this 
was  significant,  non-parametric  analysis  was  performed  using  the  Mann- 
Whitney test, as stated.  If Levene’s test was significant for a behaviour where 
an  interaction  between  treatments  was  suspected,  two-way  ANOVA  was 
performed on the Iog10 or square-root transformed data, as stated.
Analysis of Covariance (ANCOVA) was performed in all behavioural analysis to 
determine whether any differences in behavioural measures could be explained 
by differences in locomotor activity.  This analysis was also used to disclose any 
effect that may otherwise be obscured by difference in locomotor activity.
For all experiments the criterion for significance was P^0.05
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Chapter 3
Comparison  of  the  Effects  of  Systemic 
Fluoxetine on Noradrenaline Efflux in the Frontal 
Cortex and Hypothalamus of Freely-Moving Rats
3.1.  Introduction
In  vitro  studies  demonstrate  that  fluoxetine  inhibits  reuptake  of  5-HT  with 
greater potency that that of NA (see Chapter 1).  Based on this evidence, the 
possibility that modulation of NA transmission contributes to the clinical effects 
of fluoxetine has been neglected, largely.  However, interpreting effects from in 
vitro studies could  be misleading, as  microdialysis studies in rats demonstrate 
that  fluoxetine  increases  NA  efflux  in  vivo.  If fluoxetine,  and  possibly  other 
SSRIs, augment NA transmission, as well as that of 5-HT, this could contribute 
to their therapeutic mode of action.
When  given  systemically,  reports  of the  effect  of fluoxetine  on  NA efflux  are 
markedly inconsistent.  Several studies report increased  efflux, (Perry & Fuller, 
1997; Gobert et al,  1997; Zhang et al, 2000; Hatanaka et al, 2000; Bymaster et 
al, 2002; Zocchi et al, 2003;  Koch et al,  2004), while others report no change, 
(Page & Abercrombie, 1997; Li et al, 2002; Beyer et al, 2002; Koch et al, 2004). 
Moreover,  even  studies  from  the  same  laboratory  demonstrate  this 
inconsistency, (Li et al, 2002; Perry & Fuller, 1997).  So far, no explanation has 
been given for these disparate findings.
Although the number of studies is limited, fluoxetine’s effects on NA efflux may 
depend  on  brain  region.  Increased  efflux  has  been  reported  in  the  frontal 
cortex,  but  not the  hypothalamus  (Koch  et al,  2004;  but  see  Perry  &  Fuller, 
1997),  hippocampus,  (Page  &  Abercrombie,  1997),  or  nucleus  accumbens, 
(Koch et al, 2004).  However, given that variable effects of fluoxetine have been 
reported  in  the  same  brain  area  (see  Chapter  1:  Table  1.1),  it  is  not  known 
whether these differences reflect region- or drug effect-dependent variation.
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Here,  dual-probe  microdialysis  was  used  to  compare  the  effect  of  systemic 
fluoxetine  in  the  frontal  cortex  and  hypothalamus.  This  is  the  first  time 
fluoxetine’s  effects  on  NA  efflux  have  been  compared  simultaneously  in  two 
brain  regions.  These  were  chosen  because  they  receive  noradrenergic 
innveration  from  different  brainstem  sources:  NA  cells  of  LC  innervate  the 
frontal cortex while the hypothalamus is innervated predominantly by neurones 
projecting from the lateral tegmental nuclei (Moore and Bloom, 1979).
Microdialysis  has  shown  that  noradrenergic  neurones  of  these  areas  can 
respond differently to a drug challenge.  For example,  both systemic and local 
infusion  of  d-amphetamine  increases  NA  efflux  to  a  greater  extent  in  the 
hypothalamus  than  frontal  cortex,  (Geranton  et  al,  2003).  Also,  systemic 
injection  of the  mixed  NA/5-HT  uptake  inhibitor,  sibutramine,  causes  a  rapid 
increase  in  NA efflux of short  duration  in  the  hypothalamus,  but a  sustained 
increase in the frontal  cortex,  (Wortley et al,  1999).  Performing  microdialysis 
simultaneously in these two areas will establish whether fluoxetine’s effects are 
similarly region-dependent.
Fluoxetine  could  increase  NA  efflux  by  increasing  the  extracellular 
concentration  of  5-HT,  thereby  activating  heteroceptors  on  noradrenergic 
neurones  (see  Chapter 1).  To  test  this,  fluoxetine was  administered  to  rats 
pretreated  with  the 5-HT  synthesis  inhibitor,  pCPA (Koe  & Weissman,  1966). 
This  amino  acid  depletes  tissues  stores  of  5-HT  (Reader  et  al,  1986)  and 
lowers  its extracellular concentration,  (O’Connell  et al,  1991;  Yan  et al,  1994; 
Pozzi  et al,  1999).  If the effects of fluoxetine are secondary to an  increase in 
the  extracellular  concentration  of  5-HT,  they  should  be  diminished  in  pCPA 
pretreated rats.  However, if fluoxetine’s effects on NA are due to a direct action 
at noradrenergic neurones, these will occur irrespective of pCPA pretreatment.
Fluoxetine  inhibits  uptake  of  [3H]-NA  into  synaptosomes  from  the  cortical 
(Richelson  &  Pfenning,  1984) and  hypothalamic tissue (Thomas  et al,  1987). 
Therefore,  fluoxetine could  elevate  NA efflux  by inhibiting  its  uptake from  the 
extracellular space.  The NA transporter on noradrenergic axon terminals in the 
most likely site of action.  However,  inhibition  of NA uptake at other sites  is a 
possibility.  For example,  the ability of low concentrations of the NA reuptake
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inhibitor  desipramine  (DMI)  to  inhibit  uptake  of  [3H]-NA  into  rat  cortical 
synaptosomes was diminished  by selective destruction  of noradrenergic axon 
terminals using the neurotoxin, DSP-4 (Hughes & Stanford,  1996).  This agent 
depletes tissue stores of NA, (Johnsson et al,  1981; Fritschy & Grzanna,  1989) 
reduces D|3H staining (Ross, 1976) and reduces the number of NA uptake sites 
labeled by [3H]-DMI (Lee et al,  1982) or [3H]-nisoxetine (Cheetham et al,  1996). 
However, a higher concentration of DMI (50pM) inhibits NA uptake to the same 
extent into synaptosomes from  tissue  of DSP-4  lesioned  and  unlesioned  rats 
(Hughes  &  Stanford,  1996).  This  is  evidence  for a  second,  low-affinity  DMI 
binding site,  which  is  not present on  NA neurones,  since  it is  not affected  by 
DSP-4 pretreatment.
Infact,  inhibition  of  [3H]-NA  uptake  into  cortical  synaptosomes  by  a  low 
concentration  of  fluoxetine  is  greater  in  DSP-4  pretreated  rats,  (Hughes  & 
Stanford,  1996).  This suggests that fluoxetine binds to uptake sites for NA that 
survive a DSP-4 lesion of NA axon terminals.  DSP-4 pretreatment was used 
here to investigate the site of fluoxetine’s effects.  If DSP-4 pretreatment blunts 
the effects of fluoxetine on NA efflux, noradrenergic axon terminals are likely to 
be  the  site  of  its  action.  However,  if fluoxetine  increases  NA  efflux  in  both 
saline and  DSP-4  pretreated  rats,  then  another site,  not  present on  NA axon 
terminals, must mediate its effects.
3.2.  Aims
•  To  determine  whether  systemic  administration  of  fluoxetine  increases 
central  NA  efflux  in  both  the  frontal  cortex  and  hypothalamus  of  freely 
moving rats. (Experiments 1-3.)
•  To  determine  whether  the  effects  of  systemic  fluoxetine  on  NA  efflux 
depend on its effects on 5-HT transmission. (Experiment 2).
•  To  determine whether the  effects  of systemic fluoxetine  on  NA efflux are 
due to an action at NA axon terminals.  (Experiment 3).
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3.3.  Methods
3.3.1  In vivo microdialysis
Experiments  were  performed  on  freely-moving  rats  (240-320g  on  day  of 
surgery).  For  experiments  using  pCPA,  animals  received  either  250  mg/kg 
pCPA i.p. or 1  ml/kg 0.9% saline 48 hours and 24 hours before experimenting. 
A 2 day pretreatment with pCPA was used to allow maximum depletion of brain 
5-HT  (Koe  &  Weissman,  1966).  For  experiments  using  DSP-4,  animals 
received  either  40mg/kg  DSP-4  or  1  ml/kg  0.9%  saline  (i.p.)  5  days  before 
microdialysis.  A  5  day  pretreatment  was  chosen  as  this  corresponds  to  the 
optimum  period  for  loss  of  dopamine-|3-hydroxylase  staining  of  NA  axon 
terminals, but does not allow sufficient time for axonal regeneration, (Fritschy & 
Grzanna, 1990; see Chapter 2).  Rats were implanted with microdialysis probes 
in  both the frontal cortex and hypothalamus on the day before experimenting. 
See  Chapter  2  (section  2.3)  for  details  of  the  probe  design  and  surgical 
procedure.
Fluoxetine was dissolved in distilled H20 to make a 10mg/ml solution.  This was 
administered in a volume of 1  ml/kg (i.e.  10mg/kg). The dose of fluoxetine was 
chosen  based  on  studies  where an  increase  in  NA efflux  has  been  reported 
(see  Chapter  1 ).  Once  basal  efflux  was  established  and  at  least  3  basal 
samples were taken fluoxetine or 1  ml/kg H20  was administered systemically by 
i.p.  injection.  The  last  three  basal  samples  were  designated  T^o  -  To,  with 
injection  of fluoxetine  immediately after To-  Sampling  continued  for a further 
4 h after drug or vehicle injection.  At the end of each experiment animals were 
killed  immediately  by  halothane  overdose  and  cervical  dislocation  and  their 
brains removed for analysis of monoamine content.
•  Experiment 1   compared the effect of systemic fluoxetine with vehicle.
•  Experiment 2 compared the effect of pCPA and saline pretreatment on the 
effect of systemic injection of fluoxetine.
•  Experiment 3 compared the effect of DSP-4 and saline pretreatment on the 
effect of systemic injection of fluoxetine.
76Chapter 3
3.3.2.  Analysis of brain region monoamine content.
To determine the extent of pCPA and DSP-4- induced reduction of brain region 
monoamine  content,  homogenates from  the frontal  cortex  and  hypothalamus 
were  analyzed  for  concentration  of  NA,  DA  and  5-HT,  using  HPLC.  See 
Chapter 2 (section 2.4.4) for a detailed description of the tissue preparation and 
analytical methods used.
3.3.3. Statistical analysis
The  concentration  of  NA  in  the  brain  dialysates  is  expressed  as  fmol/20min 
without correction for probe recovery.  In addition to the raw data, net changes 
were calculated  by subtracting the mean of the last three basal  samples from 
all  samples  in  the  time  course,  for  each  subject.  Raw  and  net  data  for  all 
subjects were  pooled  and  the  mean  and  standard  error of the  mean  (s.e.m.) 
calculated.
All data were analyzed for significance of differences using two-way analysis of 
variance (ANOVA) with  repeated  measures  using  SPSS  7.5.  For experiments 
comparing the effect of systemic fluoxetine with vehicle,  ‘time’ was the ‘within 
subjects’ factor and ‘drug’ (i.e. fluoxetine or vehicle) was the ‘between subjects’ 
factor.
For  microdialysis  experiments  using  DSP-4  or  pCPA,  ‘time’  was  a  ‘within 
subjects’  factor  and  ‘pretreatment’  (i.e.,  saline,  DSP-4,  or  pCPA)  was  a 
‘between  subjects’  factor.  For  all  experiments  using  repeated  measures 
ANOVA,  the  Greenhouse  Geisser  ‘s’  correction  was  performed  where 
Mauchley’s test of sphericity of the variance-covariance matrix was significant.
Brain  region  monoamine  content  was  analyzed  using  two-way  ANOVA  with 
‘pretreatment’  (saline,  pCPA  or  DSP-4)  and  ‘brain  region’  as  main  factors. 
Where  an  effect  of  ‘pretreatment’  was  found,  data  for  frontal  cortex  and 
hypothalamus was analyzed using one-way ANOVA with ‘pretreatment’ as the 
main factor.
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3.4.  Results
3.4.1.  Experiment 1: Effect of systemic fluoxetine on NA efflux 
Frontal Cortex
There  was  no  difference  in  basal  efflux  of  animals  receiving  vehicle  or 
fluoxetine,  (T.40-T0;  fmoles/20min:  vehicle,  15.5±2.6;  fluoxetine,  14.3±1.5). 
Fluoxetine  increased  NA  efflux  relative  to  vehicle  (Figure  3.1A):  whereas 
vehicle  injection  did  not  affect  efflux,  fluoxetine  increased  it  (T.40-T180:  main 
effect of ‘time’: F4i7 o =3.8, P=0.01; main effect of ‘drug’: Fi,i8= 5.0, P=0.04; ‘drug’ 
x ‘time’ interaction: F4i7o= 2.9, P= 0.03).  At each hour after injection, NA efflux 
was greater in animals given fluoxetine, (Table 1.1).  Analysis of all time points 
after  injection  (T20-T240)  revealed  a  main  effect  of  ‘drug’  (Fi,i7=7.3,  P=0.02). 
Analysis of net changes in NA efflux revealed a similar pattern of results as the 
raw data, (Figure 3.2A and Table 3.2).
Hypothalamus
There  was  no  difference  in  basal  efflux  of  animals  receiving  vehicle  or 
fluoxetine  (vehicle,  15.0±0.8;  fluoxetine,  17.9±1.4).  Injection  of  fluoxetine 
caused a transient increase in NA efflux, relative to vehicle (Figure 3.1 B). Thus, 
NA  efflux was  influenced  by  an  interaction  between  main  factors  ‘drug’  and 
‘time’,  over  the  first  8  time  points  only  (T^0-Tioo‘  ‘drug’  x  ‘time’  interaction 
F3)4 4=3.0,  P=0.05:  main  effect  of  ‘time’  F3i44=6.4,  P=0.001,  Figure  3.1 B). 
Analysis  of  all  time  points  after  injection  revealed  a  main  effect  of  ‘drug’, 
(F1,15=4 .6 ,  P=0.05)  However,  comparison  of  time  points  T120-T240  (/-e.  those 
time  points  after  the  period  where  a  ‘drug’  x  ‘time’  interaction  was  found) 
revealed no difference in NA efflux between fluoxetine and vehicle groups (i.e. 
no main effect of ‘drug’, Fi,i5=3.5, P=0.08). Also, comparison of each hour after 
injection  revealed  no  differences  in  NA  efflux  due  to  drug  treatment,  (Table
3.1.)
Analysis of net changes revealed the same transient effects of fluoxetine in the 
hypothalamus  (Figure  3.2B).  Again,  comparison  of  time  points  T120-T240 
revealed no difference in NA efflux between fluoxetine and vehicle groups (i.e. 
no  main  effect  of  ‘drug’,  Fi i5=1.7,  P=0.2).  Comparison  of  each  hour  after 
injection  revealed  that  NA  efflux  was  greater  in  fluoxetine  treated  animals 
during the first hour after injection, only (Table 3.2.).
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Figure  3.1.  Effect of systemic fluoxetine or vehicle on  NA efflux  in  A) frontal 
cortex and  B) hypothalamus of freely moving  rats.  Plots show mean  efflux ± 
s.e.m.  Arrows  indicate time of fluoxetine/vehicle  injection.  n=8-12  per group. 
See section 3.4.1. for details of statistical analysis.
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Frontal Cortex  Hypothalamus
T20-T60 Fi,i8=6.7 P=0.02 Fi,i6=3.3 P=  0.09
T80-T120 F1,18=6.7 P=0.02 F1,18=2.6 P=0.13
T140-T180 F1,18=4.3 P=0.05 Fi,i8=1 -7 P=  0.21
T200“T  240 F1,17=4.6 P=0.05 Fi,15=4.1 P=0.06
Table  3.1.  Statistics  generated from  two-way ANOVA comparing  raw data  of 
NA efflux at each hour after injection of fluoxetine or vehicle in the frontal cortex 
and hypothalamus, (main factor = ‘drug treatment’).  Significant differences are 
in bold. N=8-12.  See Figure 3.1.
Frontal cortex  Hypothalamus
T20-T60 Fi,18=5.4 P=0.03 Fi, 16=6.5 P=  0.02
T80-T120 F1,18=3.9 P=0.06 Fi, 16=3.0 P=0.10
T  140"T  180 Fi,18=3.1 P=0.09 Fi,i6 = 1 -0 P=0.30
T200-T240 Fi ,17=4.5 P=0.05 Fi, 15=2.2 P=  0.20
Table  3.2.  Statistics  generated  from  two-way ANOVA  comparing  net data  of 
NA efflux at each hour after injection of fluoxetine or vehicle in the frontal cortex 
and hypothalamus, (main factor = ‘drug treatment’).  Significant differences are 
in bold. N=8-12.  See Figure 3.2.
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Figure 3.2. Effect of systemic fluoxetine and vehicle on net changes in efflux in 
A) frontal cortex and B) hypothalamus of freely moving rats.  Plots show mean 
change in efflux  ± s.e.m.  n=8-12 per group.  Arrows indicate time of fluoxetine 
or vehicle injection. See section 3.4.1 for details of statistical analysis.
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3.4.2.  Experiment 2: Effect of pCPA pretreatment on the action of 
fluoxetine on NA efflux
3.4.2.1.  Depletion of brain 5-HT content by pCPA.
pCPA  pretreatment  decreased  5-HT  content  in  the  frontal  cortex  (-72%, 
Fi,n=8.7,  P=0.02)  and  hypothalamus  (-90%,  Fi,n=  190,  P0.001) compared 
with  saline  pretreated  animals.  The  tissue  concentration  of  NA  in  the 
hypothalamus  was  also  reduced  by  pCPA  (-45%,  Fifn=15,  P=0.03).  The 
concentration  of NA in the frontal  cortex,  as well  as that of DA in  both  brain 
regions, was unchanged by pCPA.  Table 3.3.
Frontal Co rtex  Hypothalam us
SAL pCPA SAL pCPA
NA 472±72 292±19 3060±314 1691±153*
DA 376±861 155±2 719±284 375±73
5-HT 307±48 86±85* 789±48 78±19**
Table 3.3.  Monoamine  content  in  frontal  cortex  and  hypothalamus  of saline 
and  pCPA-pretreated  rats  receiving  systemic fluoxetine.  Table  shows  mean 
content (ng/g wet tissue weight) ± s.e.m.  n=7.  Significant differences  are  in 
bold. *P<0.05; **P<0.005.
3.4.2.2.  Effect of systemic fluoxetine on NA efflux in saline and pCPA 
pretreated rats.
Frontal cortex
There was no difference in basal NA efflux of saline and pCPA pretreated rats 
(fmoles/20min  saline,  31.2±2.0;  pCPA,  28.1±0.3).  Unlike  Experiment  1, 
fluoxetine did  not increase  NA efflux  in  either saline or pCPA  pretreated  rats 
(Figure  3.3A).  Also,  NA  efflux  did  not  differ  in  saline  and  pCPA  pretreated 
animals  at  any  hour  injection  of fluoxetine,  (Table  3.4).  Analysis  of all  time 
points  revealed  a  main  effect of ‘time’  (F14)112=3.7,  P<0.001),  but  no  effect of 
‘pretreatment’  and  no  ‘time’  x  ‘pretreatment’  interaction.  Analysis  of  net 
changes  in  NA  efflux  gave  a  similar pattern  of results,  with  a  main  effect of 
‘time’  (T.40-T240:  Fi4,i26=2.2,  P=0.01),  but  no  effect  of  ‘pretreatment’,  and  no 
‘time’ x ‘pretreatment’ interaction.
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Hypothalamus
There was no difference in basal NA efflux of saline and pCPA pretreated rats 
(fmoles/20min;  saline,  23.5±1.7;  pCPA,  26.3±1.4).  Unlike  the  previous 
experiment,  fluoxetine  injection  had  no  effect on  NA efflux  in  either saline or 
pCPA-pretreated  rats  (Figure  3.3B).  Thus,  there  were  no  effects  of  ‘time’, 
‘pretreatment’  and  no  ‘time’  x  ‘pretreatment’  interaction  (T.40  -  T240,  Figure 
3.3B).  NA efflux was not different in saline or pCPA pretreated rats at any hour 
after  fluoxetine  injection  (Table 3.4).  Likewise,  analysis  of  net  changes  also 
revealed  no effect of fluoxetine in either group of rats,  i.e.  no effects of ‘time’, 
‘pretreatment’ and no ‘time’ x pretreatment interaction.
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Figure 3.3.  Comparison of systemic administration of fluoxetine on NA efflux in 
saline  and  pCPA-pretreated  rats  in  A) frontal  cortex  B)  hypothalamus.  Plots 
show mean NA efflux ± s.e.m. N=7.  Arrow indicates time of fluoxetine injection. 
See section 3.4.2. and Table 3.4 for details of statistical analysis.
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Frontal cortex Hypothalamus
T20-T60 Fi h=0.27, P=0.62 F^^l.0, P=0.33
T80-T120 Fi,h=0.71, P=0.80 Fi.1^0.7, P=0.80
T140-T-I80 Fi,i2=0.11, P=0.75 Fi,n=0.7, P=0.80
T200-T240 Fi,io=0.14, P=  0.72 Fi,8=0.1, P=0.77
Table 3.4. Statistics generated from two-way ANOVA of raw data, showing no 
difference  in  NA  efflux  in  either frontal  cortex  or  hypothalamus  of pCPA and 
saline pretreatment animals, at any hour after injection of fluoxetine. n=7 (main 
factor -  pretreatment’).
3.4.3  Experiment  3:  Effect  of  DSP-4  pretreatment  on  the  action  of 
systemic fluoxetine.
3.4.3.1.  Depletion of brain NA content by DSP-4
DSP-4 reduced the tissue content of NA in the frontal cortex (-65%, Fi n=5.2, 
P=0.05) and  hypothalamus,  (-47%,  Fi,n=4.9,  P=0.05).  DSP-4 did  not affect 
tissue content of DA or 5-HT in either brain region, (Table 3.5.).
Frontal C ortex  Hypothalamus
SAL DSP-4 SAL DSP-4
NA 749±179 261±115* 1531±148 817±388*
DA 292±91 183±58 895±38 8803±250
5-HT 686±60 373±241 748±595 167±167
Table  3.5.  Monoamine  content  in  frontal  cortex  and  hypothalamus  of saline 
and  DSP-4-pretreated  rats  receiving  systemic fluoxetine.  Values  show mean 
content (ng/g wet tissue weight) ± s.e.m.  n=8 .  Significant differences  are in 
bold. *P<0.05; main factor = ‘pretreatment’
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3.4.3.2.  Effect of systemic fluoxetine in DSP-4 and saline pretreated rats 
Frontal Cortex
Basal  efflux  of  NA  was  greater  in  DSP-4  pretreated  animals  than  saline 
pretreated controls, (T.40-Tofmoles/20min: saline, 7.85 ± 0.5; DSP-4, 17.29±1.0: 
main  effect of  ‘pretreatment’;  F1,12=13.1,  P=0.003  (Figure 3.4A).  Fluoxetine 
had  no effect on saline pretreated  rats,  but transiently increased  NA efflux in 
DSP-4 pretreated rats during the first hour after injection, but thereafter caused 
a decrease,  relative to saline basal efflux.  Thus, there was an effect of ‘time’ 
(F k 168=2.4,  P=0.004),  ‘pretreatment’  (Fi,12=6 .8 ,  P=0.02)  and  a  ‘time’  x 
‘pretreatment’  interaction  (Fi4,i68=4.0,  P<0.001)  when  all  time  points  were 
analyzed  (T_40-T24o).  Table  3.6 shows  statistical  comparison  between  saline 
and DSP-4 pretreated rats for each hour after in injection of fluoxetine.
Analysis of net changes  in  efflux also revealed that NA efflux was different in 
DSP-4 and saline pretreated animals each  hour after fluoxetine administration 
(Table 3.7).  In DSP-4 pretreated animals, NA efflux was greater during the first 
hour  after  fluoxetine  was  given.  For  the  subsequent  3  hours  of  dialysis, 
however,  NA  efflux was  reduced  in  DSP-4  pretreated  animals  (Figure  3.5A). 
Analysis of all time points revealed a main effect of time (Fi4ii96=2.4, P=0.004), 
and a ‘time’ x ‘pretreatment’  interaction (Fi4)i68=4.0,  P<0.001),  but no effect of 
‘pretreatment’ (Fi,i2=3.6, P=0.08, T^0 - T24o,).
Hypothalamus
Basal NA efflux appeared greater in DSP-4 pretreated animals, (fmoles/20min, 
saline,  10.14±1.4;  DSP-4,  18.57±0.3),  but this failed to  reach significance (no 
effect of ‘pretreatment’,  Fi,i2=3.2, P=0.1).  However, extending the comparison 
from  T^0-T40  revealed  greater  NA  efflux  in  DSP-4-pretreated  rats  (Fi,i2=5.7; 
P=0.03.  Figure  3.4B).  Fluoxetine  injection  had  no  effect  in  saline  pretreated 
rats,  but decreased  NA efflux in the DSP-4 pretreated  group.  Analysis of raw 
data  revealed  an  effect  of  ‘time’  (Fi4ii68=3.5,  P<0.001),  and  a  ‘time’  x 
‘pretreatment’  interaction (Fi4ii68=1.99, P=0.02),  but no effect of ‘pretreatment’ 
(T^o-T24o :  Fi4,i68=1.3,  P=0.3).  There  was  no  difference  in  NA  efflux  between 
DSP-4 and saline pretreated animals during any of the 4 hours after fluoxetine 
administration (Table 3.6).
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Analysis  of  net  changes  also  revealed  a  reduction  in  NA  efflux  in  DSP-4 
pretreated  animals  given  fluoxetine.  (Figure  3.5B).  Thus,  there  was  a  main 
effect  of  ‘time’,  (T-40-T240: Fi4> i68=3.5,  P<0.001)  and  a  ‘time’  x  ‘pretreatment’ 
interaction, (F14168=2.0, P=0.02),  but no effect of ‘pretreatment’. There was no 
difference  in  NA efflux  between  saline and  DSP-4  pretreated  animals for the 
first hour after acute fluoxetine.  During the second  hour,  (T8o-Ti2o),  NA efflux 
was significantly reduced  in the DSP-4 group only.  During the third  hour, this 
just missed the criterion for significance. However, reduced NA efflux in DSP-4 
pretreated rats was restored during the final hour after fluoxetine injection, (see 
Table 3.7).
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Figure 3.4. Comparison of raw data on the effects of systemic administration of 
fluoxetine on NA efflux in saline and DSP-4 pretreated freely moving rats in A) 
frontal  cortex  B)  hypothalamus.  N=8 .  Arrow  indicates  injection  of fluoxetine. 
See section 3.4.3.2 and Table 3.6 for details of statistical analysis.Chapter 3
Frontal cortex  Hypothalamus
t 20-t 60 Fi,12=16-3, P=0.002 Fi, 12-3.7, P=0.10
T80-T-I20 Fi,i2=1-9. P=0.19 Fi,i2=0.009, P=0.93
T140-T180 Fi,i2=0.03,
C
O
C
O
0
4 Fi, 12=0.03, P=0.86
T200-T240 F i ii 2=2.3, P=0.16 Fi,12=0.18, P=0.68
Table 3.6. Statistics generated from two-way ANOVA using raw data, showing 
effect of  DSP-4  pretreatment on  NA  efflux  in  frontal  cortex  or  hypothalamus 
animals,  at  each  hour  after  systemic  fluoxetine  injection  (main  factor 
-pretreatment’).  Significant differences are in bold. N=8 .
Frontal cortex___________ Hypothalamus
Tzo-Teo Fi,i2=5.1, P=0.04 Fi.i2-0.03, P=0.86
T80-Tl20 Fi.i2=6.4, P=0.03 Fi ,12=5.1, P=0.04
T 140-T180 Fi,i2=9-5, P=0.01 Fi,i2=4.4. P=  0.06
T200"T  240 Fi ,12=5.5, P=0.04 Fi ,12=7.3, P=0.02
Table 3.7. Statistics generated from two-way ANOVA using net data, showing 
effect of  DSP-4  pretreatment  on  NA  efflux  in  frontal  cortex  or hypothalamus 
animals,  at  each  hour  after  systemic  fluoxetine  injection  (main  factor 
-pretreatment’).  Significant differences are in bold. N= 8
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Figure 3.5.  Net change in  NA efflux in A) frontal cortex and B) hypothalamus 
in  DSP-4 and  saline pretreated  rats,  in  response to systemic fluoxetine.  N=8 . 
Arrow indicates  injection  of fluoxetine.  See section  3.4.3.2 and  Table 3.7 for 
details of statistical analysis.
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3.5.  Discussion
The objectives of experiments described in this chapter were:  1) to determine if 
fluoxetine’s effects on central  NA efflux depend on brain region,  by comparing 
them simultaneously in the rat frontal cortex and hypothalamus;  2 ) to establish 
whether  these  effects  are  dependent  on  intact  5-HT  transmission;  3)  to 
determine if any fluoxetine-induced changes in NA efflux are due to an action at 
noradrenergic axon terminals.
In Experiment 1   systemic injection of fluoxetine increased NA efflux in both the 
frontal  cortex and  hypothalamus,  compared  to  vehicle  injection.  However,  a 
regional  difference was apparent: the effect in the frontal  cortex lasted  longer 
than that in the hypothalamus.  In  the frontal  cortex,  NA efflux after fluoxetine 
injection was greater than  in vehicle treated  rats for the remaining  4 hours  of 
the experiment.  In  contrast,  in the hypothalamus this difference lasted for 100 
min only (i.e. until T120, Figures 3.1 B and 3.2B).
This  pattern  of  results  is  strikingly  similar  to  that  reported  for  the  mixed 
NA/5-HTuptake  inhibitor,  sibutramine.  Using  single-probe  microdialysis  in 
separate groups of freely-moving rats, Wortley et al, (1999) reported increased 
NA efflux in the frontal  cortex and  hypothalamus after systemic administration 
of  sibutramine.  However,  the  effect  in  the  frontal  cortex  was  sustained 
throughout the experiment,  whereas  that  in  the  hypothalamus was  of shorter 
duration.  The  different  response  to  sibutramine  and  fluoxetine  could  reflect 
differences  in  regulation  of  NA  transmission  in  these  brain  regions.  For 
example,  there  is  evidence  that the  NA transporter in  the frontal  cortex  and 
hypothalamus  differs  with  respect  to  binding  of  DSP-4,  the  catecholamine 
uptake inhibitor, mazindol, as well as NA itself (Zaczek et al,  1990).  Also, the 
proportion  of  pre-  to  postsynaptic  a2-adrenoceptors  is  greater  in  the 
hypothalamus  (Heal  et  al,  1993),  which  could  result  in  greater  feedback 
inhibition of NA in this brain region.  Consistent with this, Wortley et al, (1999) 
reported  a  greater  potentiation  of  the  effect  of  sibutramine  by  the 
a2-adrenoceptor  antagonist,  RX821002,  in  the  hypothalamus  than  frontal 
cortex.  This regional difference in the effects of RX821002 was seen when  it
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was administered  systemically, or infused  locally.  Regional differences  in the 
NA response to locally applied fluoxetine are investigated in Chapter 4.
In contrast to the results described above, fluoxetine did not increase NA efflux 
in saline-pretreated animals in Experiments 2 and 3.  This adds to the empirical 
evidence that fluoxetine has a variable, unpredictable effect on NA efflux when 
given acutely by the systemic route.  Previous microdialysis studies have found 
either  increased  NA  efflux,  (e.g.,  Jordan  et  al,  1994;  Gobert  et  al,  1997; 
Hatanaka et al, 2000; Koch et al, 2004; Perry & Fuller,  1997) or no effect (Li et 
al,  2002;  Beyer  et  al,  2002)  of fluoxetine.  Even  studies  of the  same  brain 
region, or from the same laboratory, (Perry & Fuller, 1997; Li et al, 2002) report 
this  variability,  which  has  never  been  formally  acknowledged.  Thus,  the 
variable effects of fluoxetine in the present experiments reflect the inconsistent 
reports  in  the  literature.  However,  this  is  the  first  time  a  variable  effect  of 
fluoxetine of NA efflux has been explicitly noted within a single study.
The  variable  NA  response  to  fluoxetine  bears  striking  similarity  to  the 
inconsistent  reports  gathered  from  the  much  larger  body  of  evidence  from 
microdialysis  studies  of  the  effects  of  SSRIs  on  5-HT  efflux.  These  too 
demonstrate either increased  (Jordan  et al,  1994;  Hajos-Korcsok et al,  2000; 
Gobert & Millan,  1999) or unchanged (Hervas & Artigas,  1998; Gartside et al, 
1995,  1999;  Sharp  et  al,  1997;  Invemizzi  et  al,  1992)  5-HT  efflux  after 
administration of SSRIs.  This effect is true also of the tricyclic antidepressant 
and  preferential  5-HT  uptake  inhibitor,  clomipramine  (Adell  &  Artigas,  1991). 
This  variable  effect  of acute  SSRIs  is  now  known  to  be  due  to  activation  of 
autoreceptors  that  diminish  cell  firing  and  release  of  5-HT.  Thus,  co­
administration of SSRIs with 5-HTia antagonists,  (e.g. WAY100635,  Hervas & 
Artigas,  1998; Romero et al,  1996; Gartside et al,  1995) consistently increases
5-HT efflux in the frontal cortex (for reviews see Hjorth et al, 2000; Kinney et al, 
2000; Romero etal, 1996; Gardier ef al, 1996).
Interestingly, a variable response to systemic administration of uptake inhibitors 
extends  to  drugs  regarded  as  selective  for the  NA transporter:  for  instance,
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desipramine (DMI) either increases (Mateo et al,  1998; Yan et al,  1993) or has 
no effect (Nutt et al, 1997) on NA efflux when given systemically.  This is due to 
activation  of  somatodendritic  and  terminal  a2-adrenoceptors  (for  review  see 
Invernizzi  &  Garattini,  2004).  Thus,  co-administration  of  DMI  with 
a2-adrenoceptor antagonists (e.g. idazoxan) produces a greater elevation of NA 
efflux than DMI alone (Dennis et al, 1987; Thomas & Holman, 1991; Nutt et al, 
1997).  Also,  the  a2-adrenoceptor  antagonist,  atipamezole,  potentiates  the 
increase in  NA efflux produced  by administration of sibutramine  in  the frontal 
cortex and hypothalamus (Wortley et al,  1999).  A similar mechanism appears 
to constrain the effect of systemic fluoxetine on  NA efflux since,  in the frontal 
cortex,  this  is  potentiated  by  pretreatment  with  atipamezole  (Gobert  et  al, 
1997).
The  effectiveness  of a2-adrenoceptor  antagonists  to  potentiate  the  effects  of 
NA  reuptake  inhibitors  is  due  to  increased  activation  of  autoreceptors  when 
clearance  of  NA  is  reduced.  The  NA  transporter  removes  NA  from  the 
extracellular space and  normally renders  a2-adrenoceptors  inactive,  since the 
receptors seem to  be located  beyond the site of release and  are not normally 
exposed  to  NA  (Callado  &  Stamford  2000).  When  uptake  is  blocked  (or 
overwhelmed  during  periods  of  high  NA  release  rate),  a2-adrenoceptors  are 
activated,  rendering  the  extracellular  concentration  of  NA  sensitive  to 
a2-adrenoceptor antagonists.  Presumably, whether or not there is an increase 
in NA efflux after administration of fluoxetine would depend on the tonic rate of 
NA release.  Therefore, the neurochemical status of the animals at the time of 
the experiment would influence the drug’s effect.
Given  that  5-HT  modulates  NA  transmission  in  vivo  (see  Chapter  1),  it  is 
possible that fluoxetine’s  effects on  NA are secondary to  its ability to  elevate 
the concentration of extracellular 5-HT.  To investigate this, Experiment 2 used 
pCPA pretreatment to determine whether fluoxetine increases NA efflux in rats 
with  diminished  5-HT  transmission.  However,  given  the  variable  nature  of 
fluoxetine’s effects on NA efflux (see above) the contribution of 5-HT could not 
be  determined.  No  effect  of fluoxetine  was  seen  in  either  saline  or  pCPA 
pretreated rats.
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Nevertheless, an interesting observation from  Experiment 2 was the reduction 
in  hypothalamic NA whole tissue content, as well as that of 5-HT.  This effect 
has  been  reported  previously (Reader et al,  1986;  Geranton  et al,  2004) and 
could be due to depletion of NA stores in this brain region following loss of an 
inhibitory  5-HT-mediated  input.  The dose of pCPA used  here depletes tissue 
stores  of  5-HT  and  reduces  its  extracellular  concentration  (O’Connell  et  al, 
1991; Yan et al,  1994;  Pozzi et al,  1999).  Despite this reduction in tissue NA 
stores,  NA  efflux  was  not  changed  by  pCPA,  in  either  brain  region.  Other 
studies  have  also  shown  that  pCPA  pretreatment  does  not  change 
spontaneous efflux of NA (Geranton et al, 2004; Mateo et al, 2000).  Yet, this is 
at odds with experiments measuring the firing rate of LC neurones, (Reader et 
al,  1986;  Ferron,  1988;  but  see:  Shiekhattar  &  Aston-Jones  1993)  and  LC 
tyrosine  hydroxylase activity (McRae-Degrueurce et al,  1982), which are  both 
increased by pCPA pretreatment.  These parameters were not measured in the 
present  study,  but  the  results  here  add  to  the  body  of  evidence  that pCPA 
pretreatment  does  not  change  spontaneous  efflux  of  NA.  Therefore,  studies 
using  pCPA demonstrate  dissociation  between  the  rate  of  NA synthesis,  LC 
firing rate and efflux at axon terminals.
Experiment  3  compared  the  effect  of  systemic  fluoxetine  in  animals  with  a 
partial  lesion  of  NA  axon  terminals,  induced  by  DSP-4.  This  neurotoxin 
selectively  destroys  NA  axon  terminals,  but  leaves  cell  bodies  intact  (Ross, 
1976;  Fritschy &  Grzanna,  1989).  The  principal  finding  from  this  experiment 
was that fluoxetine markedly reduced  NA efflux in  both the frontal  cortex and 
hypothalamus of DSP-4 pretreated rats only.  A reduction in NA efflux will occur 
following  an  increase  in  its  reuptake  and/or a  reduction  it  its  rate  of release. 
Reduced NA release is more likely, since fluoxetine binds to the NA transporter 
and  inhibits  uptake of [3H]-NA into both  cortical  (Richelson  &  Pfenning,  1984) 
and  hypothalamic (Thomas et al,  1987) synaptosomes (reviewed  by Stanford, 
1996).
The site of action of fluoxetine that leads to decreased  NA release cannot be 
determined  with  any  certainty,  since  it  was  administered  systemically. 
However,  it  is  unlikely to  be a  target on  NA  axon  terminals,  since  these  areChapter 3
extensively lesioned  by  DSP-4.  An  effect on  NA  neurones,  upstream  of the 
terminals,  is  more  likely  to  mediate  the  reduction  in  NA  efflux.  This  could 
involve activation of somatodendritic 0 2-adrenoceptors on  NA neurones. Thus, 
if fluoxetine increases the extracellular concentration of NA in the LC,  as well 
as  frontal  cortex  and  hypothalamus,  this  would  decrease  LC  cell  firing  and 
release  (Van  Gaalen  et  al,  1997).  In  support  of  this,  Mateo  et  al,  (1998) 
reported increased NA efflux in the LC, and simultaneously decreased efflux in 
the  cingulate  cortex  after systemic administration  of a  low dose  (1 mg/kg)  of 
DMI.  The  reduction  of  NA  efflux  in  the  cortex  was  prevented  by  intra-LC 
infusion of RX821002, demonstrating an a2-adrenoceptor-mediated inhibition of 
NA release.
Therefore,  the  effects  of  fluoxetine  administration  on  NA  transmission  are 
similar to the known  effects of NA uptake-inhibiting  drugs  and  are consistent 
with the known regulatory process of NA neurones (Cedarbaum & Aghajanian, 
1976).  Experiments here also suggest that the hypothalamic  NA innervation, 
from cells of the lateral tegmental brainstem  nuclei, possess similar regulatory 
processes.  If this  is the case,  local  administration  of fluoxetine to the frontal 
cortex and hypothalamus should increase NA efflux since the inhibitory effects 
upstream of axon terminals will not be activated.  This prediction was tested in 
the next experiments (Chapter 4).
An important finding from  experiments using  DSP-4 was the marked increase 
in spontaneous NA efflux in both the frontal cortex and hypothalamus.  Despite 
reduced  tissue  content of  NA  in  the frontal  cortex  (-67%)  and  hypothalamus 
(-42%),  NA  efflux  was  elevated  approximately  2-fold  in  both  these  areas. 
There are few studies of NA efflux in DSP-4 pretreated animals.  The majority 
of studies  using this toxin  use measurements of whole tissue stores of NA or 
immunohistochemical measurements as indicators of a lesion (see Chapter 1). 
However,  Hughes & Stanford (1996,  1998) similarly reported a 2-fold increase 
in  NA  efflux,  in  the  frontal  cortex  of  rats,  using  the  same  protocol  for 
administration of DSP-4 as that used here.  This increase is thought to reflect a 
compensatory increased firing rate of surviving NA neurones, coupled with the 
loss  of  NA  uptake  sites  on  lesioned  axon  terminals.  Studies  by  Kask  et al,
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(1997),  using  DSP-4,  and  Abercrombie  &  Zigmond,  (1989)  using
6 -hydroxydopamine (6 -OHDA), reported no decrease in NA efflux in the frontal 
cortex  or  hippocampus  respectively,  despite  both  these  treatments  causing 
more than 50% reduction in tissue content of NA.  The above studies, and the 
results presented here, demonstrate that, although tissue content of transmitter 
may be a useful  indication of the extent of a neurotoxin lesion, caution should 
be taken when extrapolating this to effects on neurotransmission, which will be 
determined by the extracellular concentration of transmitter.
It  should  be  noted  that  considerable  variation  was  found  in  baseline  (saline 
pretreated) tissue concentrations of NA and 5-HT between experiments 2 and 3 
(see Tables  3.3  and  3.5).  The  precise  explanation  for this wide variability is 
unclear.  Preparation  of  samples  for  analysis  by  HPLC-ED  requires 
homogenization,  centrifugation  and  extraction  of  the  supernatant  fluid.  This 
extraction was performed once only for each sample.  It may be that if several 
repetitions  of  the  extraction  were  performed,  the  values  for  monoamine 
concentration  would  be  more  consistent  across  experiments.  Additionally, 
unavoidable  discrepancies  in  the  time  between  collection  of  samples  and 
analysis  may  have  contributed  to this  variability.  Similar discrepancies  were 
noted  between  basal  concentrations  of  tissue  monoamine  between 
experiments (see Chapters 4 and 5).  However, brain tissue concentration was 
used solely as a demonstration of an effect of treatment (i.e.  DPS-4 or pCPA) 
rather than to quantify absolute concentration of transmitter.
This  is  the  first  microdialysis  study  to  report  increase  NA  efflux  in  the 
hypothalamus  of  DSP-4  pretreated  rats.  DSP-4  preferentially  destroys  axon 
terminals  in  areas  innervated  by  NA  cells  of  the  LC  (Jonsson  et  al,  1981; 
Fritschy & Grzanna 1989). This is thought to reflect the greater affinity of DSP-4 
for the NA transporter of these LC neurones (cortex Kj=179nM;  hypothalamus 
/C,=460nM, Zaczek et al,  1990).  However, if the DSP-4 dose is increased, LTA 
neurones  are  also  lesioned.  Thus,  Heal  et  al,  (1993)  reported  an  83% 
reduction  in  hypothalamic  tissue  content  of  NA  after  pretreatment  with 
100mg/kg  DSP-4.  Therefore,  DSP-4  can  destroy  NA  axons  in  the 
hypothalamus,  albeit with  less  efficacy than  those  in  the  cortex,  as  was  the
96Chapter 3
case here (-65% reduction of tissue content in the frontal  cortex,  -47%  in the 
hypothalamus).
3.6. Conclusion
Systemic fluoxetine produce a variable,  unpredictable increase in  NA efflux in 
the frontal cortex and hypothalamus.  Thus, using the same drug dose, strain of 
animals and route of administration, fluoxetine either increased or had no effect 
on  NA efflux  in  the frontal  cortex  and  hypothalamus.  This  indicates that the 
disparity  between  studies  reported  in  the  literature  is  a  result  of  drug-effect 
variation,  rather  than  inter-studv  variation.  Likewise,  although  there  was  a 
difference  in  the  duration  of  fluoxetine’s  effects  in  the  frontal  cortex  and 
hypothalamus,  a  variable  response  was  seen  in  both  these  regions.  This 
suggests that, with respect to the frontal cortex and hypothalamus at least, the 
disparate  effects  of fluoxetine  on  NA  efflux  reported  in  the  literature are due 
primarily to drug-effect variation, as opposed  to  brain-region variation.  In this 
respect, the effects of systemic fluoxetine on  NA efflux are strikingly similar to 
the reported effects of SSRIs on 5-HT transmission.
Unfortunately,  given  the  nature  of  fluoxetine’s  effect  on  NA  efflux,  the 
contribution of 5-HT transmission could not be determined.
Finally,  systemic  fluoxetine  reduced  NA  efflux  in  the  frontal  cortex  and 
hypothalamus  after  a  DSP-4  lesion.  This  suggests  an  inhibitory  effect  of 
fluoxetine  on  NA  transmission  upstream  of  axon  terminals.  This  affects 
neurones innervating both the frontal cortex and hypothalamus.
To determine whether this inhibition  masks an opposing effect of fluoxetine at 
axon  terminals  experiments  in  Chapter  4  use  local  infusion  of  fluoxetine  to 
determine its effects on NA efflux in the frontal cortex and hypothalamus.  The 
contribution of 5-HT transmission is also determined.
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Chapter 4
Comparison of the Effects of Local Infusion 
of Fluoxetine or Citalopram on 
Noradrenaline Efflux in the Frontal Cortex 
and Hypothalamus of Freely-Moving Rats.
4.1.  Introduction
Experiments  described  in  Chapter  3  demonstrate  that,  when  given 
systemically,  fluoxetine  either  increased  (Experiment  1)  or  had  no  apparent 
effect (Experiments 2 & 3) on NA efflux in the frontal cortex and hypothalamus. 
Such  inconsistency in fluoxetine’s effects is borne out by previously published 
microdialysis studies.  Overall, these inconsistent reports suggest that that the 
effects  of systemic fluoxetine  on  NA (and  5-HT)  efflux  in  forebrain  areas  are 
truly variable.  Whereas this variability has been explicitly acknowledged for the 
effects of acute SSRIs on 5-HT efflux, until now it has been overlooked for their 
effects on NA efflux.
Variable  effects  of  reuptake  inhibitors  on  5-HT  efflux  are  due  to  opposing 
effects  at the  somatodendritic  and  terminal  level.  Experiments  in  Chapter  3 
suggest this could also be the case for fluoxetine’s effects on NA. Thus, when 
the contribution  of its  effects  at NA axon  terminals  is diminished  (by  DSP-4), 
systemic  fluoxetine  decreased  NA  efflux  in  the  frontal  cortex  and 
hypothalamus.  Therefore,  if fluoxetine has opposing effects at NA cell  bodies 
and terminals,  it should  increase NA efflux when applied  locally to both these 
brain regions.
To  test  this  hypothesis,  the  effects  of  fluoxetine  at  NA  axon  terminals  was 
determined by infusing the drug directly to the frontal cortex and hypothalamus, 
via a microdialysis probe.  This technique of ‘reverse dialysis’ can be thought of 
as equivalent to experiments  using tissue slice preparations in situ.  It is  used 
widely to determine the effects of drugs at sites within the brain.
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Few studies have applied this method to the study of fluoxetine’s effect on  NA 
efflux.  However, those that have consistently report increased NA efflux in the 
frontal  cortex,  at  least.  Jordan  et al,  (1994)  infused  fluoxetine  in  the frontal 
cortex  of  freely-moving  rats.  100pM  fluoxetine  elevated  NA  efflux  in  the 
prefrontal cortex, (+200% of baseline).  Similarly,  Hughes and Stanford (1996) 
reported  increased  NA  efflux  in  the frontal  cortex  of  both  anaesthetized  and 
freely-moving  rats  during  local  infusion  of  5  and  50|iM  fluoxetine.  Only  one 
study  has  examined  the  effects  of  local  infusion  of  fluoxetine  to  the 
hypothalamus  (Perry  &  Fuller,  1997).  They  reported  only  a  minor  effect  of 
10pM fluoxetine on NA efflux.  To date, no study has compared simultaneously 
the effects of local fluoxetine infusion on NA efflux in two brain regions.
Whether or not the effects of fluoxetine on NA efflux are due to 5-HT dependent 
mechanisms remains undetermined.  Local infusion of fluoxetine could increase 
NA efflux  by elevating  the  extracellular concentration  of 5-HT,  which  causes 
secondary activation 5-HT heteroceptors (see Chapter 1).  Experiments in this 
chapter  use  the  5-HT  synthesis  inhibitor  pCPA  to  deplete  stores  of  this 
neurotransmitter.  If the effects of fluoxetine on  NA efflux are secondary to an 
increase  in  extracellular  5-HT,  they  will  be  diminished  in  pCPA  pretreated 
animals.  However, if the effects are due to direct inhibition of NA uptake, they 
will not be affected by pCPA pretreatment.
If the augmentation of NA efflux by local infusion of fluoxetine occurs solely as 
a result of its actions on  5-HT transmission, this should  be replicated  by local 
infusion of other SSRIs.  Citalopram is the most selective SSRI for inhibition of 
5-HT  versus  NA  uptake  in  vitro  (see  Stanford,  1996).  Experiment  2  of this 
chapter tested  the effects of local  infusion  of citalopram  on  NA efflux.  Since 
this  compound  is  a  more  potent inhibitor of 5-HT uptake than fluoxetine (see 
Chapter 1), if the effects of fluoxetine on NA uptake are secondary to an action 
on 5-HT transmission, citalopram should also increase NA efflux.  If the effects 
of  local  infusion  of fluoxetine  are  due  to  inhibition  of  NA  uptake,  citalopram 
should  not produce as great an  increase in  NA efflux,  given  its  lower binding 
affinity for the NA transporter (Thomas et al, 1987).
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The  effect  of  DSP-4  pretreatment  on  local  infusion  of  fluoxetine  was  also 
examined  in  this  chapter.  Experiments  in  Chapter  3  showed  that  systemic 
fluoxetine  decreased  NA  efflux  in  the  frontal  cortex  and  hypothalamus  of 
animals  pretreated  with  DSP-4.  This  neurotoxin  partially  destroys  NA  axon 
terminals  but  leaves  cell  bodies  intact  (Fritschy  &  Grzanna,  1989).  The 
inhibitory effect of systemic fluoxetine on  NA efflux is unlikely to be due to an 
action  at  NA  axon  terminals  since  these  are  destroyed  by  DSP-4.  If  this 
hypothesis is correct, the effects of local  infusion of fluoxetine on  NA efflux in 
the frontal cortex and hypothalamus will be diminished by DSP-4 pretreatment. 
However,  if  fluoxetine  increases  NA  efflux  by  acting  on  a  site  not  on  NA 
terminals, its effects should remain in rats given DSP-4.
4.2.  Aims
•  To  compare  the  effect  of  local  infusion  of fluoxetine  on  NA  efflux  in  the
frontal  cortex  and  hypothalamus,  two  brain  areas  receiving  noradrenergic 
innervation  from  different  brainstem  sources  and  with  differences  in 
regulation of NA transmission.  (Experiments 1   & 3).
•  To  determine whether the effects of local  fluoxetine  infusion  on  NA efflux
are  5-HT  dependent,  using  the  5-HT  synthesis  inhibitor,  pCPA. 
(Experiment 1).
•  To  determine  whether  infusion  of  the  more  selective  SSRI,  citalopram,
elevates NA efflux to a greater extent than fluoxetine.  If so, this will suggest 
the  effects  of  fluoxetine  are  secondary  to  inhibition  of  5-HT  reuptake. 
(Experiment 2)
•  To  determine whether the effects of local infusion of fluoxetine on NA efflux
in  the  frontal  cortex  and/or  hypothalamus  are  diminished  by  selective
destruction of NA axon terminals using DSP-4 (Experiment 3).
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4.3. Methods
4.3.1. Microdialysis
Experiments  were  performed  on  freely-moving  rats  (240-320g  on  day  of 
surgery).  For  experiments  using  pCPA,  animals  received  either  250  mg/kg 
pCPA i.p. or 1   ml/kg 0.9% saline 2 days and 1 day before dialysis experiments. 
For experiments  using  DSP-4,  subjects  were  pretreated  with  either 40mg/kg 
DSP-4  i.p.  or  1 ml/kg  0.9%  saline  i.p.  5  days  before  dialysis  experiments. 
Microdialysis  probes  were  implanted  to  both  the  frontal  cortex  and 
hypothalamus on the day before experimenting.  See Chapter 2 (section 2.3) 
for details of probe design and surgical procedure.
Fluoxetine or citalopram  were dissolved  in  Ringer’s  solution to  make  0.5,  5.0 
and  50pM  solutions.  Once  basal  NA efflux  was  stable  and  at  least  3  basal 
samples  taken,  fluoxetine  or  citalopram  was  administered  by  changing  the 
perfusion  solution  for  Ringer’s  containing  the  drug.  Each  concentration  was 
perfused  for  80min,  in  the  order  0.5,  5.0  then  50pM.  The  last  three  basal 
samples  were  designated  T-40-T0,  with  perfusion  of  fluoxetine  or  citalopram 
starting immediately after T0. Microdialysis sampling continued for a further 4 h. 
At the end  of each  experiment animals were  killed  immediately by halothane 
overdose and cervical dislocation.
4.3.2. Measurement of brain region monoamine content
To determine the extent of pCPA and DSP-4- induced reduction of whole tissue 
monoamine  content,  homogenates  from  the frontal  cortex  and  hypothalamus 
were analyzed for their content of NA, dopamine and 5-HT,  using  HPLC.  See 
Chapter 2 (section 2.4.4) for a detailed description of the tissue preparation and 
analytical methods used.
4.3.3. Statistical analysis
Data for monoamine content were analyzed  using two-way ANOVA with ‘brain 
region’ as a  ‘within subjects’ factor and  ‘pretreatment’ (i.e. pCPA vs saline,  or 
DSP-4  vs  saline)  as  a  ‘between  subjects’  factor.  The  total  concentration  of 
monoamines in the frontal cortex and hypothalamus is expressed as mean ng/g 
wet tissue, (± s.e.m).
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All  data from  microdialysis  experiments  were  analyzed  for significance  using 
two-way ANOVA with  repeated  measures.  The  concentration  of NA  in  brain 
dialysates  is  expressed  as  fmol/20min  without  correction  for  recovery.  In 
addition to raw data,  net changes were calculated  by subtracting the mean of 
the last three  basal  samples  from  all  samples  in  the time course.  Data  were 
pooled and the mean and s.e.m. calculated.
•  Experiment  1   compared  the effect of pCPA-pretreatment on  the action  of 
locally infusion of fluoxetine.
•  Experiment 2  compared  the effect of pCPA pretreatment on  the action  of 
local infusion of citalopram.
•  Experiment 3 compared the effect of DSP-4 pretreatment on  local  infusion 
of fluoxetine.
For  each  of  these  experiments,  ‘time*  was  a  ‘within  subjects’  factor  and 
‘pretreatment’  (i.e.  pCPA  vs  saline  or  DSP-4  vs  saline)  a  ‘between  subjects’ 
factor.
The data were divided into four ‘bins’ with three consecutive samples per bin. 
Bins  of  data  were  compared  for  differences  in  both  within  and  between 
treatment  groups.  ‘Bin  1’  represents  basal  efflux  (i.e.  T.4o-T0).  For  bins 
representing  NA  efflux  during  drug  infusion,  the  last  three  samples  during 
infusion  of each  concentration  of drug  were  used.  Therefore,  bin  2  =0.5  pM 
(T40-T80),  bin 3 =5.0pM  OW-ieo),  and  bin  4  =50  pM  (T200-T240).  The 
Greenhouse-Geisser  ‘e’  correction  was  performed  where  Mauchley’s  test  of 
sphericity was significant.
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4.4  Results
4.4.1  Experiment 1:  Effect of local infusion of fluoxetine on NA efflux in 
pCPA and saline pretreated rats
4.4.1.1 Effect of pCPA pretreatment on monoamine content
pCPA pretreatment reduced tissue content of 5-HT in the frontal cortex (-84%, 
Fi,i2=114, P<0.001) and hypothalamus (-85%, Fi.i3=3 3 , P<0.001, Table 4.1). In 
the  frontal  cortex,  changes  in  other  monoamines  did  not  reach  significance 
(NA:  Fi i2=0.23,  P=0.64;  DA:  F1> 12=1.0,  P=0.34).  However,  in  the 
hypothalamus, the tissue content of NA (-34%,  Fi> 13=6.0, P=0.03),  but not that 
of DA (Fi 13=0.35, P=0.56) was reduced by pCPA.
Frontal cortex  Hypothalam us
SAL dCPA SAL dCPA
NA 277±39 241±29 2234±203 15601217*
DA 517±140 395±114 653±153 5471115
5-HT 270±19 41 ±9.5** 697±108 111122**
Table 4.1.  Monoamine  content  in  frontal  cortex  and  hypothalamus  of saline 
and  pCPA-pretreated  rats  receiving  local  infusion  of  fluoxetine.  Data  show 
mean content (ng/g wet tissue weight) ± s.e.m.  n=7-9.  Significant differences 
are in bold. *P<0.05; **P<0.005 c.f. saline.
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4.4.1.2.  Effect of fluoxetine on NA efflux 
Frontal cortex
There was no difference in basal NA efflux of saline and pCPA pretreated rats 
(fmoles/20min; T^o_T0: saline,  16.7 ±  1.4, pCPA,  19.3 ±  1.3).  Local  infusion of 
0.5pM fluoxetine had no effect of NA efflux in the frontal cortex in either pCPA 
or saline pretreated animals (Figure 4.1 A).  Thus, comparison of bin 1  and bin 2 
(T40-T80) showed  no effect of ‘bin’,  ‘pretreatment’  and  no  ‘bin’  x  ‘pretreatment 
interaction’
Infusion  of  5.0pM  fluoxetine  increased  NA  efflux  (c.f.  basal  efflux)  in  saline 
pretreated animals only (see Figure 4.1 A).  Thus, comparison of bin 1  and bin 3 
(T120-T160)  showed  a  main  effect  of  ‘bin’,  (Fit26=6.9,  P=0.01)  a  ‘bin’ 
x ’pretreatment’  interaction,  (F1i26=6.7,  P=0.02),  but no effect of ‘pretreatment’ 
(F1 i26=0.6, P=0.4). Analysis of saline pretreated animals alone revealed that NA 
efflux was increased after 5.0pM fluoxetine, relative to basal (main effect of ‘bin’ 
Fi, 16=13.1,  P=0.02).  5.0pM  fluoxetine  did  not  increase  NA  efflux  in  pCPA 
pretreated animals relative to basal, (no main effect of ‘bin’).
Infusion  of  50pM  fluoxetine  increased  NA  efflux  in  both  saline  and  pCPA 
pretreated  animals,  compared  with  basal  efflux  (Figure  4.1A).  Thus, 
comparison  of  bin  1  and  bin  4  (T20o-T24o)  showed  a  main  effect  of  ‘bin’, 
(Fi> 2 o=19.6,  P<0.001),  but no ‘bin’ x  ‘pretreatment’  interaction  and  no effect of 
‘pretreatment’.
Analysis of raw over all time points analyzed (T.4o-T24o) revealed a main effect 
of ‘time’,  (F4 > 266=3.3,  P=0.01),  but no  ‘time’ x  ‘pretreatment’  interaction  and  no 
effect  of  ‘pretreatment’.  NA  efflux  was  not  different  in  saline  and  pCPA 
pretreated animals at each hour during fluoxetine infusion (see Table 4.2).
Analysis  of net  changes  in  NA  efflux  revealed  a  similar  pattern  of results  as 
analysis  of  raw  data,  with  the  addition  of  a  main  effect  of  ‘pretreatment’  at 
T8o-Ti2o(Fi> 2 6 =5,7, P=  0.03).  Figure 4.2A and Table 4.3.
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Hypothalamus
There  was  no  difference  in  basal  NA  efflux  between  saline  and  pCPA 
pretreated  rats  (fmoles/2 0 min;  T.4o-T0:  saline,  16.8  ±  1.0;  pCPA  ,  17.3  ±  0.4 
Figure 4.1 B).
Neither 0.5pM nor 5.0pM fluoxetine increase NA efflux in either saline or pCPA 
pretreated  rats.  Thus,  comparison  of time  bins  (T40-T8o)  and  (T120-T160) with 
basal  efflux  (T^o-To)  revealed  no  effects  of  ‘bin’,  ‘time’  or  ‘bin’  x  ‘time 
interactions, (Figure 4.1 B).
50pM fluoxetine elevated NA efflux in saline and pCPA pretreated rats.  Thus, 
analysis of time points Ti40-T24o  (i.e.  immediately before and during infusion of 
50pM fluoxetine) revealed  a main  effect of ‘time’, (F5 > 80=4.5,  P=0.001),  but no 
effect of ‘pretreatment’ and  no ‘time’ x ‘pretreatment’ (see Figure 4.1 B).  This 
effect was  present when  data  for saline  pretreated  rats  was  analyzed  alone 
(main  effect  of  time,  F5) 55=4.0,  P=0.004),  but  not  pCPA  pretreated  rats  (no 
effect  of  ‘time’).  Analysis  of  raw  data  for  each  hour  during  fluoxetine 
administration found no main effects of ’pretreatment’.  Table 4.2.
Analysis of net changes revealed the same pattern of results as analysis of raw 
data.  Figure 4.2B and Table 4.3.
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Frontal cortex  Hypothalamus
T20-T60 Fi,2i=0.16, P=0.7 Fi,i7_0.004, P=0.95
T80-T120 Fif2i=2.3, P=0.14 F1,16=0.74, P=0.4
T  140“T  180 Fi,2i=2.6, P=0.12 Fl,13=1.1, P=0.3
T200-T240 Fi,i5=0.004, P=0.95 F1 14=0 .8 6 , P=0.37
Table 4.2 Statistics generated from two-way ANOVA using raw data, showing 
effect  of pCPA  pretreatment  on  NA  efflux  in  frontal  cortex  or  hypothalamus 
animals, during local infusion of fluoxetine (main factor ‘pretreatment’).
F  rontal Cortex  Hypoth  alam us
T20-T60  Fi2i— 0.78,  P=0.39  F i2i— 0.3,  P=0.59
T80"T|20  Fi> 2i=5.4,  P=0.03  Fiti8=0.85,  P=  0.31
Ti40“Ti80  Fi2i=3.1,  P=0.09  Fii6=1.4,  P=0.26
T200”T  240  F1 ii9=0.12,  P=0.73  Fii7=0.64,  P=0.44
Table 4.3 Statistics generated from two-way ANOVA using  net data,  showing 
effect  of pCPA  pretreatment  on  NA  efflux  in  frontal  cortex  or  hypothalamus 
animals,  during  local  infusion  of  fluoxetine  (main  factor  ‘pretreatment’). 
Significant differences in bold.
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Figure 4.1.  Effect of local  infusion of fluoxetine on  NA efflux (raw data)  in A) 
frontal  cortex  and  B)  hypothalamus  of  saline  and  pCPA  pretreared  animals. 
Graphs show mean ± s.e.m. (n= 9-17 each time point).  Infusion of 0.5, 5.0 and 
50pM  fluoxetine  for  80  min  each  as  marked  by  bar.  See  section  4.4.1  for 
details of statistical analysis.
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Figure 4.2.  Effect of local infusion of fluoxetine on net changes in NA efflux in 
A) frontal cortex and  B) hypothalamus of saline and pCPA pretreated animals. 
Graphs show mean ± s.e.m. (n= 9-17). Infusion of 0.5, 5.0 and 50pM fluoxetine 
for 80 mins each as marked  by bar.  See section 4.4.1  for details of statistical 
analysis.
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4.4.2.  Experiment 2: Local infusion of citalopram in the frontal cortex 
and hypothalamus of pCPA and saline pretreated rats.
4.4.2.1.  Effect of pCPA pretreatment on monoamine content.
pCPA pretreatment reduced tissue content of 5-HT in the frontal cortex (-70%, 
Fi,13=24, P<0.001) and hypothalamus (-71%,  Fi,i3=6 .8 , P<0.02; Table 4.4).  In 
the frontal cortex, there were no changes in other monoamines (NA: Fi,i3=1.5, 
P=0.2;  DA:  Fi,i3<0.001,  P=0.99).  In  the  hypothalamus,  tissue  content  of  DA 
was unchanged (Fi,i3<0.001, P=0.99) and the apparent reduction of NA failed 
to reach the criterion for significance ( Fi,i3=3.3, P=0.09).
Frontal cortex  Hypothalam us
SAL dCPA SAL dCPA
NA 414±150 225±33 341±160 129±48
DA 303±24 62±40 208±33 217±18
5-HT 908±85 269±100** 712±131 210±140*
Table 4.4.  Monoamine  content  in  frontal  cortex  and  hypothalamus  of saline 
and pCPA-pretreated  rats receiving  local  infusion of citalopram.  Table shows 
mean content (ng/g wet tissue weight) ±s.e.m.  n=7-11 .  Significant differences 
are in bold. *P<0.05; **P<0.005 c.f. saline pretreated rats
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4.4.2.2.  Effect of local citalopram infusion on NA efflux 
Frontal Cortex.
There  was  no  difference  in  basal  NA  efflux  between  saline  and  pCPA 
pretreated  rats  (fmoles/20min;  T^o.T0:  saline,  17.6  ±  0.8;  pCPA,  16.1±  2.4). 
Local infusion of citalopram did not change NA efflux in either saline or pCPA 
pretreated  rats  (Figure  4.3A).  Analysis  of  raw  data  over  all  time  points 
(T-40-T240)  revealed  no  effects  of  ‘time’,  ‘pretreatment’,  and  no  ‘time’  x 
‘pretreatment’ interaction.
Infusion of 0.5pM citalopram had no effect on NA efflux in either saline or pCPA 
pretreated  animals.  Thus  comparison  of  bin  1  (T-40-T0)  with  bin  2  (T40-T80) 
found no effect of ‘bin’, ‘pretreatment’, and no ‘bin’ x ‘pretreatment’ interaction.
Infusion of 5.0pM  citalopram  did  not change NA efflux in  either group of rats, 
(Figure 4.3A). Thus comparison of bin  1 with bin 3 (T120-T160) revealed no effect 
of ’bin’, ‘pretreatment’, and no ‘bin’ x ‘pretreatment’ interaction.
50jiM citalopram had  no effect on NA efflux, (Figure 4.3A).  Thus, comparison 
of bin  1  with bin 4 (T200-T240) revealed no effects of ‘bin’, ‘pretreatment’ and no 
‘bin x ‘pretreatment’ interaction.
Hypothalamus
There  was  no  difference  in  basal  NA  efflux  between  saline  and  pCPA 
pretreated  rats  (fmoles/20min;  T^o.T0:  saline,  18.7.5 ±0.3; pCPA,  16.5  ± 0.8) 
Local infusion of citalopram did not change efflux in saline- or pCPA-pretreated 
rats (Figure 4.3B).  Analysis of raw data over all time points, (T-40-T240) revealed 
no effects of ‘time’, ‘pretreatment’ and no ‘time’ x ‘pretreatment’ interaction.
Infusion of 0.5|nM citalopram had no effect on NA efflux in either group of rats. 
Thus,  comparison  of  bin  1  with  bin  2   (T40-T8o)  revealed  no  effects  of  ‘bin’, 
‘pretreatment’, and no ‘bin’ x ‘pretreatment’ interaction.
Infusion  of  5.0pM  citalopram  did  not  change  NA  efflux  in  either  group  of 
animals  (Figure  4.3B).  Thus,  comparison  of  bin  1   with  bin  3  (T120-T160)
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revealed  no  effects  of  ‘bin’,  ‘pretreatment’  and  no  ‘bin’  x  ‘pretreatment’ 
interaction.
Infusion of 50pM citalopram did  not modify NA efflux in either saline or pCPA 
pretreated  animals  (Figure  4.3B).  Thus  comparison  of bin1  with  bin  4  (T2o o - 
T240)  revealed  no  effects  of  ‘bin’,  ‘pretreatment’  and  no  ‘bin’  x  ‘pretreatment 
interaction.  Analysis  of raw data  revealed  no difference  in  NA efflux  between 
saline  and  pCPA  pretreated  in  either  brain  regions  during  each  hour  of 
citalopram infusion, (Table 4.5.).
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Figure 4.3.  Effect of local infusion of citalopram on  NA efflux (raw data) in A) 
frontal  cortex  and  B)  hypothalamus  of  saline  and  pCPA  pretreated  animals. 
Graphs show mean  ± s.e.m.  (n  =  7-10  each  time  point).  0.5,  5.0 and  50pM 
citalopram  were  infused  for  80  min  each,  as  marked  by  bar.  See  section 
4.4.2.2 for details of statistical analysis.
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Frontal C ortex  Hypothalamus
T20-T60
0
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O
T
-
L
L P=0.43 Fi,i6=2.0, P=0.18
T80-T120 F1,16=0.3, P=0.62 Fi,i6=1-4, P=0.25
T140-T180 Fi,ie=1-5f P=0.24 Fi,i6=1 -8 , P=0.20
T200-T240 Fi,i6=0.2, P=0.7 Fi,i6=1.0, P=0.33
Table 4.5. Statistics generated from two-way ANOVA using raw data, showing 
effect  of pCPA pretreatment  on  NA  efflux  in  frontal  cortex  or  hypothalamus 
animals, during local infusion of citalopram (main factor ‘pretreatment’).
4.4.3.  Experiment 3: Local infusion of fluoxetine to DSP-4 and saline 
pretreated rats
4.4.3.1.  Effect of DSP-4 pretreatment on monoamine content
DSP-4 pretreatment reduced tissue content of NA in the frontal  cortex (-39%, 
F1i17=5.6, P=0.03).  In the hypothalamus, the apparent reduction in NA content 
did  not reach the criterion for significance, (Fi,i7=3.3,  P=0.09).  DSP-4 did  not 
reduce tissue content of 5-HT or dopamine in either brain region.  Table 4.6
F  RONTAL CORTEX  H  YPOTHALAM US
SAL DSP-4 SAL DSP-4
NA 338±39 206±38* 838±107 528±127
DA 286±133 166±32 154±41 148±38
5-HT 117±80 152±105 181 ±151 129±129
Table 4.6.  Monoamine content in frontal cortex and hypothalamus of saline 
and DSP-4-pretreated rats receiving local infusion of fluoxetine.  Table shows 
mean content (ng/g wet tissue weight) ± s.e.m.  n=11.  Significant differences 
are in bold. *P<0.05 c.f. saline pretreated rats
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4.4.3.2.  Effect of local fluoxetine infusion of NA efflux 
Frontal Cortex
Basal efflux of NA was greater in DSP-4 pretreated animals, (saline, 12.8 ± 0.5 
fmoles/20min;  DSP-4,  22.0  ±  0.8;  effect  of ‘pretreatment’,  F1i23=4.6,  P=  0.04; 
Figure 4.4A).  NA efflux  increased  after fluoxetine  infusion,  in  saline,  but  not 
DSP-4 pretreated rats.  Analysis of all time points (T-40-T24o) revealed significant 
effects  of  ‘time’,  (F6ii49=4.7,  P<0.001),  a  ’time’  x  ‘pretreatment’  interaction, 
(F6,148=4.3, P<0.001), but no main effect of ‘pretreatment’.
Infusion of 0.5pM fluoxetine had no effect on NA efflux in either saline or DSP-4 
pretreated rats, (Figure 4.4A).  Thus, comparison of bin  1   (basal efflux; T^o-To) 
with bin 2 (T40-T80) found no effect of ‘bin’, no ‘bin’ x ‘pretreatment’ interaction, 
but  a  main  effect of ‘pretreatment’,  (Fii23=4.7,  P=0.04),  reflecting  the  greater 
efflux of NA in DSP-4 pretreated rats.
Infusion  of 5.0pM fluoxetine  increased  NA efflux  in  saline  pretreated  animals 
only, (Figure 4.4A). Thus, comparison of bin 1  with bin 3 (Ti20-Ti6o) revealed no 
main  effect  of  ‘bin’,  or  ‘pretreatment’,  but  a  ‘bin’  x  ‘pretreatment’  interaction, 
(Fi,23=7.1,  P=0.01).  The  lack  of  effect  of  ‘bin’  may  have  been  due  to  the 
difference in basal between DSP-4 and saline pretreated rats.  Analysis of data 
for saline  pretreated,  but not  DSP-4  pretreated  rats  revealed a  main  effect of 
‘bin’, Fi,i3=13.4, P=0.003), i.e. NA efflux was increased in the saline group, with 
respect to basal efflux.
Infusion  of  50pM  fluoxetine  increased  NA  efflux  in  saline  pretreated  animals 
only, (Figure 4.4A). Thus, comparison of bin 1  with bin 4 (T20o-Ti24o) revealed a 
main  effect of  ‘bin’,  (Fi)23=13.7,  P=0.001)  a  ‘bin’  x  ‘pretreatment’  interaction, 
(Fi,23=9.8, P=0.05) but no effect of ‘pretreatment’.  Analysis of data from saline 
pretreated rats only revealed a main effect of ‘bin’, (Fiii3=41.7, P<0.001).
The loss of effect of DSP-4 ‘pretreatment’ during 5.0pM and 50pM is due to the 
increase  in  NA  efflux  in  saline  pretreated  animals,  with  no  corresponding 
increase in efflux in the DSP-4 pretreated group.  Analysis of raw data revealed 
no difference in NA efflux between saline and DSP-4 pretreated animals at any
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hour  during  fluoxetine  infusion,  in  either  the  frontal  cortex  or  hypothalamus 
(Table 4.7)
Analysis of net changes in NA efflux revealed similar pattern of results, with a 
main  effect  of  ‘time’  (F7ii55=4.7,  P<0.001),  ‘pretreatment’,  (F1)23=4.2,  P=0.05; 
and  a  ‘time’  x ‘pretreatment’  interaction,  (F7 > 1 55=4.7,  P<0.001:  T.40-T240, Figure 
4.5A).
0.5pM  fluoxetine  had  no  effect  on  NA  efflux  in  either  group  of  rats.  Thus, 
comparison  of  bin  1   (T^0-T0)  with  bin  2  (T40-T80)  found  no  effects  of  ‘bin’, 
‘pretreatment’, and no ‘bin’ x ‘pretreatment’ interaction, (Figure 4.5A).
5.0pM fluoxetine increased  NA efflux in saline pretreated animals only.  Thus, 
comparison  of  bin1  with  bin  3  (T12o-Ti6o)  revealed  a  main  effect  of  ‘bin’, 
(Fi> 2 3=4.6,  P=0.04),  ‘pretreatment’,  (F1i23=6.5,  P=  0.02),  and  a  ‘bin’  x 
‘pretreatment’ interaction, (Fi)2 3=8.3, P=0.01, Figure 4.5A).
Infusion  of  50pM  fluoxetine  increased  NA  efflux  in  saline  pretreated  animals 
only, (Figure 4.5A).  Thus, comparison of bin 1  with bin 4 (T20o-T24o) revealed a 
main  effect of ‘bin’,  (F1 > 2 3 =13.8,  P=0.001),  ‘pretreatment’,  (Fi i23=8.4,  P=0.008) 
and  a  ‘bin’  x  ‘pretreatment’  interaction,  (Fi)23=8.4,  P=0.008).  Analysis  of time 
points  during  infusion  of 5.0  and  50pM  fluoxetine  (Ti0o-T24o)  revealed  a  main 
effect of ‘time’,  (F7> 161=2.1,  P=0.05),  ‘pretreatment’,  (Fii23=6.4,  P=0.02)  and  a 
‘time’  x  ‘pretreatment’  interaction,  (F716i=4.3,  P<0.0001),  indicating  that 
fluoxetine elevated NA efflux in saline pretreated animals only.
Hypothalamus
DSP-4  pretreatment  had  no  effect  on  basal  NA  efflux  (saline,  17.9  ±  0.4; 
DSP-4,17.7  ±  0.7;  no  effect  of  ‘pretreatment’).  NA  efflux was  increased  by 
infusion  of fluoxetine (Figure 4.4B).  Thus,  analysis  of raw data  over all  time 
points (T-4o-T2 4o) revealed  a main  effect of ‘time’, (F7ii32=3.2,  P=0.004),  but no 
effect of ‘pretreatment’, and no ’time’ x ‘pretreatment’ interaction.
Infusion  of  0.5pM  fluoxetine  had  no  effect  on  NA  efflux  in  saline  or  DSP-4 
pretreated rats.  Thus, comparison of bin  1   with bin 2 (T40-T80) found no effectChapter 4
of  ‘bin’,  no  effect  of  ‘pretreatment’  and  no  ‘bin’  x  ‘pretreatment’  interaction, 
(Figure 4.4B).
Infusion  of  5.0pM  fluoxetine  had  no  effect  on  NA  efflux  in  either  group  of
animals. Thus, comparison of bin  1   with bin 3 (T120-T160) revealed  no effects  of
‘bin’, ‘pretreatment’, and no ‘bin’ x ‘pretreatment’ interaction. Figure 4.4B
Infusion  of  50pM  fluoxetine  increased  NA  efflux,  (Figure  4.4B).  Thus, 
comparison of bin  1  with  bin 4 (T200-T1240) revealed a significant effect of ‘bin’, 
( F i ,2o= 8 .3 ,  P=0.01) but no effect of ‘pretreatment’, and  no ‘bin’ x ‘pretreatment’ 
interaction.  Analysis of data from  DSP-4 pretreated  rats only revealed a main 
effect of ‘bin’,  F110=11.9,  P=0.006).  However, when saline pretreated rats only 
were analyzed, there was no main effect of ‘bin’, (Fi i0=1.2, P=0.3).
Analysis  of net changes  in  NA efflux  revealed  the same  pattern  of results as
analysis of raw data.  Figure 4.5B and  Table 4.8.
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Figure  4.4.  Effect  of  local  infusion  of fluoxetine  in  A)  frontal  cortex  and  B) 
hypothalamus  of  animals  receiving  saline  or  DSP-4  pretreatment.  Graphs 
show mean ± s.e.m.  (n =  11-14).  0.5,  5.0 and  50pM fluoxetine infused for 80 
min  each  as  marked  by  bar.  See  section  4.4.3.2  for  details  of  statistical 
analysis
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T20-T60 Fi,  23-3.7, P=0.07 F i ,2o= 0 .6 3 , P=0.44
T80-T120 F1.23=2.7, P=0.12 Fi,  20=0.9, P=0.36
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L P=0.66 F i ,2o= 0 .0 9 , P=0.77
T200-T240 Fi, 13-0.84, P=0.37 F i i2o= 0 1 .4 , P=0.25
Table 4.7 Statistics generated from two-way ANOVA using raw data, showing 
effect of  DSP-4  pretreatment  on  NA  efflux  in  frontal  cortex  or  hypothalamus 
animals, during local infusion of fluoxetine (main factor ‘pretreatment’).
Frontal co rtex  hypothalam us
T  20” 1"   60 Fl,23-0.1, P=0.75 Fi,2i=1-4, P=0.24
T  80”T  120 Fi,  23=0.2, P=0.69 Fi2i=0.3, P=0.60
T14O-T18O F1.23=7.5, P=0.01 Fi,21=0.39, P=0.54
T200"T  240 Fl,23=9.4, P=  0.005 Fi,20=2.5, P=0.13
Table 4.8 Statistics generated from two-way ANOVA using NET data, showing 
effect of DSP-4 ‘pretreatment’  on  NA efflux in frontal  cortex or hypothalamus, 
during local infusion of fluoxetine (main factor ‘pretreatment’).
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Figure 4.5.  Effect of local infusion of fluoxetine on net changes in NA efflux in 
frontal  cortex  and  B)  hypothalamus  of saline  and  DSP-4  pretreated  animals. 
Graphs  show mean  ± s.e.m.  (n= 11-14).  0.5,  5.0 and  50  pM  fluoxetine were 
infused  for 80  min  each  as  marked  by bar.  See section 4.4.3.2 for details of 
statistical analysis
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4.5.  Discussion
The aim of experiments reported in this chapter was to determine the effects of 
local infusion of fluoxetine on NA efflux in the frontal cortex and hypothalamus, 
to establish the contribution of 5-HT to these effects and to determine whether 
an  action  at NA axon terminals  is  involved.  This  is the first study to use dual 
probe microdialysis to compare the effects of local administration of an SSRI in 
the frontal cortex and hypothalamus and to determine the contribution of 5-HT 
and NA axon terminals to these effects.
In the frontal cortex, infusions of 5.0 and 50pM fluoxetine increased NA efflux in 
saline pretreated rats (Experiments 1   and 3).  This confirms that, when applied 
directly  in  the  vicinity  of  noradrenergic  axon  terminals  of  LC  neurones, 
fluoxetine  elevates  NA  efflux.  However,  in  DSP-4  pretreated  rats,  neither 
concentration of fluoxetine was effective.  DSP-4 diminished tissue content and 
elevated  efflux of NA in the frontal  cortex,  suggesting a  marked  lesion  of NA 
axon  terminals  had  occurred.  Thus,  intact  NA  neurones  are  required  for 
fluoxetine to modulate NA transmission in this brain region.
Infusion  of  drugs  that  inhibit  NA  reuptake  such  as  DMI  (Dailey  &  Stanford, 
1995),  imipramine  (Jordan  et  al,  1994),  BTS  54354  (Geranton  et  al,  2004), 
reboxetine  (Owens  &  Whitton,  2003),  cocaine,  (Thomas  et  al,  1994)  and 
zotepine  (Rowley  et  al,  1998),  elevate  the  extracellular  concentration  of  NA 
when  infused  to  the  frontal  cortex  of freely  moving  rats.  Unlike  the  variable 
effect  produced  by systemic administration,  the  results  here  and  of  previous 
studies (Jordan etal, 1996; Hughes & Stanford, 1996; 1998) consistently report 
increased  NA efflux when fluoxetine is  infused to the frontal  cortex.  Thus the 
route of administration  seems  critical  in  determining fluoxetine’s effects  in the 
forebrain (see below).
Experiments  described  in  Chapter  3  showed  a  decrease  in  NA  efflux  in  the 
frontal  cortex when fluoxetine was administered to rats with a  partial  lesion  of 
NA axon  terminals.  This  decrease was  not seen  in  rats with  intact  NA axon 
terminals. Taken together with results of this chapter, it appears that fluoxetine 
has  opposing  effects  on  NA  transmission:  an  enhancing  effect  at  axon 
terminals  (see  above)  and  an  inhibitory  effect  at  a  site  upstream  of  these
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(Chapter 3).  This is entirely consistent with established regulatory mechanisms 
of  central  NA  transmission  (Cedarbaum  &  Aghajanian,  1976).  Thus,  an 
increase  is  the  extracellular concentration  of NA at the  somatodendritic  level 
will  activate  a2-adrenoceptors,  inhibiting  cell  firing  (Mateo  et  al,  1998)  and 
release of NA in  the forebrain  (Thomas  et al,  1994;  Van  Gaalen  et al,  1997; 
Mateo et al,  1998).  This effect becomes apparent when the opposing actions 
of fluoxetine at the axon terminals are diminished by pretreatment with DSP-4.
The effects of fluoxetine on  NA transmission in the frontal cortex are strikingly 
similar  to  those  reported  for  SSRIs  on  5-HT  transmission  (see  Chapter  3), 
suggesting  that  fluoxetine  modulates  both  transmitters  in  a  similar  way. 
However, in the case of 5-HT, a lack of effect of systemic fluoxetine on efflux in 
the  forebrain  is  attributed  to  activation  of  somatodendritic  and  terminal 
autoreceptors  (Hervas  &  Artigas,  1998;  Romero  et  al,  1996;  Gartside  et al, 
1995;  see  Chapter  3).  The  results  presented  here  suggest  that  systemic 
fluoxetine  modulates  NA transmission  in  vivo  but  this  may go  undetected  by 
microdialysis due to the balance of opposing effects on NA axon terminals and 
soma. If fluoxetine modulates NA transmission, in a similar way to that of 5-HT, 
a lack of effect on NA efflux should not been taken as evidence for selectivity of 
this drug for effects on  5-HT versus  NA in  vivo,  as  has  been  assumed  in the 
past (Beyer et al, 2002).
For  this  hypothesis  to  be  correct  two  conditions  must  be  met.  Firstly,  co­
administration  of  a2-adrenoceptor  antagonists  with  fluoxetine  will  result  in 
consistent increases  in  forebrain  NA efflux,  as  opposed  to  the variable  effect 
reported  on  administration  of  fluoxetine  alone.  Secondly,  local  infusion  of 
fluoxetine  to  the  LC  will  elevate  NA  efflux  there,  while  simultaneously 
decreasing  LC  cell  firing  and  release of NA the cortex.  This  reduction  in  LC 
firing  and  release will  be  blocked  by  intra-LC  infusion  of an  (^-adrenoceptor 
antagonist.
Although  published  studies  are  limited,  evidence  that  the  first  of  these 
conditions  may have  been  met comes from  the study of Gobert et al,  (1997). 
They reported  potentiation  of the fluoxetine-induced  increase  in  frontal  cortex 
NA  efflux  by  co-administration  of  the  a2-antagonist,  atipamezole.  Co-
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administration  of  buspirone  also  potentiates  the  effects  of  fluoxetine  on  NA 
efflux,  an  effect  attributed  to  the  a2-adrenoceptor  antagonist  properties  of  its 
metabolite,  1-(2-pyrimidinyl-piperazine),  (1PP;  Gobert  et al,  1999).  However, 
these authors consistently report elevated  NA efflux in the frontal  cortex after 
systemic fluoxetine and  have  not so far reported  a  lack of effect of this drug. 
For the effects of systemic fluoxetine on NA efflux to be the same as those on 
5-HT,  ideally,  a2-adrenoceptor  antagonist  administration  should  disclose  an 
effect that is not otherwise evident.
The second  condition  has  been  demonstrated  by  Mateo  et al,  (2000).  Local 
infusion  of the SSRI  citalopram,  elevates  NA efflux in  the  LC,  simultaneously 
decreases  the  firing  rate  of  LC  neurones  and  decreases  NA  efflux  in  the 
cingulate cortex.  The effects of citalopram on LC firing and release of NA were 
prevented by intra-LC infusion of the a2-adrenoceptor antagonist, RS79948.  It 
would be interesting to known if this effect generalizes to other SSRIs.
The question remains whether the effect of fluoxetine on NA efflux is secondary 
to  increase  extracellular  5-HT  concentration.  Using  pCPA  pretreatment 
(Experiment 1), the effect of the lower concentration of fluoxetine (5.0pM) was 
abolished  and  is  therefore  5-HT  dependent.  However,  at  the  higher 
concentration  (50pM)  the  effect  was  present  in  both  saline  and  pCPA 
pretreated rats.  The 5-HT independent effect of 50pM fluoxetine on NA efflux 
could be due to direct inhibition of NA reuptake.  It is not possible to determine 
the  exact concentration  of fluoxetine  in  the  area  of the  brain  surrounding the 
probe.  However,  estimates  of  probe  efficiency  suggest  only  around  10%  of 
drugs  in  the  perfusate will  enter the  brain.  Therefore,  50pM  fluoxetine  in  the 
probe  approximates  to  around  5pM  in  the  extracellular  fluid  immediately 
surrounding the probe.  This is within the range of inhibition of [3H]-NA uptake 
by fluoxetine into cortical synaptosomes (0.28pM,  Richelson & Pfenning,  1984; 
see Stanford, 1996).
The NA response to 50pM fluoxetine infusion was greater in the frontal  cortex 
than  hypothalamus.  As was  noted  in Chapter 3, these brain areas differ with 
respect to  NA transporter pharmacology,  (Zaczek  et al,  1990).  For example, 
fluoxetine  inhibits  NA  uptake  with  greater  affinity  in  synaptosomes  prepared
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from  cortical  tissue  (Kj=0.28pM,  Richelson  &  Pfenning,  1984)  than  from  the 
hypothalamus  (Kj=0.5pM;  Thomas  et  al,  1987).  This  greater  affinity  for  the 
cortical NA transporter could contribute to the greater magnitude of fluoxetine’s 
effect on  NA efflux in the frontal cortex. Alternatively, the greater proportion of 
presynaptic  a2-adrenoceptors  (Heal  et  al,  1993)  and  their  greater  inhibitory 
control  of NA transmission  in  the  hypothalamus (Wortley et al,  1999)  may be 
involved.
Since the effect of 5pM fluoxetine on  NA efflux in the frontal  cortex was 5-HT 
dependent, this should occur after local infusion of the more potent inhibitor of 
5-HT reuptake, citalopram (Experiment 2).  However, local infusion of this drug 
did  not  increase  NA  efflux  even  at  the  highest  concentration  (50pM).  This 
demonstrates that while 5-HT  is  necessary for the increase in  NA efflux seen 
with 5pM fluoxetine, it is not sufficient to induce an increase in NA efflux per se. 
This is consistent with the finding that local  infusion of exogenous 5-HT (5pM) 
to  the frontal  cortex  did  not  increase  NA  efflux,  (Hughes  &  Stanford,  1998). 
Also,  systemically  administered  fluvoxamine,  despite  causing  a  marked 
increase in  5-HT efflux  in the frontal cortex,  had  no effect on  NA efflux  in the 
same brain region, (Jordan etal, 1994).
It is seems that merely increasing the extracellular concentration of 5-HT does 
not  elevate  NA  efflux  in  the  frontal  cortex,  (although  5-HT  efflux  was  not 
measure  here).  However,  the  effects  of  5|uM  fluoxetine  infusion  are  clearly 
dependent on 5-HT, since they are abolished by pCPA pretreatment.  It can be 
deduced that,  although  5-HT is  necessary for the effect of 5pM fluoxetine,  an 
additional  property  of this  drug,  not  shared  by  citalopram  (and  therefore  not 
obviously related to inhibition of 5-HT reuptake), is required for its effect on NA 
efflux to occur.  Fluoxetine binds to 5-HT2c receptors, with greater affinity than 
citalopram, where it acts as an antagonist,  (Palvimaki  et al,  1996;  Ni & Miledi,
1997).  Fluoxetine  also  inhibits  [3H]-GABA  binding  to  the  GABAa  receptor 
(Tunnicliff et al,  1999) and inhibits K+ channel currents in cultured hippocampal 
neurones (Choi  et al,  2004).  Whether or not any of these properties explains 
the 5-HT-dependent effects of fluoxetine on NA efflux not shared by citalopram 
is as yet, unknown.  It is interesting that a property of fluoxetine, additional to its
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established  effects  on  5-HT  uptake,  could  contribute  to  effects  on  another 
neurotransmitter system relevant to the treatment of depression (NA).
The effects of local infusion of fluoxetine in the hypothalamus differ from those 
in  the  frontal  cortex  in  several  important  respects.  Firstly,  the  lower 
concentration (5.0pM) had  no effect in this  region.  This  is  in  agreement with 
the study of Perry & Fuller (1997), who reported only a modest increase in NA 
efflux  in  the  hypothalamus  after  infusion  of  10pM  fluoxetine.  Therefore, 
whereas  5pM  fluoxetine  increased  NA  efflux  in  the frontal  cortex  by  a  5-HT 
dependent  mechanism,  this  effect was  not  seen  in  the  hypothalamus.  This 
echoes the findings of Geranton  et al (2004),  who also demonstrated  a  5-HT 
dependent  increase  of  NA  in  the  frontal  cortex,  but  not  the  hypothalamus, 
following  infusion  of  a  mixed  reuptake  inhibitor.  Thus,  local  infusion  of the 
NA/5-HT reuptake inhibitor,  BTS  54354,  elevated  NA efflux in  both  the frontal 
cortex and hypothalamus.  However, the effect in the frontal cortex, but not the 
hypothalamus,  was  abolished  by  pCPA  and  is,  therefore,  5-HT  dependent. 
Thus,  the  study  of Geranton  et al,  using  BTS 54354,  and  experiments  here, 
using  fluoxetine  (5pM),  demonstrate  a  5-HT-dependent  modulation  of  NA 
transmission  in  the  frontal  cortex,  which  is  not  seen  in  the  hypothalamus. 
Further support for this comes from the finding that 10pM fluoxetine, infused to 
the  hypothalamus,  does  not  increase  NA  efflux  in  this  brain  region,  despite 
increasing 5-HT efflux 7-fold (Perry & Fuller, 1997).
Unlike  experiments  in  Chapter  3,  DSP-4  pretreatment  did  not  elevate 
spontaneous  NA  efflux  in  the  hypothalamus.  It  is  interesting  that,  in  this 
experiment,  DSP-4  not  deplete  tissue  stores  in  the  hypothalamus,  either. 
Previous  studies  have  reported  variation  in  the  extent  of  a  DSP-4  induced 
lesion  of  NA  tissue  content  (Hughes  &  Stanford,  1996;  Hughes  &  Stanford,
1998).  This suggests that the  increase in  NA efflux  in  DSP-4  pretreated  rats 
requires  appreciable  damage  to  nerve  terminals.  This  absence  of  a  lesion 
would explain why DSP-4 did not prevent the effects of 50pM fluoxetine in the 
hypothalamus.
Considerable  variation  was  seen  in  measurements  of  monoamine  tissue 
content  (see  Tables  4.1,  4.4.,  4.6).  The  explanation  for  this  variability  is
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unclear,  but  may  be  related  to  the  method  of  sample  preparation  or 
discrepancies in the time between collection of samples and analysis.  Similar 
discrepancies  were  found  in  Chapters  3  and  5.  However,  brain  tissue 
concentration  was  used  solely as  a  demonstration  of treatment  effect,  rather 
than absolute concentration of transmitter.
4.6.  Conclusion
A  5-HT-dependent  increase  in  NA  efflux  at  a  low  concentration  (5pM)  of 
fluoxetine was  seen  in  the frontal  cortex  of saline,  but  not pCPA,  pretreated 
rats. Local infusion of citalopram did not elevate NA efflux in either brain region, 
demonstrating that,  although  5-HT  dependent,  the  effect of 5pM  fluoxetine  is 
not  explained  simply  by  its  ability  to  block  5-HT  uptake.  Other  effects  of 
fluoxetine  (antagonism  of  5-HT2c,  GABAa  receptors  or  K+   channel 
conductance) may be involved, but this remains to be tested.
Infusion  of 50pM  fluoxetine  elevates  NA efflux  in  both  the frontal  cortex  and 
hypothalamus.  The effects of this concentration were not 5-HT-dependent and 
are  most  likely  due  to  inhibition  of  NA  reuptake.  The  response  to  local 
fluoxetine  was  greater  in  the  frontal  cortex,  which  may  reflect  regional 
differences  in  regulation  of  NA  transmission  but  further  work  is  needed  to 
identify the factors responsible for this difference.
DSP-4  pretreatment  prevented  the  effects  of fluoxetine  (5  and  50pM)  in  the 
frontal cortex.  DSP-4  pretreatment did  not prevent the effects of fluoxetine in 
the hypothalamus,  but no effect on tissue content or efflux of NA was seen  in 
this region, suggesting there was no appreciable lesion of NA axon terminals.
Results from  local and systemic fluoxetine studies suggest opposing effects at 
axon  terminals  and  soma  (see  also  Chapter  3).  It  is  proposed  that  co­
administration of an a2-adrenoceptor antagonist in  microdialysis studies would 
result  in  more  consistent effects  of systemic fluoxetine (and  other SSRIs) on 
forebrain  NA efflux.  Experiments  in  Chapter 5  use  the  light/dark  exploration 
box to determine whether an action on  central  NA transmission contributes to 
the effect of fluoxetine on behavioural.
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Chapter 5
Noradrenaline  and  5-HT-related  effects  of 
fluoxetine:  analysis  of behaviour of DSP-4 and 
pCPA  pretreated  rats  in  the  light/dark 
exploration box.
5.1. Introduction
Experiments  described  in  Chapters  3  and  4  demonstrate  modulation  of 
central  NA  transmission  by  fluoxetine.  The  aim  of  this  chapter  was  to 
establish  whether this  modulation  could  influence  behaviour  in  a  modified 
light/dark  exploration  box.  This  procedure  was  used  because  the 
behavioural  response  of  rodents  to  spatial  novelty  involves  changes  in 
central  NA  transmission  (see  below).  Moreover,  drugs  that  target  NA 
transmission  modulate behaviour in tests where exposure to spatial  novelty 
is  a  component  (e.g.  Haller  et  al,  1997;  Mason  et  al,  1998;  Stone  et  al, 
2004).
5.1.1.  Spatial Novelty
Rodents  respond to novel situations and environments with a characteristic 
pattern  of  behaviour.  When  faced  with  an  unfamiliar  environment,  they 
display a behavioural adaptation that facilitates investigation for any potential 
benefit (e.g. food, mate, resources,  etc: “approach”) and assessment of any 
potential  threats  (risk  assessment:  “avoidance”).  This  is  known  as 
exploration (Montgomery, 1955).
The  response  of  rats  and  mice  exposed  to  a  novel  enclosure,  (spatial 
novelty)  has  been  exploited  in  a  number  of  behavioural  tests.  These 
ethological models (e.g. light/dark test, open field, elevated plus-maze) were 
used originally because behaviour in these tests is changed consistently by 
established  anxiolytics  drugs,  (e.g.  benzodiazepines  and  barbiturates; 
Crawley  &  Goodwin,  1980;  Crawley,  1981).  Drugs  such  as  diazepam 
increase  the  proportion  of  time  that  rats  and  mice  spend  exploring  and
126Chapter 5
reduce  avoidance  of the  situation  threat.  This  has  been  described  as  an 
‘anxiolytic’  effect,  but  its  relationship  with  the  symptoms  of  human  anxiety 
disorders is far from clear.
5.1.2.  Spatial novelty and NA
The  behavioural  response  of  rodents  on  exposure  to  spatial  novelty  is 
paralleled  by  changes  in  central  NA  transmission.  Using  in  vivo 
microdialysis  in  freely-moving  rats,  Dailey  &  Stanford,  (1995)  reported 
increased NA efflux in the frontal cortex when rats were exposed to a novel 
cage.  Efflux increased  incrementally,  in  parallel with transfer of the rats to 
test situations of increasing salience.  For example, transfer to a novel arena 
that was  5-fold  more  brightly illuminated  the animal’s  homecage  increased 
NA efflux, relative to basal.  The most marked increases in efflux (compared 
to efflux in  handled  controls) were seen when  rats were placed  in  a  novel, 
brightly-lit chamber that also contained an unfamiliar rat.  Likewise, Mason et 
al, (1998) reported elevated NA efflux in the frontal cortex of rats placed in a 
novel environment (circular enclosure with equal illumination as the animal’s 
homecage).  Later  studies  demonstrated  increased  NA  efflux  in  the 
hypothalamus,  as  well  as  frontal  cortex,  of freely-moving  rats  placed  in  a 
novel,  brightly-lit  arena  (McQuade  et  al,  1999).  All  these  studies 
demonstrate  that  central  NA  transmission  is  augmented  when  rats  are 
exposed to environments that are known to induce a behavioural response.
That  central  NA  transmission  is  responsive  to  changes  in  an  animal’s 
environment is in  line with  electrophysiological  and  behavioural  studies.  In 
rats, (Aston-Jones & Bloom,  1981) and primates (Rajkowski et al,  1994), the 
firing activity of neurones in the LC  is closely paralleled  by the behavioural 
state.  Thus,  tonic  LC  firing  activity  is  greatest when  rats  are  engaged  in 
‘exploratory alertness’.  This led to the idea that NA neurones are important 
in  maintaining vigilance, defined  as “as state of surveillance of the external 
environment and readiness to respond to unexpected stimuli”, (Aston-Jones 
&  Bloom,  1981).  This  aptly describes the  behaviour of rodents  in  a  novel, 
brightly-lit  environment,  i.e.  stretch  attend  postures,  thigmotaxis,  rearing, 
sniffing and locomotor exploration of the environment occur.  On this basis, it 
should  be  possible to  use  behavioural  responses  to  spatial  novelty as  an
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‘assay’  for  changes  in  central  NA  transmission.  To  this  end,  a  modified 
light/dark  exploration  test  is  used  here,  specifically  to  determine  whether 
fluoxetine has  behavioural effects that could  be due to an action on central 
NA function.
In  support  of  this  approach,  several  studies  have  reported  modulation  of 
behaviour  in  novel  environments  by  drugs  that  target  NA  transmission. 
Thus, the (12-adrenoceptor antagonist, idazoxan, increased locomotor activity 
of rats in a novel, open field, (Haller et al, 1997).  This effect was blocked by 
either  an  ai  or  (3   adrenoceptor  antagonist,  (prazosin  and  propranolol 
respectively),  suggesting  a  postsynaptic-adrenergic  mediated  behavioural 
change.  Mason  et  al,  (1998)  reported  increased  NA  efflux  in  the frontal 
cortex of freely moving rats on exposure to spatial novelty (see above).  The 
anxiogenic drugs,  yohimbine and  FG7142,  both  modulated  the  increase in 
NA efflux (yohimbine prevented it,  FG7142 enhanced  it).  These drugs also 
modulated  the  locomotor  activity  in  the  novel  enclosure  i.e.  yohimbine 
enhanced  locomotor activity in the novel  enclosure, while  FG7142  reduced 
it.  These  studies  demonstrate  that  drugs  that  modulate  central  NA 
transmission  have  a  detectable  effect  on  the  behavioural  response  to 
novelty.  This supports the presumption that,  if fluoxetine has effects on NA 
transmission, this will influence the behavioural response to novelty.
5.1.3.  Spatial novelty and 5-HT
Behaviour  in  response  to  spatial  novelty  is  not  responsive  to  changes  in 
noradrenergic function  alone.  5-HT  is  also  implicated  in  such  behaviours. 
This  is important for the present study,  where effects of an SSRI  are to be 
determined.  Several  studies demonstrate 5-HT modulation of behaviour in 
the  light/dark  test.  Cheng  et al,  (1994)  augmented  5-HT  transmission  in 
mice  by  administering  the  5-HT  precursor,  5-hydroxytryptophan  (5-HTP). 
This  raised  5-HT  concentration  in  the  frontal  cortex,  hippocampus  and 
striatum. However, this was assessed by post-mortem tissue content and so 
does not indicate effects on 5-HT transmission in vivo.  Nevertheless, these 
animals spent less time in the light,  novel zone,  reared  less in the light and 
had  a  reduced  latency to  leave the  light for the first time.  The  effects  of 
5-HTP  treatment  were  antagonized  by  the  non-selective  5-HT2  receptor
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antagonist,  methsergide,  and  reversed  by  the  5 -HT2A /2C   antagonist, 
ritanserin,  the  5-HTia  agonist,  8-OHDPAT,  and  the  5 -HT3  receptor 
antagonists,  ondansetron  and  tropisetron.  A  similar  pattern  of  all  these 
effects  was  reported  by  Artaiz  et  al,  (1998).  However,  Sanchez  (1995), 
reported an increase in activity in light after 5-HTP administration.
The above studies demonstrate that drugs that modulate 5-HT transmission 
modify the  response  of  mice to  a  novel  environment.  Less  attention  has 
been paid to the effect of 5-HT manipulation in rats than in mice.  However, 
Miura  et  al,  (2002)  demonstrated  increased  5-HT  turnover  (defined  as 
increased  5-HIAA/5-HT  tissue  content  ratio  in  the  prefrontal  cortex  and 
hippocampus)  in  rats  exposed  to  ‘novelty  stress’  ( 2 0   min  placement  in  a 
novel semi-transparent plastic arena).  Noguchi et al, (2001) exposed rats to 
a  novel  environment  (communication  box):  30  min  exposure  augmented 
5-HT  turnover  in  the  medial  prefrontal,  anterior  cingulate  and  prelimbic 
cortices, again defined as an increase in 5-HT/5HIAA ratio.
Thus, 5-HT transmission is important in the behavioural response to novelty. 
Therefore,  effects  of  fluoxetine  in  the  light/dark  test  could  be  due  to 
modulation  of  5-HT,  rather  than  (or  in  addition  to)  any  effects  of  NA 
transmission.  For this  reason,  the  present  experiments  used  both  DSP-4 
and  pCPA  pretreatments.  If  modulation  of  behaviour  by  fluoxetine  in  the 
light/dark test involves an action at NA neurones, then behavioural effects of 
this drug will be identified that are modulated by DSP-4 pretreatment, but not 
pCPA.
In some respects this approach is similar to studies employing the modified 
rat  forced  swim  test  (Detke  et  al,  1995;  see  Cryan  et  al,  2005).  All 
antidepressants reduced the time that rats spend immobilized when confined 
to a  cylinder of water.  Antidepressant drugs that target 5-HT transmission 
primarily  increase  the  proportion  of  time  rats  spend  swimming,  whereas 
drugs that target NA transmission increase climbing at the side of the tank. 
Thus,  the  neurochemical  substrates  of  antidepressant  drugs  can  be 
distinguished  by their divergent effects on  behaviour.  However,  the forced 
swim  test has  produced  some inconsistent results,  e.g.  fluoxetine does  not
129Chapter 5
increase climbing  behaviour,  despite its  effects on  NA transmission  in vivo 
(see  Chapters  1   &  3).  Also,  duloxetine  selectively  increases  climbing 
behaviour,  (indicating  effects  on  NA  transmission  primarily),  despite  its 
greater  affinity  for  the  5-HT  transporter.  Likewise,  paroxetine  increases 
swimming,  with  no  effect  on  climbing,  even  at  doses  (40mg/kg)  that  are 
known to elevate NA efflux (Beyer et al, 2002).
Here,  the  light/dark  exploration  box was  used  since  it  employs  a  situation 
similar  to  that  which  modulates  transmission  of  NA  (and  5-HT)  and  is 
sensitive to drugs that target these systems.  The aim was to detect effects 
of fluoxetine on NA, and possible 5-HT transmission also, as opposed to just 
the system on which fluoxetine acts predominantly (5-HT) as is the case with 
the modified rat forced swim test.
5.1.4.  Effects of fluoxetine in the light/dark exploration test
Despite the role of NA and 5-HT systems in behavioural responses to spatial 
novelty,  no  clear-cut  effects  of fluoxetine  in  the  light/dark  test  have  been 
reported,  hitherto.  Rather, inconsistent effects have been found.  Increased 
transitions  between  compartments,  (Bourin  et  al,  1996),  suppressed 
locomotor  activity,  (Belzung  et  al,  2001,  Krzyanowska  et  al,  2001), 
decreased  (Kshama  et  al,  1990)  and  increased,  (de  Angelis,  1996)  time 
spent  in  the  novel  compartment,  and  no  effect  on  behaviour  (Sanchez  & 
Meier, 1997) have all been reported.
These  inconsistent  effects  could  reflect  the  lack  of  standardization  of 
protocols  across  experiments.  Thus,  species  (rat  or mouse)  and  strain  of 
animals used, as well as differences in experimental apparatus vary across 
these studies.  Another possibility is the variable effect of acute fluoxetine on 
5-HT  and  NA  transmission  (see  Chapter  3).  Indeed,  it  is  surprising  that 
drugs  with  known  variable  effects  should  produce  predictable  changes  in 
certain  behavioural  tests  on  acute  administration  (e.g.  forced  swim,  tail 
suspension).  Behaviour  in  the  light/dark  test  is  modulated  by 
antidepressants in a more variable way.
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A previous study from this laboratory demonstrated  effects of fluoxetine on 
locomotor activity in  both the light (novel) and dark (familiar) compartments 
of the same test apparatus as the that used here (Krzyanowska et al, 2001). 
For  this  reason,  the  light/dark  exploration  box  was  used  to  determine 
whether any of the behavioural effects of fluoxetine are due to an action on 
NA transmission.
Unlike most light/dark shuttle box experiments, which record only behaviours 
considered to related to “anxiolysis”,  a more extensive profile of behaviours 
was recorded in the present study, (see Chapter 2, section 2.6.1).  This was 
to increase the likelihood of identifying NA-related behaviours, which will not 
necessarily  be  the  same  as  those  related  to  the  effects  of  established 
anxiolytics.
5.1.5.  Time of day of testing
Rodents  exhibit  circadian  cycles  of  locomotor activity  (Gorka  et al,  1996), 
body temperature, (Weinert et al,  1999), corticosterone secretion, (Windle et 
al,  1998)  and  pain  sensitivity  (Konecka  et  al,  1998).  Time-dependent 
biological  rhythms  may  also  determine  behavioural  responses.  Thus, 
Valentinuzzi  et  al,  (2000)  found  increased  locomotor  activity  of  CB7BL/6 
mice in the open field when tested during the active (dark) phase.  However, 
Jones &  King (2001) found  no variation due to time of day of testing of rat 
behaviours  in  a variety of procedures (elevated  plus-maze,  open field  test, 
holeboard test).
The behavioural  effects of drugs also  may also depend  on the time of the 
light/dark  cycle.  Lu  &  Nagayama  (1996)  reported  greater  behavioural 
responses to the  5-HTia agonist  8 -OHDPAT during  the  mid-inactive phase 
(i.e.  1 2 : 0 0   h) with  the  lowest  responses  seen  during  the  mid-active  phase 
(0 0 : 0 0  h).
Time-dependent  behavioural  effects  of fluoxetine have also  been  reported. 
Indeed,  previous  work  from  this  laboratory  (Krzyzanowska  et  al,  2001) 
demonstrated time-dependent effects of fluoxetine in the same test as that 
used  here.  Fluoxetine  reduced  locomotor  activity  during  the  morning  but
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increased  it  during  the  afternoon.  Thus,  time of day  of testing  may  be  a 
source  of variation,  both  for  baseline  behaviour in  the  exploration  box,  as 
well  as  the  behavioural  effects  of  fluoxetine.  Therefore,  experiments 
described  in  this  chapter  were  performed  both  in  the  morning  and  the 
afternoon and time of testing was included as an independent variable.
5.2.  Aims
The aim of experiments in this chapter was to determine whether fluoxetine 
produces  behavioural  effects  in  rats that could  be  related  to  effects  of NA 
transmission.  The  hypothesis  to  be  tested  is  that fluoxetine  modifies  the 
behavioural  response to  a  novel,  brightly  lit environment  by  modulation  of 
central NA transmission.  The second aim of this chapter was to discriminate 
any 5-HT related behavioural effects of fluoxetine.  These effects should  be 
selectively modulated by DSP-4 and pCPA pretreatment, respectively.
If  NA-related  behavioural  effects  of fluoxetine  can  be  identified,  this  would 
support evidence from the microdialysis experiments of Chapters 3 & 4 that 
fluoxetine modulates NA transmission in vivo.
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5.3.  Methods
5.3.1. Animals and pretreatments
Adult,  male  Sprague  Dawley  rats  (200-320g)  were  used  throughout.  For 
experiments  using  DSP-4,  rats were  administered  either 0.9%  saline,  or a 
single dose of DSP-4 (40mg/kg) five days prior to testing.  For experiments 
using pCPA,  rats were administered either 0.9% saline or 250mg/kg pCPA, 
48 and 24 h before testing.  DSP-4 and pCPA were dissolved in 0.9% saline. 
All drugs were administered in a volume of 1 ml/kg, by i.p. injection.
5.3.2.  Treatment groups.
Three separate experiments were performed:
Experiment 1:  Rats  were  randomly  assigned  to  receive  either  DSP-4  or 
saline  pretreatment.  Immediately prior  to  testing,  all
subjects received vehicle injection.
Experiment 2:  Rats  were  randomly  assigned  to  receive  either  DSP-4  or 
saline  pretreatment.  Immediately prior  to  testing,  all
subjects received fluoxetine injection (1 0 mg/kg i.p). 
Experiment3:  Rats  were  randomly  assigned  to  receive  either  pCPA  or 
saline  pretreatment.  Immediately prior  to  testing,  all
subjects received fluoxetine injection, (1 0 mg/kg i.p.)
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5.3.3.  Test Procedure.
See Chapter 2 (section 2.7.1) for a detailed description of the experimental 
protocol  used.  At the end  of the experiments,  rats were killed  immediately 
by  stunning  and  cervical  dislocation,  their  brains  removed  and  frozen  for 
subsequent analysis of monoamine content.
5.3.4.  Behavioural analysis
A complete list of the behavioural parameters recorder is given in Chapter 2 
(section 2 .6 .1 ).
5.3.5. Analysis of brain monoamine content
See  Chapter  2,  (section  2.4.4)  for  a  description  of  the  method  used  to 
determine brain monoamine content.
5.3.6. Statistical Analysis
Each of the behaviours in the light/dark exploration box was analyzed using 
two-way ANOVA with ‘time of day’ and  ‘pretreatment’ as ‘between subjects’ 
factors.  If no significant effect of ‘pretreatment’  or ‘time of day’ was seen, 
data from these groups were pooled and one-way ANOVA performed to test 
the effect of the remaining factor.
When  a  main  effect of either ‘time of day’  or ‘pretreatment’ was  observed, 
data were analyzed  using one-way ANOVA with  ‘treatment group’ (n=4; i.e. 
pretreatment/time of day) as a  between subjects factor, with  post-hoc LSD 
test.
The  Levene’s  test  of  equality  of  error  variances  was  performed  routinely. 
Where  error variances  across  treatment  groups  were  different,  data  were 
analyzed  using the Mann-Whitney non-parametric test,  or normalized  using 
Logio transformation, as stated.  For these behaviours, one-way ANOVA and 
post-hoc analysis were not performed.
Analysis  of  covariance  (ANCOVA)  was  routinely  performed  to  investigate 
whether any changes in  behaviour were independent of any main  effect on 
locomotor activity.
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Mead’s resource equation was  used to determine whether sample sizes of 
treatment groups were sufficient to detect significant differences should any 
exist.
The effects of DSP-4 and pCPA on brain monoamine content were analyzed 
using  two-way  ANOVA,  with  ‘pretreatment’  as  a  ‘between  subjects’  factor 
and ‘brain region’ as a ‘within subjects’ factor.  Where a main effect of either 
factor, or an interaction between these factors was evident, one-way ANOVA 
was performed with ‘pretreatment’ as the main factor.
135Chapter 5
5.4.  Results
5.4.1.  Effect of DSP-4 pretreatment on monoamine content in the frontal 
cortex  and  hypothalamus  in  animals  destined  for  vehicle  injection 
(Experiment 1).
DSP-4  pretreatment  reduced  NA  content  in  the  frontal  cortex,  (-54%, 
Fi,24=19.7,  P<0.001)  and  hypothalamus,  (-39%,  Fi> 22=6 .0 ,  P=0.02).  There 
was  no  effect  of  DSP-4  on  content  of  DA  or  5-HT  in  either  brain  region 
(Table 5.1)
Frontal Cortex  Hypothalam us
SAL DSP-4 SAL DSP-4
NA 488 ± 47 230 ±42** 2292 ± 177 1388 173*
DA 266 ± 64 500 ± 282 286 ± 65 309 ± 78
5-HT 1010± 151 740 ± 81 1379 ±311 917 ±139
Table  5.1.  Effect  of  DSP-4  pretreatment  on  monoamine  content  in  the 
frontal  cortex  and  hypothalamus.  Displayed  are  mean  ±  s.e.m. 
concentration  (ng/g  wet  tissue;  n=11-14).  Significant  effects  are  in  bold. 
**P<0.001; *P=0.02 c.f. saline pretreated rats
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5.4.2.  Effect of DSP-4 pretreatment on monoamine content in the 
frontal cortex and hypothalamus in animals destined for fluoxetine 
injection (Experiment 2).
DSP-4  pretreatment  reduced  NA  content  in  the  frontal  cortex,  (-60%, 
Fi) 5i=21,  P0.001)  and  hypothalamus,  (-42%,  Fi,5i=6 .4 ,  P=  0.02  ).  There 
was no effect of DSP-4 on content of DA or 5-HT in brain region (Table 5.2)
Frontal cortex  Hypothalam us
SAL DSP-4 SAL DSP-4
NA 625±71 250±41 ** 1354±131 789±137*
DA 313±46 237+33 520±134 382±85
5-HT 399±141 427+88 591±150 463±112
Table  5.2.  Effect  of  DSP-4  pretreatment  on  monoamine  content  in  the 
frontal  cortex  and  hypothalamus.  Displayed  are  mean  ±  s.e.m. 
concentrations  (ng/g  wet  tissue;  n=24/26).  Significant  effects  are  in  bold. 
**P<0.001; *P=0.02 c.f. saline pretreated rats.
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5.4.3.  Effect of pCPA pretreatment on monoamine content in the 
frontal cortex and hypothalamus in animals destined for fluoxetine 
injection (Experiment 3).
pCPA  pretreatment  reduced  in  5-HT  content  in  the  frontal  cortex,  (-80%, 
Fi> 54=6.7,  P=  0.01  )  and  hypothalamus,  (-72%,  F1i53=21,  P<0.001).  There 
was no effect of pCPA on content of NA or DA in either brain region (Table 
5.3).
Frontal cortex________________________Hypothalam us
SAL pCPA SAL pCPA
NA 261±26 199±27 1052±186 733±179
DA 440±70 359±72 448±93 387±64
5-HT 272±85 56±10* 840±127 238±38**
Table 5.3.  Effect of pCPA pretreatment on monoamine content in the frontal 
cortex  and  hypothalamus.  Displayed  are  mean  ±  s.e.m.  concentrations 
(ng/g wet tissue; n=25-28).  Data were analyzed using one-way ANOVA with 
‘pretreatment’ as a between subjects factors.  Significant effects are in bold. 
*P=0.01; **P<0.001  c.f. saline pretreated rats
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5.4.4.  Experiment 1: Effect of DSP-4 pretreatment and time of day on 
behaviour of rats receiving acute vehicle
Neither  DSP-4  pretreatment  nor  time  of  day  alone  had  any  effect  on 
behaviour in the light/dark exploration box.  Thus,  neither two-way nor one­
way  ANOVA  revealed  any  effects  of  ‘pretreatment’,  ‘time  of  day’  or 
‘pretreatment’  x  ‘time of day’  interactions for any of the  behaviours tested. 
For  behaviours  where  Levene’s  test  of  homogeneity  of  variance  was 
significant,  data  were  analyzed  using  the  Mann  Whitney  test,  with 
‘pretreatment’  or ‘time of day’  as  grouping  variables.  Again,  no significant 
effects were evident (see Figure 5.1  and Table 5.4).
Performing Mead’s Resource Equation for individual behaviours gave values 
of 21-23,  indicating that increasing the sample size would  not increase the 
likelihood of revealing differences between treatment groups.
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Figure 5.1.  Effect of DSP-4 pretreatment and time of day on behaviour of 
rats  receiving  acute  vehicle.  Charts  show  mean  ±  s.e.m.  n=6-8  per 
treatment  group.  Neither  two-way  nor  one-way  ANOVA  revealed  any 
significant effects of ‘pretreatment’ or ‘time of day’.  [Continued over].
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Figure 5.1.  Effect of DSP-4 pretreatment and time of day on behaviour of 
rats  receiving  acute  vehicle.  Charts  show  mean  ±  s.e.m.  n=6-8  per 
treatment  group.  Neither  two-way  nor  one-way  ANOVA  revealed  any 
significant effects of ‘pretreatment’  or  ‘time of day’.  SAP=  Stretch Attend 
Posture.  [Continued over].
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Figure 5.1.  Effect of DSP-4 pretreatment and time of day on behaviour of rats 
receiving  acute  vehicle.  Charts  show  mean  ±  s.e.m.  n=6-8  per  treatment 
group.  Neither two-way nor one-way ANOVA revealed any significant effects of 
‘pretreatment’ or ‘time of day’.  [Continued over].
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Figure 5.1.  Effect of DSP-4 pretreatment and time of day on behaviour of rats 
receiving  acute  vehicle.  Charts  show  mean  ±  s.e.m.  n=6-8  per  treatment 
group.  Neither two-way nor one-way ANOVA revealed any significant effects of 
‘pretreatment’ or ‘time of day’.  TZ activity/min= Test Zone (light compartment) 
locomotor activity per minute.
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Activity in dark 
Activity in light*
No. grooms in dark 
No. grooms in light 
Time grooming in dark* 
Time grooming in light* 
Time to leave light*
Time to return 
Time in light
Number of returns to light
SAP in dark
SAP in light
Rears in dark
Rears in light*
Activity/min in light
TIME
Fl,23-26  P
0.7 0.4
1.7 0.2
0.7 0.4
0.6 0.5
3.1 0.1
0.7 0.4
0.5 0.5
1.2 0.3
0.2 0.7
0.02 0.9
0.1 0.7
0.2 0.7
0.01 0.9
0.1 0.8
1.5 0.2
PRETREAT
Fl,23-26  P
0.02 0.9
0.02 0.9
0.1 0.7
0.6 0.5
0.3 0.6
0.7 0.4
1.7 0.2
0.2 0.6
1.8 0.2
0.3 -  0.6
0.1 0.8
0.6 0.5
0.1 0.8
0.9 0.4
0.9 0.4
TIMEX
PRETREAT
F1,23-26  P
0.3 0.6
2.8 0.1
0.04 0.9
2.2 0.2
0.02 0.9
0.8 0.4
1.1 0.3
0.02 0.9
1.9 0.2
0.3 0.6
0.02 0.9
1.1 0.3
0.3 0.6
1.7 0.3
0.004 0.95
Table 5.4.  Effect of DSP-4 pretreatment and time of day on behaviour of rats 
in  the light/dark  exploration  box.  Table shows  results  of two-way analysis  of 
variance, (n=6-8).  There were no significant effects of ‘pretreatment’ or ‘time of 
day’.  Data  from  ‘pretreatment’  and  ‘time  of  day’  groups  were  pooled  and 
analyzed  with  one-way ANOVA,  (n=  12/16).  No  significant  differences  were 
found.  * denotes  behaviours where  Levene’s test of homogeneity of variance 
was significant. Behaviours were analyzed using Mann Whitney test, (n=13/14). 
No significant effects of ‘pretreatment’ or ‘time of day’ were found.
144Chapter 5
5.4.5.  Experiment 2:  Effect of DSP-4 pretreatment and time of day in rats 
receiving acute fluoxetine
Locomotor ‘activity in the dark’ compartment was lower in the afternoon in both 
DSP-4 and saline pretreated rats (Figure 5.2).  Thus, there was a main effect of 
‘time’ ( F ii5o = 1 2 .4 ,  P=0.001), but no effect of DSP-4 ‘pretreatment’ and no ‘time’ 
x ‘pretreatment’ interaction.  Data for ‘activity in dark’ were also analyzed using 
the  Mann-Whitney  test,  since  the  Levene’s  test  was  significant  for  this 
behaviour.  Again,  Mann-Whitney test revealed  an  effect of ‘time’,  (P<0.001), 
but not DSP-4 ‘pretreatment’
Locomotor  ‘activity  in  the  light’  compartment was  lower  in  DSP-4  pretreated 
animals  (Figure  5.2).  Thus,  there  was  a  main  effect  of  ‘pretreatment’, 
(Fi,50=4.05  P=0.05),  but  no  effect  of  ‘time’,  and  no  ‘time’  x  ‘pretreatment’ 
interaction.  Data for ‘activity in  light’, were analyzed  using the  Mann-Whitney 
test, since the Levene’s test of homogeneity of variance was significant for this 
behaviour.  Mann-Whitney  analysis  revealed  an  effect  of  ‘pretreatment’, 
(P=0.02), but no effect of ‘time’.
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Figure 5.2.  Effect of DSP-4 and time of day on locomotor activity in dark and 
light compartments.  All subjects received  acute fluoxetine.  Bars charts show 
mean ± s.e.m. (n=13/14 per treatment group):  note difference in scale.  Activity 
in  dark  was  lower  in  the  afternoon  (main  effect  of  ‘time  of  day’,  P=0.001). 
DSP-4 pretreatment reduced ‘activity in the light’ (main effect of ‘pretreatment’, 
P=0.02).
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Animals  made  fewer  ‘rears  in  the  dark’  compartment  in  the  afternoon 
(Figure 5.3).  Two-way  ANOVA  revealed  a  main  effect  of  ‘time’,  (F153=5.4, 
P=0.03) but no effect of ‘pretreatment’ and no ‘time’ x ‘pretreatment’ interaction. 
Data  were  analyzed  using  Mann-Whitney  test  due  to  significance  of  the 
Levene’s  test.  There  was  a  main  effect  of ‘time’,  (P=0.02),  but  no  effect  of 
‘pretreatment’.  However,  ANCOVA  revealed  an  effect of  ‘activity  in  the  dark’ 
(Fi,53=48, F<0.001), with no residual variance due to ‘time’,  indicating that the 
decreased number of rears in the dark compartment in the afternoon could be 
explained by the reduction in locomotor activity during this period (see above).
The  number of stretch  attend  postures  ‘(SAP)  in  the  dark’  compartment was 
lower in  the afternoon  in  both  DSP-4 and  saline  pretreated  rats  (Figure  5.3). 
Two-way ANOVA revealed  a main effect of ‘time’, (Fi i53=25,  P<0.001),  but no 
effect  of  ‘pretreatment’,  and  no  ‘time’  x  ‘pretreatment’  interaction.  One-way 
ANOVA revealed an effect of ‘treatment group’,  (Fi> 53=8.5,  P<0.001).  Multiple 
comparisons  using  the  LSD  test  revealed  differences  between  treatment 
groups:  both  saline  and  DSP-4  pretreated  rats  made  more  stretch  attend 
postures  in  the  dark  compartment  during  the  morning  than  the  afternoon. 
ANCOVA revealed no effect of ‘activity in dark’,  indicating that the reduction in 
stretch attend postures in the afternoon was not accounted for by the observed 
reduction in locomotor activity during this period.
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Figure 5.3.  Effect of DSP-4 pretreatment and time of day on behaviour of rats 
receiving  acute  fluoxetine.  Bar  charts  show  mean  ±  s.e.m.  n=13/14  per 
treatment group. Both ‘rears in dark’ and ‘Stretch Attend Postures in dark’ were 
both  lower in  the afternoon.  Post-hoc  LSD  test  I;  P=0.001,  II;  P=0.002,  III; 
P<0.001, IV; P<0.001
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The ‘number of returns’ to the light compartment was lower in the afternoon of 
both DSP-4 and saline treated rats (Figure 5.4).  Thus, there was a main effect 
of  ‘time’,  (Fi 50=4.4,  P=0.04),  but  no  effect  of  ‘pretreatment’  and  no  ‘time’  x 
‘pretreatment’  interaction.  Data  for  ‘number  of  returns’  were  also  analyzed 
using  the  Mann-Whitney test,  since the  Levene’s  test was  significant for this 
behaviour:  there  was  a  main  effect  of  ‘time’,  (P=0.02),  but  no  effect  of 
‘pretreatment’.  ANCOVA revealed an effect of ‘activity in the dark’, (Fii53=109, 
P<0.001),  with  no  residual  variance  due  to  ‘time  of  day’,  indicating  that  the 
reduced  ‘number of returns’  to the light compartment in the afternoon  can  be 
accounted for by the reduction in locomotor activity during this period.
Two-way ANOVA revealed  a  main effect of DSP-4 ‘pretreatment’  on  the total 
time spent in the light compartment, (Fi i50=4, P=0.05).  However Levene’s test 
of  homogeneity  of the  error  variance  was  also  significant.  Neither  log™  nor 
square root transformation of this data  normalized the error variance between 
groups.  Non-parametric analysis  using  Mann-Whitney test with  ‘pretreatment’ 
as the grouping variable did not find any significant effect of DSP-4 on time in 
light (Figure 5.5).
Two-way and one-way ANOVA revealed no effects of ‘time’, ‘pretreatment’ and 
no  ‘time’ x ‘pretreatment’  interactions for all  remaining  behaviours  (Figure 5.5 
and Table 5.5).
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Figure 5.4.  Effect of DSP-4 pretreatment and time of day on the 'number of 
returns’ to the light compartment made by rats receiving acute fluoxetine.  Bar 
charts show mean ± s.e.m. n= 13/14 per treatment group. Main effect of ‘time 
of day’ P=  0.02
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Figure 5.5. Behaviours unaffected by DSP-4 pretreatment or time of day in rats 
receiving  acute  fluoxetine.  Bar  charts  show  mean  ±  s.e.m.  n=13/14  per 
treatment  group.  Neither  two-way  nor  one-way  ANOVA  revealed  any 
significant effects of ‘pretreatment’ or ‘time of day’. See Table 5.5 for statistical 
comparisons. [Continued over].
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Figure 5.5. Behaviours unaffected by DSP-4 pretreatment or time of day in rats 
receiving  acute  fluoxetine.  Bar  charts  show  mean  ±  s.e.m.  n=13/14  per 
treatment  group.  Neither  two-way  nor  one-way  ANOVA  revealed  any 
significant effects of ‘pretreatment’ or ‘time of day’.  See Table 5.5 for statistical 
comparisons. [Continued over.]
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Figure 5.5. Behaviours unaffected by DSP-4 pretreatment or time of day in rats 
receiving  acute  fluoxetine.  Bar  charts  show  mean  ±  s.e.m.  n=13/14  per 
treatment  group.  Neither  two-way  nor  one-way  ANOVA  revealed  any 
significant effects of ‘pretreatment’ or ‘time of day’.  TZ activity/min= Test Zone 
(light compartment) locomotor activity per minute.  See Table 5.5 for statistical 
comparisons.
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TIMEX
TIME PRETREAT PRETREAT
F1,35-53  P Fl,  35-53 P Fl ,3 5 -5 3 P
No. grooms in dark 2.2 0.2 0.5 0.5 0.1 0.8
No. grooms in light* 0.2 0.7 2.8 0.1 0.4 0.5
Time grooming in dark 0.05 0.8 1.0 0.3 0.8 0.4
Time grooming in light* 0.13 0.7 0.8 0.4 2.8 0.1
Time to leave light* 1.2 0.3 0.4 0.5 0.7 0.4
Time to return 0.01 0.9 0.5 0.5 0.04 0.9
Time in light* 1.7 0.19 4.0 0.05 2.5 0.1
SAP in light* 3.4 0.07 0.2 0.65 1.4 0.2
Rears in light* 0.9 0.4 1.9 0.2 1.6 0.2
Activity/min in light 0.5 0.5 1.5 0.2 0.6 0.5
Table 5.5. Effect of DSP-4 and time of day on behaviour of rats receiving acute 
fluoxetine.  Data were analyzed  using two-way ANOVA with  ‘time of day’  and 
‘pretreatment’  as  between subject factors.  Table shows  behaviours where no 
significant  effects  of  ‘time’,  ‘pretreatment’  and  no  ‘time’  x  ‘pretreatment’ 
interactions  were  found.  *  denotes  behaviours  were  Levene’s  test  of 
homogeneity  of  variance  was  significant.  For  these  behaviours  the  Mann- 
Whitney test was  performed:  no  significant  effects  of  ‘time’  or  ‘pretreatment’ 
were observed.  N.B. Time in light’, significant effect of ‘pretreatment’ revealed 
by  two-way  ANOVA  was  not  observed  after  Mann-Whitney  test  with 
‘pretreatment’  as  the  main  factor (P=0.7)  n=6-14  per treatment group  (saline 
AM,  DSP-4  AM,  saline  PM,  DSP-4  PM).  See  Figure  5.5  for  graphical 
representation of these behaviours.
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5.4.6.  Experiment  3:  Effect  of pCPA  pretreatment  on  behaviour  of rats 
receiving acute fluoxetine
Locomotor ‘activity  in  the dark’  compartment was  greater in pCPA  pretreated 
animals  (Figure  5.6).  Two-way  ANOVA  revealed  a  main  effect  of 
‘pretreatment’,  (Fii53=13.2,  P=0.001)  but  no  effect  of  ‘time’  and  no  ‘time’  x 
‘pretreatment’  interaction.  Data  for  ‘activity  in  the  dark’  were  also  analyzed 
using  Mann-Whitney test,  since  Levene’s test was significant.  There was  an 
effect of ‘pretreatment’, (P<0.001), but not of ‘time’,
In saline pretreated animals,  the number of ‘grooms in the dark’  compartment
was greater in the morning than in the afternoon (Figure 5.6).  However, pCPA
pretreatment reversed this trend: pCPA pretreated animals made more grooms
in the dark in the afternoon than  morning.  Thus,  two-way ANOVA revealed a
‘time’ x ‘pretreatment’ interaction, (Fi i53=6.4, P=0.02), but no effect of ‘time’, or
‘pretreatment’.  Analysis of log™ transformed data for number of ‘grooms in the
dark’ was  performed, as  Levene’s test was significant and  initial  inspection of
the data suggested there was a ‘time’ x ‘pretreatment’ interaction, which cannot
be tested  using  Mann-Whitney analysis.  Two-way ANOVA of ‘log  grooms  in
the  dark’  revealed  a  ‘time’  x  ‘pretreatment’  interaction,  (Fii2i=15.8,  P=0.001),
but no effect of ‘time’ or ‘pretreatment’.  One-way ANOVA of ‘log grooms in the
dark’  revealed  an  effect of  ‘treatment  group’,  (F3,2i=5.6,  P=0.007).  Post-hoc
LSD analysis revealed differences between treatment groups (see Figure 5.6).
#
Neither  one-way  nor  two-way  ANOVA  revealed  any  effects  of  ‘time’, 
‘pretreatment’  and  no  ‘time’  x  ‘pretreatment’  interactions  for  any  other 
behaviours, (Figure 5.7, Table 5.6).
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Figure 5.6.  Effect of pCPA pretreatment and time of day on locomotor ‘activity 
in the dark compartment’ and log10 transformed number of ‘grooms in the dark’ 
compartment of animals  receiving  acute fluoxetine.  Bar charts  show  mean  + 
s.e.m. n= 13/14 per treatment group.  Activity was greater in pCPA pretreated 
animals, (main effect of ‘pretreatment’ P<0.001).  Post-hoc LSD test: I, P=  0.02; 
II, P=0.006; III, P=0.02; IV, P=0.006.  See section 5.4.6.
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Figure 5.7.  Behaviours unaffected by pCPA pretreatment or time of day in 
rats receiving acute fluoxetine. Bar charts show mean ± s.e.m of behaviours 
where two-way ANOVA revealed no effects of ‘time’,  ‘pretreatment’ and  no 
‘time’ x ‘pretreatment’ interaction.  n=5-14 per treatment group.  See Table
5.5  for details of statistical analysis. [Continued over]
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Figure 5.7.  Behaviours unaffected by pCPA pretreatment or time of day in 
rats receiving acute fluoxetine.  Bar charts show mean ± s.e.m of behaviours 
where two-way ANOVA revealed  no effects of ‘time’,  ‘pretreatment’ and no 
‘time’ x ‘pretreatment’ interaction.  n=5-14 per treatment group.  See Table
5.5  for details of statistical analysis. [Continued over]
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Figure 5.7.  Behaviours unaffected by pCPA pretreatment or time of day in 
rats receiving acute fluoxetine.  Bar charts show mean ± s.e.m of behaviours 
where two-way ANOVA revealed no effects of ‘time’,  ‘pretreatment’ and  no 
‘time’ x ‘pretreatment’ interaction.  n=5-14 per treatment group.  See Table 
5.5 for details of statistical analysis
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TIMEX
TIME PRETREAT PRETREAT
F(1,38-53)  P F(1,38-53) P F(1.38-53) P
Activity in light* 1.9 0.2 1.2 0.3 1.9 0.7
No. grooms in light 0.6 0.4 0.5 0.5 0.2 0.7
Time grooming in dark* 0.9 0.3 0.01 0.9 3.2 0.08
Time grooming in light* 0.8 0.4 0.3 0.6 0.1 0.7
Time to leave light* 1.7 0.2 1.1 0.3 1.5 0.2
Time to return 0.5 0.5 0.3 0.6 0.1 0.7
Time in light* 2.0 0.2 0.02 0.9 0.001 0.97
Total returns to light* 0.8 0.4 0.2 0.7 0.99 0.3
SAP in dark 0.3 0.6 0.4 0.5 0.05 0.8
SAP in light* 0.8 0.4 0.9 0.4 0.9 0.4
Rears in dark* 1.7 0.2 1.5 0.2 0.9 0.4
Rears in light* 3.0 0.09 0.3 0.6 0.6 0.4
Activity/min in light 0.04 0.8 0.6 0.4 0.1 0.7
Table 5.6.  Effect of pCPA pretreatment and time of day on  behaviour of rats 
receiving  acute  fluoxetine.  Data  were  analyzed  using  two-way ANOVA with 
‘time  of  day’  and  ‘pretreatment’  as  between  subject  factors.  Table  shows 
behaviours where no significant effects of ‘time’,  ‘pretreatment’ and  no ‘time’ x 
‘pretreatment’  interactions  were  found.  *  denotes  behaviours  were  Levene’s 
test  of  homogeneity  of variance  was  significant.  For  these  behaviours,  the 
Mann-Whitney  test  was  performed,  but  no  significant  effects  of  ‘time’  or 
‘pretreatment’ were observed.  See  Figure 5.7 for graphical  representation  of 
behaviours showing no significant changes.
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5.5.  Discussion
The aim of experiments in this chapter was to establish whether changes in NA 
transmission  could  contribute  to  the  behavioural  effects  of  fluoxetine.  The 
responses  of  rats  to  spatial  novelty  and  bright  light  were  measured  to 
determine  such  effects,  since these  are  paralleled  by  changes  in  central  NA 
transmission  (Dailey  &  Sanford,  1995;  Mason  et  al,  1998;  McQuade  et  al, 
1999).  Also,  preliminary  work  from  this  laboratory  shows  that  fluoxetine 
modulates locomotor activity in this test (Krzyzanowska et al, 2001).  However, 
behaviour in tests involving exposure to novelty is also modulated by 5-HT.  For 
this  reason,  DSP-4  and  pCPA  pretreatments were  used,  in  combination with 
fluoxetine,  to  identify  NA  and  5-HT  dependent  behaviours,  respectively. 
Finally, since circadian period can influence behaviour, as well as the response 
to drugs (e.g. Valentinuzzi etal, 2000; Lu and Nagayama,  1996; Krzyzanowska 
et al, 2001) the effect of time of day of testing was investigated throughout.
Pretreatment with both DSP-4 and pCPA produced robust, selective reductions 
of tissue content of their target amines.  Thus, DSP-4 pretreatment reduced NA 
content  in  Experiments  1   and  2,  both  in  the  frontal  cortex  (-54/-60%)  and 
hypothalamus,  (-39/-42%)  with  no  effects  on  5-HT  or  DA.  In  Experiment 3, 
pCPA  pretreatment decreased  5-HT  content  in  the frontal  cortex  (-80%)  and 
hypothalamus (-72%), with no effects on the other monoamines.  However, the 
(possibly artifactual) variability of basal  monoamine tissue concentrations was 
present, as in Chapters 3 and 4.
Since  previous  studies  demonstrate  that  DSP-4  pretreatment  can  modulate 
behaviour of rodents (see below),  it was necessary to determine the effects of 
this  pretreatment  alone,  so  effects  of fluoxetine  could  be  discriminated  from 
those of DSP-4.  Therefore,  Experiment  1   compared the  behaviour of DSP-4 
and saline pretreated rats, all of which received acute vehicle immediately prior 
to  testing.  Neither  DSP-4  nor  time  of  day  had  any  apparent  effects  on 
behaviour in this test.
That such a perturbation (see above) of central  NA transmission had no effect 
on  behaviour  is  remarkable.  Several  studies  report  reduced  exploration  of 
DSP-4  pretreated  rats  of arenas  containing  novel  objects  (Harro  et al,  1995)
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and in the open field (Harro et al, 2000).  In line with the present results, other 
studies report no effect of DSP-4 on the locomotor response to novelty, (Lapiz 
et al,  2000;  Haidkind  et al,  2003;  Stone  et  al,  2004).  The  lack  of  effect  of 
DSP-4 on behaviour was not due to the absence of a NA lesion, since marked 
reductions in NA tissue content were found both here and in the studies above. 
Other  differences  such  as  the  test apparatus  and  procedure,  as  well  as  the 
strain of rats used, could underlie these different results.
Whatever the reason for these differences, DSP-4 alone reduced NA content in 
the  frontal  cortex  (-54%)  and  hypothalamus  (-39%),  but  had  no  effect  on 
behaviour.  It could  be that adaptive  changes  occur as  a  result of the lesion 
{e.g. upregulation of NA release, loss reuptake sites, upregulation of adrenergic 
receptors) that restore NA function to an extent where effects on behaviour are 
minimal.  In support of this, results from the previous chapters, as well as other 
studies  {e.g.  Hughes  &  Stanford,  1996,  1998)  confirm  that  the  extracellular 
concentration of NA is not reduced under these circumstances.
Having  established  that  neither  DSP-4  nor  time  of  testing  alone  influence 
behaviour,  a further batch  of rats was pretreated with  DSP-4 or saline and all 
received  acute,  systemic  fluoxetine  prior  to  testing  (Experiment  2).  In  this 
experiment, behaviours were modulated both by DSP-4 and time of day.  Thus, 
behavioural  effects of either DSP-4 or time of day were seen  only  in animals 
given acute fluoxetine immediately prior to testing.  Therefore,  it is reasonable 
to assume that these changes are due to the effects of fluoxetine.
The  reduction  in  locomotor  activity  in  the  light  compartment  of  DSP-4 
pretreated rats is likely to be a NA-related effect of fluoxetine.  For example, the 
difference  in  locomotor activity  in  the  light  compartment  between  saline  and 
DSP-4 pretreated rats occurred only when all rats were administered fluoxetine 
{i.e.  Experiment  2).  The  previous  chapter  described  the  finding  that,  when 
given  systemically,  fluoxetine  decreased  NA  efflux  in  DSP-4  pretreated  rats. 
The reduction is found both in the frontal cortex and hypothalamus (Chapter 3). 
It  seems  that  the  reduction  in  NA  efflux  in  the  forebrain  is  paralleled  by  a 
reduction  in  locomotor activity  in  the  light  compartment  in  DSP-4  pretreated 
rats.
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Previous studies have reported  parallel  changes in  locomotor activity in  novel 
environments  with  changes  in  central  NA  transmission.  Thus,  the 
a2-adrenoceptor antagonist,  idazoxan,  increases locomotor activity of rats in a 
novel,  open field, (Haller et al,  1997).  This effect is blocked  by either ch  or p 
adrenoceptor antagonists,  (prazosin  and  propranolol  respectively),  suggesting 
a  postsynaptic,  NA-mediated  behavioural  change.  Also,  yohimbine  and 
FG7142,  both  modulate  the  incremental  increase  in  NA  efflux  which  occurs 
when rats are exposed to a novel enclosure (yohimbine prevented  it,  FG7142 
enhanced  it;  Mason  et al,  1998).  These  drugs  produced  parallel  changes in 
locomotor activity in novel arena (i.e. yohimbine enhanced locomotor activity in 
the  novel  enclosure,  while  FG7142  reduced  it).  The ai-adrenoceptor agonist, 
phenylephrine  and  the  antagonist,  terazozin  have  permissive  and  inhibitory 
effects  respectively  on  locomotor  behaviour  in  a  novel  environment  when 
infused  to the  LC  of rats,  (Stone et al,  2004).  Taken  together,  these studies 
and the results presented here suggest that locomotor activity of rodents during 
exploration  is  sensitive to  changes  in  central  NA transmission.  However,  as 
with all studies that report parallel  behavioural and  neurochemical changes, a 
causative relationship cannot be certain.
Nevertheless,  the  finding  that  fluoxetine  modulates  behaviour  in  rats  with  a 
partial lesion of NA axon terminals supports the hypothesis that this drug is not 
entirely selective for effects  on  5-HT transmission,  in  vivo.  It  is  important to 
note that, despite reducing tissue content of 5-HT by 80% in the frontal cortex 
and  72%  in  the  hypothalamus,  pCPA  pretreatment  did  not  affect  locomotor 
activity in the light compartment.  This supports the idea that the  reduction  in 
this behaviour when DSP-4 pretreated rats are administered fluoxetine is a NA- 
related, as opposed to a 5-HT-related effect.
Fluoxetine administration also revealed effects that were dependent on the time 
of day.  Thus, locomotor activity, rearing, the number of stretch attend postures 
in  the dark  compartment as  well  as  the  number of  returns  made  to  the  light 
compartment,  were  all  reduced  during  PM  relative to AM  testing,  but only  in 
animals  receiving  acute fluoxetine (i.e.  Experiment 2).  Analysis  of covariance
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demonstrated  that  the  majority  of  these  effects  could  be  explained  by  the 
decrease in locomotor activity in the dark compartment in the afternoon.
The  decrease  in  locomotor  activity  in  the  dark  compartment  during  the 
afternoon  is  likely to  be  due to fluoxetine’s  effects  on  5-HT  transmission,  for 
several  reasons.  Firstly,  this  effect  occurred  irrespective  of  DSP-4 
pretreatment,  so  is  unlikely  to  be  mediated  by  fluoxetine  acting  on  NA 
neurones.  Secondly,  pCPA  pretreated  rats  exhibited  increased  locomotor 
activity  in  the  dark  compartment  (Experiment  3),  demonstrating  that  this 
behaviour is enhanced by a marked reduction in 5-HT transmission. Moreover, 
this  behaviour  was  reduced  when  fluoxetine  was  administered  to  rats  with 
intact  5-HT  transmission  (Experiment  2).  Thus,  drugs  that  have  opposing 
effects  on  5-HT  transmission  in  vivo  (pCPA  and  fluoxetine)  have  opposing 
effects locomotor activity in the dark compartment.
The fact that the  locomotor activity in  the dark compartment was  reduced  by 
fluoxetine during  PM  relative to AM  testing,  is also consistent with  the  known 
circadian  variation  of  behaviours  modulated  by  5-HT.  For  example,  the 
behavioural effects of postsynaptic 5-H T iA receptor activation (with  8 -OHDPAT) 
exhibit marked circadian variation, with maximal responses during the mid-dark 
phase,  and  lowest  responses  during  the  mid-light  phase  (Lu  & 
Nagayama, 1996).  This is true also of the head-twitch response to by the non- 
selective 5-HT  agonist 5MeODMT  in  mice (Moser &  Redfern,  1985).  5-H T ia 
and  5-HT2  receptor  binding,  as  well  as  5-HT transmission  (determined  by in 
vivo  voltammetry)  in  the  rat  frontal  cortex  and  hypothalamus  vary  across 
different  times  of  the  light-dark  cycle  (Weiner  et  al,  1992).  As  a  reuptake 
inhibitor, the effects of fluoxetine will depend on the rate of 5-HT release. Since 
circadian  variation  is  seen  in  both  presynaptic (i.e.  release) and  postsynaptic 
(receptor  sensitivity)  elements  of  5-HT  transmission,  is  it  not  surprising  that 
some  behavioural  effects of fluoxetine are dependent on  the time of day.  In 
support  of  the  present  results,  a  preliminary  study  from  this  laboratory 
demonstrated  circadian  effects  of fluoxetine  in  the  light/dark  exploration  box. 
Thus,  fluoxetine decreased  locomotor activity in the morning,  (with  respect to 
its vehicle) but increased it during the afternoon (Krzyzanowska et al, 2001).
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Central  NA  efflux,  (Feenstra  et  al,  2000;  Kalen  et  al,  1989)  (3-adrenoceptor 
number (Vacas et al, 2001) and plasma NA concentration (De Boer & Van der 
Gugten,  1987) exhibit circadian variation,  also.  This  raises  the possibility that 
the  time-dependent  effects  of  fluoxetine  reported  here  are  NA-related. 
However, since none of these behavioural changes were modulated by DSP-4 
pretreatment, but abolished or reversed by pCPA, a 5-HT related mechanism is 
more likely.
5.6.  Conclusion
Since locomotor activity in light compartment was:
a)  reduced only when fluoxetine was administered
b)  reduced in DSP-4 pretreated animals
c)  unaffected by pCPA pretreatment
it is concluded that this the decrease in this behaviour is a NA-related effect of 
fluoxetine.
Since locomotor activity in the dark compartment was:
a)  reduced only when fluoxetine was administered
b)  unaffected by DSP-4
c)  increased by pCPA
it is concluded that this the decrease in this behaviour is a 5-HT-related effect 
of fluoxetine.
Thus,  the  results  are  consistent  with  5-HT-  and  NA-related  effects  that 
influence different components of the behavioural response to fluoxetine.
DSP-4  pretreatment  alone  did  not  modulate  any  behaviour  in  this  situation. 
This  could  reflect  the  compensatory  mechanisms  that  occur  after, a  partial 
lesion of NA axon terminals (see Chapters 3 & 4).
This  behavioural  approach  was  used  in  mice  in  experiments  described  in 
Chapter  7  to  determine  whether  the  behavioural  consequences  of  genetic 
ablation of the NK1  receptor are related to changes in NA transmission.
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Chapter 6 
Comparison of Noradrenaline Efflux in the 
Frontal Cortex of NK1  Receptor Wild Type 
And Knockout mice
6.1.  Introduction
Despite  both  pre-clinical  and  clinical  (albeit  equivocal)  evidence  for 
antidepressant efficacy of NK1  receptor antagonists (see Chapter 1), unlike all 
other antidepressant drugs, these compounds do not target directly monoamine 
transporters, receptors or monoamine oxidase (Kramer et al,  1998).  This led to 
the  proposal  that  these  agents  act  by  a  mechanism  independent  of 
monoamines.
For  example,  repeated  administration  of  substance  P  antagonists  does  not 
down-regulate  p-adrenoceptors,  an  effect  common  to  many  conventional 
antidepressant  strategies,  (Kramer  et  al,  1998).  Treatment  with  reserpine 
causes  ptosis  and  hypothermia  in  rodents.  This  effect  is  reversed  by 
phenelzine  or  imipramine,  suggesting  a  monoaminergic-mediated  effect. 
However, the NK1  receptor antagonist L-760735 does not reverse the effects of 
reserpine,  suggesting  that  antagonism  of  this  receptor  does  not  lead  to 
changes  in  monoamine  transmission  typical  of conventional  antidepressants, 
(Kramer et al,  1998).  5-HTP treatment,  in combination with pargyline,  induces 
wet dog shake,  forepaw treading,  hind  paw splaying  and  flat body  posture  in 
gerbils:  the  number  of  animals  displaying  these  behaviours  is  increased  by 
MAO  inhibitors,  but not by L-760735,  (Kramer et al,  1998).  Also,  acute  NK1 
receptor  blockade  has  no  effect  on  5-HT  efflux  in  the  frontal  cortex  or 
hippocampus of rats, (Milan et al, 2001).  The mechanism of NK1  antagonists 
in relieving the symptoms of depression was presumed to be distinct from that 
of conventional antidepressants, therefore.
However,  an  association  between  substance  P  and  NA-containing  neurones 
has  been  demonstrated  in  the  brain.  Substance  P-containing  fibres  form
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axodendritic  synapses  with  noradrenergic  neurones  of  the  LC  (Pickel  et  al, 
1979). Also,  100% of tyrosine hydroxylase labeled neurones in the LC display 
NK1  receptor co-immunoreactiviy, (Chen et al, 2000).  Application of substance 
P  in  vivo  (Guyenet  &  Aghajanian,  1977),  or  to  in  vitro  slice  preparations 
(Cheesman  et  al,  1983)  increases  LC  cell  firing  in  rats.  In  mice,  also,  LC 
noradrenergic  neurones  express  NK1  receptors,  (Santarelli  et  al,  2001). 
Therefore,  there  is  anatomical  and  physiological  evidence  that  substance  P 
could modulate NA transmission.
Given  the  strong  evidence  for  a  role  of  NA  in  the  treatment  of  depression, 
modulation  of  central  noradrenergic  transmission  could  contribute  to  the 
antidepressant efficacy of NK1  receptor antagonists.  In support of this, studies 
using  NK1  receptor  antagonists  in  rodents  demonstrate  effects  on  NA 
transmission.  Thus, the NK1  antagonist RP67580 increases the number of LC 
noradrenergic cells expressing c-Fos in  rats undergoing restraint stress (Hahn 
& Bannon,  1998). The NK1  antagonist, GR205171,  elevates NA efflux,  but not 
5-HT efflux,  in the frontal cortex and dorsal  hippocampus of freely-moving rats 
(Millan et al, 2001).  This drug also increases the firing rate of LC noradrenergic 
cells  in  anaesthetized  rats.  Maubach  et al,  (2002)  reported  increased  burst- 
firing of LC  neurones from  brain  slices  prepared  from  guinea  pigs  chronically 
treated  with  L-760735.  However,  the  NK1  antagonists,  WIN51708 and  CP- 
96345,  did  not modify the firing-rate,  but diminished  the suppressant effect of 
the  0 2-adrenergic  agonist,  clonidine  on  LC  noradrenergic  neuronal  firing  in 
anaesthetized  rats,  (Haddjeri  &  Blier,  2000).  These studies demonstrate that 
NK1  receptor blockade has a permissive effect of NA transmission.
Experiments in this chapter use the NK1  receptor knockout mouse as a model 
for lifelong  inhibition of the NK1  receptor,  (see  Chapter 1).  These  mice  have 
been generated so as not to express functional  NK1  receptors (see Chapter 1  
&  De  Felipe  et al,  1998).  For the first time,  in  vivo  microdialysis  is  used  to 
examine NA efflux in these mice.  If ablation of the NK1  receptor modulates NA 
transmission in vivo, this should influence NA efflux in NK1  knockout mice.
Receptor knockout mice were used in  place of NK1  receptor antagonist drugs 
because  compounds  that  have  high  affinity  for  rat  or  mouse  NK1  receptors
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have  poor  brain  penetrance  and  short  half  lives  (Rupniak  et  al,  1997).  To 
overcome this, large doses are often used to demonstrate effects in vivo.  This 
can  produce  non-specific effects,  unrelated  to  NK1  receptor  blockade.  Also, 
NK1  receptor  ablation  represents  as  a  model  of  ‘lifelong’  inhibition  of  this 
receptor and  therefore,  may be more  representative  of the adaptive changes 
which occur as a result of chronic antidepressant therapy.
If the antidepressant effects of NK1  antagonists involve an action at central NA 
neurones, genetic depletion of these receptors could lead to long-term changes 
in NA function, similar to those seen with conventional antidepressant therapy. 
Chronic treatment with antidepressants increases NA efflux in terminal regions 
and leads to desensitization of somatodendritic and terminal a2-adrenoceptors, 
(Charney et al,  1981; Thomas et al,  1998;  Mateo et al, 2001, see  Invernizzi & 
Garattini, 2004).  If loss of NK1  receptor function increases NA transmission in 
a  similar  way,  this  may  also  decrease  a2-adrenoceptor  function.  This  was 
investigated,  by  comparing  the  effect  of  the  selective  a2-adrenoceptor 
antagonist, atipamezole, on NA efflux in NK1  knockout and wild type mice.
An  abnormality in  NA efflux in  NK1  receptor knockout  mice could  also  occur 
because of differences in NA transport.  An interaction between NK1  receptor 
ablation  and  NA transport is feasible,  since the  NA transporter is  a target for 
many antidepressant drugs (Chapter 1).  Infusion of the selective NA reuptake 
inhibitor, desipramine (DMI) increases NA efflux in the cingulate cortex, (Mateo 
et al,  1998),  hippocampus, (Thomas &  Holman,  1991),  ventral tegmental area 
(Chen & Reith,  1994) and hypothalamus (Morris et al,  1994). NA transport was 
compared in  NK1  receptor wild type and  knockout mice using local  infusion of 
DMI to the frontal cortex of both genotypes.
168Chapter 6
6.2.  Aims
The aim  of experiments in this chapter was to determine the effect of genetic 
ablation of the NK1  receptor on NA transmission, using in vivo microdialysis.  If 
mice lacking the NK1  receptor have disrupted, or abnormal, NA function and, in 
particular, changes resembling those reported with conventional antidepressant 
therapy,  this will  support a  role for the  NA system  in the  putative therapeutic 
efficacy of NK1  receptor antagonist drugs.
Two experiments were performed:
•  Experiment 1: Basal efflux of NA was measured in the frontal cortex of NK1 
knockout and wild type mice.  The effect of a2-adrenoceptor blockade was 
then compared by systemic administration of atipamezole.
•  Experiment 2: Basal efflux of NA was compared, again followed by systemic 
administration  of  atipamezole.  After  80  min,  the  effect  of  NA  uptake 
inhibition was compared by locally infusing DMI by reverse dialysis.
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6.3.  Methods
6.3.1  In vivo microdialysis
Adult, male NK1  receptor wild type (+/+) and knockout (-/-) mice (25-30g) were 
used.  See Chapter 2 (section 2.3.2) for details of probe implantation.
Once NA efflux was stable,  at least 3  basal  samples were then taken  before 
administration  of  any  drugs.  Atipamezole  (4-(2-ethyl-2,3-dihydro-1H-inden- 
2-yl)-1 H-imidazole)  hydrochloride  (“Antisedan”,  Pfizer,  UK)  was  dissolved  in 
0.9% saline and administered by intraperitoneal injection at a dose of 3mg/kg in 
a volume of 10ml/kg. This dose of atipamezole was chosen on the basis of a 
previous  experiment  that  reported  modulation  of  rodent  behaviour  in  novel 
environments  (Kauppila  et al,  1992).  Atipamezole was  given  systemically so 
that  both  somatodendritic  and  terminal  a2-adrenoceptors  would  be  inhibited, 
maximizing any effects on NA efflux.  Local infusion of DMI (Sigma, UK) via the 
probe was achieved  by switching the perfusion  medium to Ringer’s containing 
5pM  DMI.  This drug was administered locally to avoid the inhibitory effects of 
increased  NA  efflux  in  the  LC  (Mateo  et  al,  1998).  At  the  end  of  each 
experiment mice were killed by cervical dislocation.  The probes were removed 
and inspected for any damage or leaks.  Only data from experiments where the 
probes were removed intact were used in the final analysis.
6.3.2.  Statistical analysis.
Data  were  analyzed  using  two-way  analysis  of  variance  with  repeated 
measures.  ‘Time’  was  a  within  subjects  factor  and  ‘genotype’  a  between 
subjects factors.  In addition to analysis of raw data, net changes in efflux were 
calculated by subtracting the mean basal efflux from all other points on the time 
course,  for  each  case.  The  effect  of  DMI  infusion  was  determined  by 
comparing  time  ‘bins’  of three time  points  each.  Basal  efflux was  compared 
with the last three successive time points during DMI infusion. The Greenhouse 
Geisser ‘e’  correction  was  performed  where  Mauchley’s test of sphericity was 
significant.
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6.4.  Results
6.4.1.  Experiment 1: Effect of systemic atipamezole on NA efflux
6.4.1.1. Basal efflux of NA in NK1 knockout and NK1 wild type mice
Basal  efflux of NA was approximately two-fold  greater in  NK1  knockout mice, 
(Figure 6.1A;  T-40-T0,  fmoles/20min;  NK1 knockout, 19.57 ± 1.0;  NK1  wild 
type,10.0 ± 0.5; main effect ‘genotype’, Fii 2i=5.1, P=0.04).
6.4.1.2.  Effect of systemic atipamezole
Administration of atipamezole did not change NA efflux in either NK1  knockout 
or wild type mice (Figure 6.1 A).  When all time points were analyzed (T-40-Tso), 
there  was  no  effect  of  ‘time’,  (F3> 69=0 .9 ,  P=0.4),  and  no  ‘genotype’  x  ‘time’ 
interaction.  NA efflux remained higher in NK1  knockout mice during this period, 
(F1, 21=6 .0 ,  P=0.02)  and  for  the  remaining  time  points  after  administration  of 
atipamezole (T20-T80, Fii2i=5.7, P=0.03).
6.4.1.3 .  Analysis of net changes in efflux.
Analysis of net changes revealed a similar pattern, with  no change in efflux in 
either  NK1  knockout  or  wild  type  mice  after  administration  of  atipamezole, 
(Figure 6.1 B; T^o-Tao; no effect of ‘time’, no ‘time x ‘genotype’ interaction).
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Figure 6.1.  Effect of systemic atipamezole on NA efflux in the frontal cortex of 
NK1 wild type and knockout mice.  Graphs show mean ± s.e.m. for A) raw data, 
B) net changes in NA efflux.  Atipamezole was administered at Time 0 (arrow), 
n = 11/12 per data point.  See section 6.4.1 for details of statistical analysis .
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6.4.2.  Experiment  2:  Effect  of  systemic  atipamezole  followed  by  local 
infusion of DMI on NA efflux
6.4.2.1. Basal efflux of NA in NK1 knockout and NK1 wild type mice
Basal efflux of NA was 7.9 ± 0.5 in wild type mice and 15.7 ± 0.5 fmoles/20min 
in the knockouts (Figure 6.2A).  On this occasion, the difference in basal efflux 
between  knockout and wild type mice was not significant (T-40-T0, no effect of 
‘genotype’, Fi,i5=2.7, P=0.12).  During the period T-40-T80, NA efflux was higher 
in  knockout  mice (Fi,i5=6.0,  P=0.02).  Also,  NA was  greater in  NK1  knockout 
mice  when  all  time  points  were  analyzed,  (effect  of  ‘genotype’,  Fi i5=5.3, 
P=0.04).
6.4.2.2.  Effect of systemic atipamezole on NA efflux
Administration of atipamezole did  not change NA efflux in either NK1  knockout 
or wild  type  mice.  Thus,  there  was  no  effect  of  ‘time’,  (T^o-Tso;  F3„69=0.9, 
P=0.4), and no ‘genotype’ x ‘time’ interaction, (F3)69=0.3, P=0.8).
6.4.2.3.  Effect of local infusion of DMI on NA efflux
Local infusion of 5pM  DMI  increased  NA efflux in both knockout and wild type 
mice (Figure 6.2).  Thus, analysis of time points Tso-Tiso revealed a main effect 
of ‘time’,  (F5i75=3.9,  P=0.03),  a  main  effect of ‘genotype’,  (Fi,i5=6.0,  P=0.03), 
but no ‘time’ x ‘genotype’  interaction,  (F5i75=0.3,  P=0.9).  Comparison of basal 
efflux  (T-40-T0:  bin  1)  with  efflux  during  infusion  of  DMI  (Tuo-Tiao^  bin  2) 
revealed  a  main  effect  of  ‘bin’  (F1> 15=6 .6 ,  P=0.02),  but  no  ‘bin’  x  ‘genotype’ 
interaction.  A  main  effect  of  ‘genotype’  was  found  (F1> 15=5 .9 ,  P=0.03), 
indicating that although there was no difference in the effects of DMI, NA efflux 
was greater NK knockout mice.
6.3.2.4.  Analysis of net changes in NA efflux
Analysis of net changes gave a similar pattern.  Injection of atipamezole did not 
change  NA  efflux  in  either  genotype  (T^o-Tso;  no  effect  of  ‘time’,  F3 9o=0 .4 , 
P=0.8;  Figure  6.2B).  Infusion  of  DMI  increased  NA efflux  in  both  genotypes, 
(effect  of  ‘time’,  F4i64=3 .0 ,  P=0.02).  Comparison  of  basal  efflux  with  efflux 
during DMI  infusion revealed a main effect of ‘bin’, (Fi,i5=6 .6 , P=-0.02),  but no 
‘bin’ x ‘genotype’ interaction, (Fi,i5=0.002, P=0.97).
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Figure 6.2.  Effect of systemic atipamezole and local infusion of DMI on NA 
efflux in the frontal cortex of NK1 wild type and NK1  knockout mice.  Graphs 
show mean ± s.e.m. for A) raw data, B) net changes.  Atipamezole was 
administered at T0 (arrow); DMI was infused during Tioo-Ti8o  (solid line),  n = 
8/9.  See section 6.4.2 for details of statistical analysis.
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6.5.  Discussion
The aim of experiments described in this chapter was to determine the effect of 
NK1  receptor ablation  on  NA transmission  in  vivo,  in  vivo microdialysis was 
used to measure NA efflux in the frontal cortex of NK1  receptor knockout and 
wild  type mice.  Anaesthetized  animals were  used  since these were the first 
microdialysis experiments performed in mice in this lab, before the technique of 
recovery  surgery  had  been  developed  in  this  species.  Knockout  mice  were 
used  as  a  model  of  lifelong  inhibition  of  the  NK1  receptor  and  to  avoid 
complication of any lack of selectivity of NK1  receptor antagonists.
In  Experiment  1,  there  was  a  marked  increase  in  basal  NA  efflux  in  mice 
lacking the NK1  receptor.  The difference in basal efflux in the knockout mice 
failed  to  reach  significance  in  Experiment  2.  However,  analysis  of raw data 
over  the  entire  time  course  revealed  that  NA  efflux  was  greater  in  NK1 
knockout  mice,  despite  no  differences  in  the  NA  response  of these  mice  to 
either drug  (see  below).  Greater  basal  NA  efflux  in  NK1  receptor  knockout 
mice has been confirmed in two subsequent studies from this lab (Fisher et al, 
2004; Herpfer et al, 2005).
Elevated  NA  efflux  is  reported  after  chronic  treatment  with  a  variety  of 
antidepressants (see Invemizzi & Garattini, 2004).  Repeated administration of 
NA selective drugs, such as reboxetine, (Invemizzi  et al, 2001; Sacchetti et al, 
1999;  Page  &  Lucki,  2002),  and  DMI  (Seo  et  al,  1999;  Mateo  et  al,  2001) 
elevates  NA  efflux  in  the  frontal  cortex  and  hippocampus  of  rats.  Chronic 
treatment with the SSRIs, paroxetine (Hajos-Korcsok et al, 2000) and sertraline 
(Thomas  et al,  1998)  elevate  basal  NA efflux,  also.  Thus,  the effect of NK1 
receptor ablation on NA efflux is similar to the effects of chronic treatment with 
antidepressants.  This supports a role for the NA system in the antidepressant 
efficacy of NK1  receptor antagonist.
Chronic treatment with  antidepressants  decreases  the  density and  activity of 
a2-adrenoceptor  in  the  brain  (Chamey  et  al,  1981;  Thomas  et  al,  1998; 
Invemizzi et al, 2001; Mateo et al, 2001; Subhash et al, 2003; see Invemizzi & 
Garatitini, 2004).  This is thought to be an adaptive response to the prolonged 
activation  of these receptors,  due to increased  release of NA (see above).  If
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NK1  receptor antagonists modulate NA function  in similar way to conventional 
antidepressants,  decreased  responsiveness  of  a2-adrenoceptors  would  be 
expected.
0 2-Adrenoceptors are inhibitory autoreceptors on the cell  bodies and terminals 
of  NA  neurones  (Cedarbaum  &  Aghajanian,  1977).  Therefore,  inhibition  of 
these  receptor  reduces  negative  feedback  on  NA  cell  firing  and  NA  efflux, 
(Svensson  et al,  1980;  Laitinen  et al,  1995; Wortley et al,  1999;  Gobert et al, 
2004;  Fernandez-Pastor  et  al,  2005).  However,  systemic  administration  of 
atipamezole had  no effect on  NA efflux in  NK1  knockout or wild type mice. A 
lack  of  effect  of  a2-adrenoceptor  antagonists  on  NA  efflux  (Geranton  et  al, 
2003),  as well  as  LC cell firing  (Mateo  et al,  1998)  been  reported  previously. 
This is thought to be due to low tonic activation of these receptors, which are 
activated  only  during  periods  of  high  NA  release-rate  (Callado  &  Stamford,
2000).
With  this  in  mind,  it  is  interesting  that  atipamezole  was  inactive  in  both 
genotypes.  The lack of effect of atipamezole in wild type mice could be due to 
the  low extracellular concentration  of  NA  in  these  animals.  However,  in  the 
knockout mice,  which  have two-fold  greater basal  NA efflux,  atipamezole  had 
no effect, also.  It could be that despite elevated extracellular NA concentration, 
0 2-adrenoceptors are  not tonically active  NK1  receptor knockout mice,  either. 
Alternatively,  0 2-adrenoceptors could  be down-regulated  in the knockout mice, 
due to the elevated  NA efflux.  This was suggested  in  a subsequent study by 
Herpfer et al,  (2005), who  reported  a  lack of effect of local  infusion of the  0 2- 
adrenoceptor antagonist,  RX821002,  on  NA  efflux  in  NK1  receptor  knockout 
mice.
Down-regulation  of  0 2-adrenoceptors  is  seen  after  chronic  treatment  with 
antidepressants, (see above).  Froger et al, (2001) and Santarelli et al, (2001) 
report  down-regulated  5-HTiA   receptors  in  NK1  receptor  knockout  mice, 
indicating that ablation of this receptor leads to long-term adaptations that are 
seen with  conventional  antidepressants  (Blier &  Montigny,  1980;  Invemizzi  et 
al,  1996).  However, given that atipamezole was inactive in  NK1  receptor wild 
type  mice  also,  the  present  evidence  suggests  that  that  case  for  disrupted
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a2-adrenoceptor function is suggestive, but not certain.  Experiments in Chapter 
7  explore  this  further,  by  comparing  the  effect  of  two  a2-adrenoceptor 
antagonists on behaviour of NK1  receptor knockout and wild type mice.
The  elevated  basal  NA efflux  the  NK1  knockout  mice  could  also  be  due  to 
impaired  NA reuptake.  However, the results here suggest that this process is 
functional  in  NK1  knockout mice.  Local  infusion of the selective NA reuptake 
inhibitor, DMI,  increased  NA efflux in both genotypes.  If the increase in  basal 
NA  efflux were  due  to  a  reduced  rate  of  NA  clearance  in  knockout  mice,  a 
diminished  response to  DMI  would  be expected.  A subsequent study,  using 
systemic  administration  of  DMI,  confirmed  that  there  is  no  difference  in  the 
effects of this uptake inhibitor on  NA efflux in NK1  receptor knockout and wild 
type mice, (Herpfer et al, 2005).  The finding that DMI was equally effective in 
both  genotypes  suggests  that  reduced  NA  clearance  is  unlikely  to  be 
responsible  for the  increase  in  basal  efflux  in  the  knockouts.  Therefore,  the 
most likely explanation for an increase in NA efflux in NK1  knockout mice is an 
increased rate of release.
An  increased  rate  of  NA  release  in  NK1  receptor  knockout  mice  appears 
paradoxical,  given  that  activation  of  NK1  receptors  in  the  LC  increases  the 
firing  rate  of  noradrenergic  neurones  (Guyenet  &  Anghajanian,  1977; 
Cheeseman  et  al,  1983;  Shen  &  North,  1992).  NK1  receptor  activation 
increases  cation  conductance  and  decreases  rectifying  K+   current,  (Shen  & 
North,  1992). Therefore, the elevated NA efflux in NK1  receptor knockout mice 
seen here cannot be explained by a loss of receptors located on LC neurones. 
In  support  of the  present findings,  previous  in  vivo  studies  demonstrate  that 
NK1  receptor  antagonists  elevate  NA  transmission.  For  example,  systemic 
administration of the NK1  receptor antagonist, GR205171, increases NA efflux 
in the frontal cortex and dorsal hippocampus of freely moving rats, (Millan et al, 
2001).  Moreover, GR205171  increases the firing-rate of noradrenergic cells in 
the LC of anaesthetized  rats.  The effect of NK1  ablation  could  be due to the 
loss of a population of receptors located on inhibitory afferents to the LC.  The 
location  of  NK1  receptors  that  inhibit  NA  transmission  indirectly  is  as  yet 
unknown,  but GABAergic afferents from the nucleus prepositus hypoglossi are
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a  possibility  (Ennis  &  Aston-Jones,  1989).  GABAergic  neurones  expressing 
NK1  receptors have been identified in the CNS (Bailey et al, 2004).
6.6.  Conclusion
In conclusion, genetic ablation of the NK1  receptor leads to an increase in NA 
transmission  as  seen  following  chronic  treatment  with  conventional 
antidepressants.  The  mechanism  behind  this  increase  in  extracellular  NA 
concentration in NK1  receptor knockout mice is unknown, but is most likely due 
to  an  increase  in  the  rate  of  release  of  transmitter.  The  lack  of  effect  of 
atipamezole  in  NK1  knockout  mice,  despite  elevated  NA  efflux,  suggests  a 
possible impairment of a2-adrenoceptor function.  Whether this is due to down- 
regulation  of these receptors as a consequence of increased  extracellular NA 
concentration is, as yet, uncertain.  Nevertheless, experiments presented here 
support a  role for the  noradrenergic  system  in  the  antidepressant  efficacy of 
NK1  receptor antagonists.
Experiments  in  the following  chapter compare  behavioural  responses  of NK1 
knockout and wild type mice in the light/dark exploration  box,  a test known to 
elicit changes  in  central  NA transmission  (see  Chapter 5).  The  possibility of 
impaired (^-adrenoceptor function was explored further.
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Chapter 7
Comparison of Behaviour of NK1  Receptor 
Wild Type and Knockout Mice: Effect of the 
a2-Adrenoceptor Antagonists, Atipamezole 
and Yohimbine
7.1.  Introduction
Experiments described in the previous chapter demonstrate elevated NA efflux 
in  NK1  knockout  mice  compared  with  spontaneous  efflux  in  wild  type  mice. 
This  is  the  first  demonstration  that  genetic  ablation  of  this  putative,  novel 
antidepressant  target  leads  to  changes  in  central  NA  transmission  that 
resemble those seen  after chronic treatment with  established  antidepressants 
(Invemizzi  et al,  2001;  Sacchetti  et al,  1999;  Page  &  Lucki,  2002;  Seo  et al 
1999;  Mateo et al,  2001;  Hajos-Korcsok et al,  2000;  Thomas et al,  1998;  see 
Invemizzi & Garattini, 2004).
NK1  receptor  antagonists  (Kramer  et  al,  1998;  Papp  et  al,  2000)  and  NK1 
receptor ablation (Rupniak et al, 2001; Santarelli et al,  2 0 0 1 ) produce changes 
in  behaviour  that  are  seen  with  established  antidepressants/anxiolytic  drugs 
(see  Chapter  1).  However,  the  neurochemical  differences  underlying  these 
effects are unknown.  The aim of experiments here was to determine whether 
any  of the  behavioural  differences  of  NK1  receptor  knockout  mice  could  be 
attributed to augmented NA transmission.
The  light/dark  exploration  box  was  used  since  marked  increases  in  NA 
transmission  are  seen  when  rodents  are  confined  to  this  test  environment 
(Dailey  &  Stanford,  1995;  McQuade  et  al,  1999).  Also,  behaviour  in  novel 
environments is modified  by drugs that target NA neurones.  For example, the 
0 2-adrenoceptor antagonist,  idazoxan,  increases exploratory behaviour of rats 
in  the  open  field,  (Siviy  et  al,  1990;  Haller  et  al,  1997).  0 2A-Adrenoceptor 
knockout  mice  make  fewer  rears  in  the  open  field  than  wild  type  mice  and 
spend more time in the dark compartment in the light/dark test (Schramm et al,
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2001).  a2-Adrenoceptor antagonists also increase locomotor behaviour in the 
light/dark test (Haapalinna et al,  1997).  Therefore, the increase in NA efflux in 
NK1  receptor knockout mice should affect these behaviours
The hypothesis to be tested is that at least some of the behavioural differences 
of NK1  receptor knockout mice are due to the elevated  NA transmission seen 
in  these  mice (Chapter  6 ).  If this  is  the  case,  then  drugs  that  augment  NA 
transmission  (e.g.  a2-adrenoceptor  antagonists)  will  produced  effects  that 
resemble  those  of  NK1  receptor  ablation.  Thus,  the  effects  of  the 
0 2-adrenoceptor antagonists,  atipamezole and  yohimbine,  were determined  in 
both strains of mice.  Also, if NK1  receptor ablation leads to down-regulation of 
0 2-adrenoceptors  (see  Chapter  6 ),  it would  be  predicted  that the  behavioural 
effects of atipamezole and yohimbine are diminished in NK1  receptor knockout 
mice.
7.2.  Aims
•  To identify behaviours in the light/dark exploration  box that are sensitive to 
changes  in  NA  transmission  and  which  are  modulated  by  the 
0 2-adrenoceptors antagonists, atipamezole and yohimbine.
•  To determine whether NK1  receptor ablation  produces  behavioural  effects 
that  are  consistent  with  elevated  NA  transmission,  to  support  the 
microdialysis evidence of Chapter 6 .
•  To  determine  whether  NK1  receptor  ablation  leads  to  a  deficit  in 
a2-adrenceptor function,  by comparing the  effects  of both  a2-adrenoceptor 
antagonists in NK1  receptor knockout and wild type mice.
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7.3.  Methods
7.3.1  Light/dark exploration box
Adult,  male NK1  wild type and  NK1  knockout mice were used.  See Chapter 2 
(2.7.2)  for  a  description  of  the  protocol  of  behaviour  testing  and  scoring  of 
behaviour.  Atipamezole, (3mg/kg), yohimbine, (2.5mg/kg) or 0.9% saline were 
administered  30  min  prior to testing.  The doses were chosen on the basis  of 
previous  experiments  that  report  modulation  of  rodent  behaviour  in  novel 
environments by these drugs (Mason et al,  1998; Kauppila et al,  1992). At the 
end  of each  experiment the  mice were  removed  and  killed  by CO2 overdose 
and  cervical  dislocation.  Atipamezole  and  yohimbine were  dissolved  in  0.9% 
saline.  All injections were given in a volume of 10mg/kg i.p.
7.3.2.  Statistical analysis
Data  were  analyzed  routinely  using  two-way  ANOVA  with  ‘genotype’  (NK1 
knockout  vs  NK1  wild  type)  and  ‘drug  treatment’  (saline  vs  atipamezole  or 
saline vs yohimbine) as ‘between subjects’ factors.  Where a significant effect 
was  revealed  by  two-way  ANOVA  data  were  also  analyzed  using  one-way 
ANOVA with  ‘treatment  group’  (n=4)  as  the  ‘between  subjects’  variable  and 
post-hoc  LSD test performed.  Levene’s test of homogeneity of the variances 
was  performed  (a  condition  required  for  use  of  ANOVA).  Where  this  was 
significant,  non-parametric  analysis  was  performed  using  the  Mann-Whitney 
test with either ‘drug treatment’ or ‘genotype’ as grouping variables.  Where an 
interaction was suspected, but Levene’s test was significant, data were Log™ or 
square-root transformed and analyzed by two-way analysis of variance.
To explore the possibility that any behavioural effects were due to differences 
in  locomotor  activity,  analysis  of  covariance  (ANCOVA)  was  performed 
routinely,  including  either locomotor activity  in the  light or dark zone as  a co- 
variate in the analysis. This was only performed for behaviours where Levene’s 
test was not significant, a prerequisite for ANCOVA.
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7.4.  Results
7.4.1.  Effects of atipamezole on NK1 knockout and wild type mice in the 
light/dark box 
Behavioural effects of NK1 receptor ablation
NK1  receptor  knockout  mice  displayed  greater  locomotor activity  in  the  light 
compartment  (Figure  7.1).  Two-way  ANOVA  revealed  a  main  effect  of 
‘genotype’,  (Fii36,=5.8,  P=0.02).  One-way  ANOVA  revealed  an  effect  of
‘treatment group’, (F3> 39=3 .3 , P=0.03).  Multiple comparisons using the LSD test 
revealed  that  spontaneous  locomotor  activity  in  the  light  compartment  of 
knockout  mice  was  greater  than  wild  types.  Also,  atipamezole  increased 
locomotor activity in wild type mice but had no effect in the knockouts.
NK1  receptor  knockout  mice  made  fewer  rears  in  the  dark  compartment, 
(Figure 7.2). Two-way ANOVA revealed a main effect of ‘genotype’, (Fii36=7.5, 
P=0.01), but no effect of ‘drug treatment’ and no ‘drug’ x ‘genotype’ interaction. 
ANCOVA revealed a main effect of ‘activity in the dark’ (Fii35=22, P<0.001) with 
residual variance due to ‘genotype’ (F1> 35=4.7, P=0.04).  Mann-Whitney analysis 
was  performed  since  Levene’s  test  of  error  variance  was  significant  for this 
behaviour.  This also revealed an effect of ‘genotype’, (P=0.01).
Behavioural effects of atipamezole
Atipamezole  increased  the  total  number of returns  to  the  light  compartment 
both  in  NK1  receptor  knockout  and  wild  type  mice,  (Figure  7.3).  Two-way 
ANOVA revealed a main  effect of ‘drug treatment’,  (Fi> 36=7.9,  P=0.01),  but no 
effect of ‘genotype’ and  no ‘drug treatment’ x ‘genotype’  interaction. ANCOVA 
revealed a main effect of ‘activity in the dark’ (F1i35=6.4,  P=  0.02) with  residual 
variance due to  ‘drug treatment’  (Fii35=7.6,  P=0.01).  Mann- Whitney analysis 
was  performed  as  Levene’s test was  significant for this  behaviour.  This  also 
revealed a main effect of ‘drug treatment’, (P=0.005).
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Figure 7.1. NK1  receptor knockout mice displayed increased locomotor activity 
in  the  light  compartment  of  the  exploration  box.  Chart  shows  mean  line 
crosses ± s.e.m.,  n=10 each group.  Post-hoc LSD test:  I:  P= 0.02;  II:  P=  0.05; 
III: P=0.007 c.f. NK1 wild type mice given saline. See section 7.4.1 for details of 
statistical analysis.
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Figure  7.2.  NK1  receptor  knockout  mice  made  fewer  rears  in  the  dark 
compartment than wild type mice.  Chart shows mean number of rears ± s.e.m. 
(n=10). See section 7.4.1 for details of statistical analysis.
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Figure  7.3.  Atipamezole  increased  the  total  number  of  returns  to  the  light 
compartment  made  by  NK1  receptor  knockout  and  wild  type  mice.  Chart 
shows  mean  ±  s.e.m.,  (n=10).  See  section  7.4.1  for  details  of  statistical 
analysis.
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Behaviours showing a drug x genotype interaction
Atipamezole  decreased  time  to return  in  wild  type  mice,  but  had  no  effect in 
knockout  mice  (Figure  7.4).  Two-way  ANOVA  revealed  a  ‘genotype’  x  ‘drug 
treatment’  interaction,  (Fii35=4 .7 ,  P=0.04).  Since  Levene’s test was  significant 
for this  behaviour,  data were subjected to a square-root transform.  Two-way 
ANOVA again  revealed  a  ‘genotype’  x  ‘drug  treatment’  interaction,  (Fii35=5 .6 , 
P=0.02).  One-way ANOVA revealed an effect of ‘treatment group’,  (F3 38=3.4, 
P=0.03).  Multiple comparisons  using the  LSD test revealed that atipamezole 
reduced  the time to  return  of wild  type  mice,  but  had  no  effect on  knockout 
mice.  Also,  regardless  of  drug  treatment,  knockout  mice  had  lower  time  to 
return  compared  with  drug-free  wild  type  mice.  ANCOVA  confirmed  that 
differences  in  time to  return  were  not due  to  underlying  effects  of  locomotor 
activity.
Atipamezole decreased time to leave the light zone of NK1  wild type mice,  but 
increased  it  in  the  knockouts  (Figure  7.5).  Two-way  ANOVA  revealed  a 
‘genotype’  x  ‘drug  treatment’  interaction,  (F1) 35=4.7,  P=0.04).  There  were  no 
effects of ‘drug treatment’ or ‘genotype’. One way ANOVA revealed no effect of 
‘treatment group’. Differences in time to leave were not due to underlying effect 
on locomotor activity, demonstrated by ANCOVA.
186Chapter 7
V Time to Return
+/+
-/-
o
<D
CO
0
I
m
SAL ATI
Figure  7.4.  Effect of atipamezole  on  time  to  return  to  light  (^-transformed 
data),  by  NK1  knockout  and  wild  type  mice.  Chart  shows  mean  ±  s.e.m., 
(n=10).  Post-hoc LSD test: I: P=0.005; II: P=0.02; III: P=0.05 c.f. wild type mice 
treated with saline.  See section 7.4.1 for details of statistical analysis.
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Figure  7.5.  Effect of atipamezole on time to leave light compartment by NK1 
knockout and wild type mice.  Chart shows mean ± s.e.m., (n=10). See section
7.4.1  for details of statistical analysis.
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The following  behaviours were unaffected  by either genotype or atipamezole, 
as  revealed  by  two-way  or  one-way  ANOVA.  Likewise,  no  effects  were 
revealed  by  ANCOVA,  when  locomotor  activity  in  the  light  and  dark  were 
included in the analysis.
•  locomotor activity in the dark
•  grooms in the dark
•  grooms in the light
•  time grooming in dark,
•  time grooming in light
•  rears in the light
•  time in light
(see Table 7.1  and Figure 7.6).
Drug  X
Drug  Genotype  Genotype
F  1,36 P F  1,36 P F  1,36 P
Activity in dark 0.3 0.6 2.4 0.1 1.7 0.2
Grooms in dark* 1.3 0.3 0.001
o
C
O
0.5 0.5
Grooms in light* 0.1 0.7 0.1 0.8 0.1 0.7
Time grooming in dark 0.3 0.6 0.03 0.9 0.6 0.4
Time grooming in light 0.2 0.6 0.2 0.7 0.9 0.3
Rears in light 1.6 0.2 0.9 0.3 0.8 0.4
Time in light 0.4 0.5 3.1 0.09 0.3 0.9
Table 7.1.  Behaviours in the light/dark exploration  unaffected  by atipamezole 
on  NK1  receptor  ablation.  n=10.  Table  shows  results  of two-way ANOVA. 
* denotes  behaviours  where  Levene’s  test  of  error  variance  was  significant. 
For these behaviours,  Mann-Whitney test was performed.  No effects of ‘drug’ 
or ‘genotype’ were seen.
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Figure  7.6.  Behaviours  of  mice  in  the  light/dark  exploration  box  that  were 
unaffected  by either NK1  receptor ablation or atipamezole.  N=10.  See Table
7.1  for statistical analysis [continued over].
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Figure 7.6 [continued]. Behaviours of mice in the light/dark exploration box that 
were unaffected  by either NK1  receptor ablation  or atipamezole.  N=10.  See 
Table 7.1 for statistical analysis
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7.4.2.  Effect  of yohimbine  on  NK1  knockout  and  wild  type  mice  in  the 
light/dark box 
Behavioural effects due to NK1 receptor ablation
NK1  knockout mice made fewer grooms in the light compartment than wild type 
mice,  (Figure  7.7).  Two-way  ANOVA  revealed  an  effect  of  ‘genotype’, 
(Fi,24=5.1, P=  0.03),  but no effect of ‘drug treatment’, and no ‘genotype’ x ‘drug 
treatment’ interaction, (F1> 24=2 .5 , P=0.1).  This difference in grooms in the light 
was  due  to  yohimbine  increasing  this  behaviour  in  wild  type  mice,  but  not 
knockout  mice.  One-way  ANOVA  revealed  an  effect  of  ‘treatment  group’, 
(F3 > 27=3.2,  P=0.04).  Post-hoc LSD test revealed that yohimbine increased the 
number  of  grooms  in  the  light  in  wild  type  mice,  only.  Regardless  of  drug 
treatment,  NK1  knockout  mice  made  fewer grooms  in  the  light  compartment 
than  wild type mice given  yohimbine. ANCOVA confirmed  that this  behaviour 
was not affected by changes in locomotor activity.
NK1  receptor knockout mice spend less time grooming in the light compartment 
(Figure 7.8).  Thus, there was a main effect of ‘genotype’,  (Fi,24=7.8,  P=0.01) 
but  no  effect of ‘drug  treatment’.  Although  yohimbine  appeared  to  decrease 
this behaviour in knockout mice, but increase it in wild types, the probability of a 
‘genotype’  x  ‘drug  treatment’  interaction  did  not  reach  the  criterion  for 
significance, (Fi,24=3.8, P=0.06). This behaviour was not affected by changes in 
locomotor  activity,  as  revealed  by  ANCOVA.  Because  Levene’s  test  of 
homogeneity  was  significant  for  this  behaviour,  Mann-Whitney  analysis  was 
performed. This revealed a main effect of ‘genotype’ (P=0.04).
NK1  receptor  knockout  mice  made  fewer  rears  in  the  dark  compartment, 
(Figure 7.9).  Two-way  ANOVA  revealed  an  effect  of  ‘genotype’,  (Fi> 23=5 .1 , 
P=0.03),  but no effect of ‘drug treatment’ and  no ‘genotype’ x ‘drug treatment’ 
interaction,  (Fii23=0 .6 ,  P=0.4).  Mann-Whitney analysis  was  performed due to 
significance of Levene’s test.  This gave the same results as ANOVA, with an 
effect of ‘genotype’, (P=0.005), but no effect of ‘drug treatment’.  The genotype 
difference in rearing in the dark could have been due to underlying differences 
in locomotor activity.  Thus, ANCOVA revealed a main effect of ‘activity in dark’ 
(Fi,22=7 .6 , P=0.01) with no residual variance due to ‘genotype’.
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Figure 7.7.  NK1  knockout mice made fewer grooms in the light compartment 
than wild type mice.  Bar chart shows mean ± s.e.m., (n=7). Post-hoc LSD test: 
I: P=0.05;  II:  P=  0.02;  III:  P=  0.01.  See  section  7.4.2  for  details  of  statistical 
analysis.
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Figure 7.8.  NK1 receptor knockout mice spent less time grooming in the light 
compartment than wild type mice.  Plots show mean ± s.e.m., (n=7). See 
section 7.4.2 for details of statistical analysis.
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Figure 7.9. NK1  receptor ablation reduced the total number of rears in the dark 
compartment.  Bar chart shows  mean  ± s.e.m.,  (n=7).  See section  7.4.2 for 
details of statistical analysis.
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Behaviours showing a drug x genotype interaction
Yohimbine  increased  locomotor activity in  the light compartment of wild  type 
mice,  but  decreased  it  in  the  knockouts  (Figure  7.10).  Two-way  ANOVA 
revealed a ‘genotype’ x ‘drug treatment’ interaction, (F1i 24=8.0,  P=0.01),  but no 
effect of ‘genotype’ or ‘drug treatment’. One-way ANOVA revealed an effect of 
‘treatment  group’  which  was  close  to  the  criterion  for significance  (F3,27=2.7, 
P=0.06).
Yohimbine decreased the time to return to the light compartment in wild type 
mice, but increased it the knockouts (Figure 7.11). Data for time to return were 
logio transformed due to significance of Levene’s test and because a ‘genotype’ 
x  ‘drug  treatment’  interaction  was  suspected.  Two-way  ANOVA  revealed  a 
‘genotype’ x ‘drug treatment’ interaction, (Fii24=17.1, P<0.001),  but no effect of 
‘genotype’ and no effect of ‘drug treatment’.  One-way ANOVA revealed a main 
effect of ‘treatment group’ (F3,27=6.5, P= 0.02). Post-hoc LSD analysis confirmed 
that yohimbine decreased time to  return  in wild type mice,  but increased  it in 
the knockouts. ANCOVA revealed no effects of locomotor activity.
Yohimbine increased the number of rears in light compartment in NK1 wild type 
mice,  but decreased  this  behaviour in  the  knockouts  (Figure  7.12).  Data for 
rears  in  the  light were  logio transformed  due to  significance  of  Levene’s  test 
and  because a  ‘genotype’ x  ‘drug treatment’  interaction was suspected. Two- 
way ANOVA  revealed  a  ‘genotype’  x  ‘drug  treatment’  interaction,  (Fi> 24=6.4, 
P=0.02) but no effects of ‘genotype’, or ‘drug treatment’.  ANCOVA revealed an 
effect of locomotor activity in  the light compartment,  (Fii28=43,  P<0.001), with 
no residual variance due to a ‘genotype’ x ‘drug’ interaction.  Despite interaction 
between genotype and drug effects, there were no differences between any of 
the treatment groups, as demonstrated by one-way ANOVA.
Behavioural effects of Yohimbine
No behaviours were influenced by a main effect of yohimbine ‘drug treatment’ 
alone,  free  from  effects  of  ‘genotype’,  or  a  ‘drug  treatment’  x  ‘genotype’ 
interaction, as revealed by two-way ANOVA.
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Figure 7.10. Yohimbine increased and decreased locomotor activity in the light 
compartment of NK1  receptor wild type and knockout mice, respectively. Chart 
shows mean ± s.e.m., (n=7).  Post-hoc LSD test: I: P=  0.03; II: P=0.04 c.f. NK1 
wild type mice given saline. See section 7.4.2. for details of statistical analysis.
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Figure 7.11.  Yohimbine decreased  logio time to  return  in wild  type  mice,  but 
increase it the knockouts.  Chart shows mean ± s.e.m., log-io transformed data, 
(n=7).  I:  P=0.006,  II:  P=0.001,  III:  P=0.01.  See  section  7.4.2  for  details  of 
statistical analysis.
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Figure 7.12.  Yohimbine increased  and  decreased  the  number of rears  in the 
light compartment of NK1  receptor wild  type and  knockout mice,  respectively 
Chart shows mean ± s.e.m., Iog10 transformed data, (n=7). See section  7 .4 .2 . 
for details of statistical analysis.
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The following behaviours were unaffected by either genotype or yohimbine, as 
revealed  by two-way or one-way ANOVA.  Likewise,  no effects were revealed 
by ANCOVA, when  locomotor activity in the light and dark were included as a 
covariate in the analysis.
•  locomotor activity in the dark,
•  grooms in the dark,
•  time spent grooming in dark,
•  time spent in the light,
•  time to leave light,
•  number or returns to light 
(see Table 7.2, Figure 7.13).
Drug x
Drug  Genotype  Genotype
F  1,36 P F  1,36 P F  1,36 P
Activity in dark 1.7 0.2 1.7 0.2 0.0 0.9
Grooms in dark* 1.9 0.2 4.0 0.06 1.9 0.2
Time grooming in dark 1.7 0.2 2.8 0.1 1.7 0.2
Time in light 0.1 0.7 0.005
o
C
O
0.08 0.8
Time to leave 1.2 0.3 0.06 0.8 0.9 0.3
Number of returns 0.1 0.7 0.0 1.0 0.2 0.6
Table  7.2.  Behaviours  in  the  light/dark  exploration  box  unaffected  by 
yohimbine  or  NK1  receptor  ablation  n=7.  Table  shows  results  of  two-way 
ANOVA.  * denotes  behaviour  where  Levene’s  test  of  error  variance  was 
significant.  For  these  behaviours,  Mann-Whitney  test  was  performed.  No 
effects of ‘drug’ or ‘genotype’ were found.
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Figure 7.13.  Behaviours in the light/dark exploration box that were unaffected 
by either yohimbine or NK1  receptor ablation.  Charts  show mean  ±  s.e.m., 
(n=7) [continued over].  See Table 7.2 for details of statistical analysis.
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Figure 7.13. [continued]  Behaviours in the light/dark exploration box that were 
unaffected by either yohimbine or NK1  receptor ablation.  Charts show mean ± 
s.e.m., (n=7). See Table 7.2 for details of statistical analysis.Chapter 7
ATI  YOH  NK1-/-
Activity in light3 T T T
Time to return3 1 1 I
Number of returnsb t
- -
Grooming in light0 - t
-
Rears in darkd - - 1
Table 7.3.  Summary of behavioural changes due to atipamezole, yohimbine 
and  NK1  receptor ablation.  |  =  increase;  I  =  decrease;  -  =  no  change,  a, 
effects shared by atipamezole, yohimbine and NK1  receptor ablation;  b, effect 
of  atipamezole  only;  c,  effect  of  yohimbine  only;  d,  effect  of  NK1  receptor 
ablation only, (c.f. drug-free NK1 wildtype mice).
7.5.  Discussion
The aim of experiments described in this chapter was to determine whether the 
behavioural  effects  of  NK1  receptor  ablation  are  consistent  with  augmented 
noradrenergic transmission (see Chapter 6 ).  This was achieved by comparing 
the effects  of NK1  receptor ablation  with those  of acute  augmentation  of NA 
transmission,  using  two  a2-adrenoceptor  antagonists  (atipamezole  and 
yohimbine).  Only behavioural  effects that were common  to  both  these drugs 
are  likely  to  be  due  to  effects  at  a2-adrenoceptors.  Modulation  of any such 
behaviour by NK1  receptor ablation would suggest a NA-related effect.
Both ‘locomotor activity’ in the light compartment and ‘time to return’ to the light 
fitted these criteria: both were modulated by atipamezole and yohimbine.  Thus, 
the  a2-adrenoceptor antagonists  increased  the  number of  line  crosses  in  the 
light compartment and decreased the time to return to the light compartment for 
the first time.  Subsequent experiments from this  laboratory demonstrate that 
both  these  effects  are  produced  by  a  third  a2-adrenoceptor  antagonist, 
RX821002  (Fisher  et  al,  2004).  Increased  locomotor  activity  in  a  novel 
compartment in response to a2-adrenoceptor blockade has been demonstrated 
previously (Siviy etal, 1990; Haller etal, 1997; Haapalinna etal, 1997).
The  ability  of  a2-adrenoceptor  antagonists  to  stimulate  locomotor  activity  is 
probably  due  to  elevated  central  NA  transmission  (due  to  blockade  of
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presynaptic  autoreceptors).  This  augmented  NA  transmission  activates 
postsynaptic  adrenoceptors  (e.g.  ai/(3)  which  has  a  permissive  role  on 
locomotor activity, generally.  For example, ch-adrenoceptor agonists,  such as 
phenylephrine  and  methoxamine,  stimulate  locomotor  activity  in  mice  (Heal, 
1984).  Elevated  locomotor activity in  the  open  field,  induced  by  idazoxan,  is 
prevented  by the ai-adrenoceptor antagonist,  prazosin, or the |3-adrenoceptor 
antagonist,  propranolol  (Haller  et  al,  1997).  Moreover,  i.c.v.  infusion  of the 
ai-adrenoceptor antagonist,  terazosin,  completely  blocks  locomotor activity of 
mice  in  a  novel  cage,  (Stone  et  al,  1999).  Locomotor  stimulation  by 
amphetamine  or  cocaine  is  also  mediated  partly  by  effects  on 
ai-adrenoceptors, (Snoddy & Tessel, 1985).  Thus, atipamezole and yohimbine 
increase  locomotor  activity  in  the  light  compartment  of  wild  type  mice  in  a 
manner consistent with elevated central NA transmission.
With this in mind, it is striking that NK1  receptor ablation consistently produced 
the same effects on ‘locomotor activity’ and ‘time to return’ as a2-adrenoceptor 
blockade (i.e.  increased locomotor ‘activity in light’, decreased ‘time to return’). 
The same behavioural effects of NK1  receptor ablation have been confirmed in 
a  subsequent  study  from  this  laboratory  (Herpfer  et  al,  2005).  This 
demonstrates that loss of NK1  receptor function leads to the same behavioural 
changes  as  a2-adrenoceptor antagonism,  presumably due  to  augmented  NA 
transmission (see above).
This  finding  is  consistent  with  the  microdialysis  experiments  of  Chapter  6 , 
which report elevated spontaneous efflux of NA in knockout mice. In support of 
the  present  findings,  evidence  for  augmented  NA  transmission  after 
pharmacological  blockade of the NK1  receptor has also been  reported (Millan 
et  al,  2001;  Maubach  et  al  2002).  Thus,  NK1  receptor  ablation  and  a2- 
adrenoceptor antagonism  have the same effect on  certain  behaviours of mice 
in a novel environment. Along with the results of Chapter 6 , this supports a role 
for central  NA transmission  in the effects of NK1  receptor antagonist drugs on 
behaviour.
It  is  interesting  that  yohimbine  and  atipamezole  decreased  ‘time  to  return’. 
Time to return’ is also reduced by benzodiazepines (Chaouloff et al,  1997), an
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effect  attributed  to  the  anti-conflict  properties  of  these  drugs  that  disinhibit 
exploration of the novel environment and  so decrease the latency to return to 
there  after  leaving  for  the  first  time.  Such  an  effect  of  a2-adrenoceptor 
antagonists  is  surprising  since  yohimbine  induces  anxiety  in  healthy  human 
subjects  (Mattila  et  al,  1989)  and  panic  attacks  in  panic  disorder  patients 
(Charney  et  al,  1987),  an  effect  attributed  to  a2-adrenoceptor  blockade 
(Charney  et  al,  1992).  However,  the  effects  of  benzodiazepines  were  not 
tested in the present study, so it is not valid to describe a reduction in ‘time to 
return’  as  an  anti-conflict  property of atipamezole  and  yohimbine.  Also,  it  is 
unlikely that the a2-adrenoceptor antagonists reduced time to return by making 
mice more active (see above),  since analysis of covariance did  not reveal  an 
effect  of  locomotor  activity  on  ‘time  to  return’.  It  is  not  clear  how 
a2-adrenoceptor antagonists reduce ‘time to return’.  However, as with ‘activity 
in light’, this effect was also produced by NK1  receptor ablation, consistent with 
an effect of this genetic ablation on NA transmission.
An  interesting  finding  was  that  effects  of atipamezole  and  yohimbine  in  wild 
type  mice  (i.e.  increased  locomotor ‘activity  in  light’,  reduced  ‘time to  return’) 
were not seen in NK1  knockout mice.  It is possible that floor and ceiling effects 
prevented  any  further  effect  of  the  antagonists  in  the  knockout  mice. 
Alternatively,  there  could  be a  deficit  in  a2-adrenoceptor-mediated  responses 
as a result of the knockout.  There is some support for the latter possibility from 
the microdialysis data of Chapter 6 :  NA efflux was unchanged  by atipamezole 
in  the  knockout  mice,  despite  elevated  spontaneous  efflux.  Together,  these 
findings are consistent with impaired a2-adrenoceptor function in NK1  receptor 
knockout mice.  However,  alternative explanations  remain  (i.e.  a lack of tonic 
activity at (^-adrenoceptors, floor and ceiling effects on behaviour).
NK1  receptor ablation  also decreased  rearing  in  the dark  compartment.  It  is 
unlikely  that this  is  a  NA-related  effect,  since  neither of the  a2-adrenoceptor 
antagonists affected rearing.  This illustrates the sensitivity and versatility of the 
light/dark  exploration  box  when  used  in  this  way.  In  addition  to  NA-related 
behavioural  changes,  effects  at  unidentified  targets  were  seen.  However, 
without  further  testing  the  effects  of  other  reference  compounds  (e.g.  5-HT
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receptor  ligands)  the  mechanism  behind  the  decreased  rearing  in  the  dark 
compartment in knockout mice cannot be identified.
For  certain  behaviours  (number  of  returns,  grooming  in  light),  the  effect  of 
yohimbine and  atipamezole were not the same.  For example,  yohimbine,  but 
not  atipamezole,  increased  grooming  in  the  light  compartment  in  wild  type 
mice.  Conversely,  atipamezole,  but  not  yohimbine,  increased  the  number of 
returns to the light zone.  These disparate effects likely reflect differences in the 
pharmacology  of  these  drugs.  The  0 2 :0 1  selectivity  ratio  of  yohimbine  is 
200-fold lower than that of atipamezole (Virtanen et al,  1989).  Yohimbine also 
has high affinity for other receptors, e.g. D2 dopaminergic, (Scatton et al,  1980, 
Van Oene et al,  1984) nicotinic acetylcholine, (Abelson & Hoglund,  2004) and 
5-H T ia  receptors,  (Winter &  Rabin,  1992)  as  well  as  Na+  channels  and  VR1 
vanilloid receptors, (Dessaint et al, 2004).  Atipamezole on the other hand, is a 
relatively  specific  a2-adrenoceptor  ligand,  (Virtanen  et  al,  1989)  although 
binding to  imadazoline receptors,  (Romer et al,  2003),  as well  as  unidentified 
binding sites (Sjoholm  et al,  1999) have been  reported.  Also, despite having 
similar  affinities  for  the  a^,  a2B   and  a2C   subtypes  of  the  a2-adrenoceptor, 
atipamezole has approximately 1 0 0 -fold greater affinity for the o2d receptor (i.e. 
the  rodent  isoform  of  the  presynaptic  a2-adrenoceptor),  compared  with 
yohimbine, (Schwartz & Clark,  1998).  As a result of these differences in drug 
selectivity,  only  behaviour  effects  that  were  common  to  both  antagonists 
(increased activity in light, decreased time to return) were considered to be NA- 
related.  The finding  that  both  drugs  had  behavioural  effects that were  likely 
due to other actions  demonstrates the  importance  of proper validation  in  this 
test (in  this  case,  for effects  on  NA transmission)  as well  as  the  breadth  of 
effects that can be detected.
It is interesting that yohimbine increased grooming in the light compartment in 
wild  type  mice,  but  not  knockouts.  This  lack  of  effect  in  the  knockout  mice 
suggests a deficit in the site through which yohimbine produces this change in 
wild type mice.  This is unlikely to be the a2-adrenoceptor, since the effect was 
not  shared  by  atipamezole  (see  above).  Yohimbine  has  agonist  actions  at 
5-H T ia  receptors  (Kd  74nM)  an  effect  not  shared  by atipamezole  (Kd,  13pM; 
Winter &  Rabin,  1992)  but these  are  desensitized  in  NK1  receptor knockout
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mice,  (Santarelli  et  al,  2001,  Froger  et  al,  2001).  It  is  possible  that  the 
increased  rearing  induced  by  yohimbine  is  due  to  activation  of  5-HT1 A  
receptors,  because it is not seen  in  NK1  knockout mice and  is not caused  by 
atipamezole.  Previous work has demonstrated an  involvement of central  5-HT 
in grooming behaviour (Elbin & Randall,  1977; del Angel-Meza etal, 1996), but 
5-H T ia  receptor activation is associated with a reduction in grooming (Higgins 
et al,  1991; Lazosky et al,  1991). Further studies using selective 5-HT receptor 
ligands  would  confirm  whether grooming  in  the  light/dark  test  is  sensitive  to 
changes in 5-HT transmission.
7.6.  Conclusion
NK1  receptor ablation changes behaviour.  Specifically, NK1  receptor knockout 
mice  showed  increased  locomotor  activity  in  the  light  compartment  and 
decreased time to return to the light zone.  The same behavioural effects were 
induced  by  two  a2-adrenoceptor  antagonists,  consistent  with  elevated  NA 
transmission.  Therefore,  the  results  presented  here  support the  microdialysis 
conclusions  predicted  from  experiments  of  Chapter  6 ,  which  demonstrated 
increased NA efflux in NK1  knockout mice. Moreover, the behavioural effects of 
a2-adrenoceptor  antagonists  are  absent  in  NK1  receptor  knockout  mice, 
consistent with  a  deficit in  a2-adrenoceptor function  in  these  mice.  This work 
supports  a  role  for  central  NA  neurones  in  the  action  of  NK1  receptor 
antagonist drugs.
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Discussion
Along with  5-HT,  NA  is  central  to the  mechanism  of action  of most,  if not all 
antidepressant drugs.  Whether effects on NA contribute to the action of SSRIs 
is  less  well  established.  Also,  the  mode  of  action  of  the  putative 
antidepressant/anxiolytic NK1  receptor antagonists is  not at all clear, although 
effects on  NA transmission are possible. The aim of experiments described in 
this thesis was to determine the effects of acute fluoxetine and  NK1  receptor 
ablation  on  central  NA  transmission  and  establish  possible  mechanisms 
contributing to these effects.
8.1.  Summary of findings
When  administered  systemically,  fluoxetine  increased  NA  efflux  in  both  the 
frontal  cortex  and  hypothalamus  of  freely  moving  rats  (Chapter  3).  In  the 
frontal  cortex,  this  increase  was  sustained  over  a  4  h  period,  but  in  the 
hypothalamus, the increase lasted only 100 min.  This difference in the duration 
of  elevated  NA  efflux  is  similar  to  that  reported  previously  using  the  mixed 
NA/5-HT reuptake inhibitor, sibutramine, and could reflect the greater inhibitory 
control of NA release by a2-adrenoceptors in the hypothalamus (Wortley et al, 
1999).
In subsequent experiments systemic fluoxetine  had  no apparent effect on  NA 
efflux in otherwise untreated rats.  Comparison of relevant microdialysis studies 
reveals that fluoxetine’s effects on  NA efflux  are inconsistent:  both  increased 
efflux  and  no  effect  have  been  reported.  However,  this  is  the first time this 
inconsistency has been confirmed in two brain regions within a single study.
Fluoxetine’s  actions  on  NA  efflux  could  depend  on  brain  region,  since  the 
limited  number  of  studies  available  report  effects  in  the  frontal  cortex  more 
consistently  than  subcortical  regions.  Whether  this  is  due  to  inter-region 
variability  in  fluoxetine’s  effects,  or  simply  the  greater  number  of  studies 
performed  in  the  frontal  cortex,  is  unknown.  The  present  experiments 
demonstrate that fluoxetine has a variable effect both  in the frontal cortex and 
hypothalamus.  This  demonstrates  that,  with  respect  to  these  two  areas  at
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least,  brain  region  is  not  the  sole  determinant  of whether  or  not  fluoxetine 
elevates NA efflux.
In both brain regions, systemic fluoxetine decreased NA efflux in rats that had a 
partial lesion of noradrenergic axon terminals (using DSP-4). The site of action 
of this  decrease  could  not  be determined,  since fluoxetine was  administered 
systemically.  However,  it  was  unlikely  to  be  noradrenergic  axon  terminals, 
since  these  are  partially  lesioned  by  DSP-4.  This  suggests  that  fluoxetine 
decreases NA efflux by an effect upstream of axon terminals.  This could be via 
increased extracellular concentration of NA and activation a2-adrenoceptors at 
the somatodendritic level.  When using microdialysis, the effects of fluoxetine at 
cell bodies could not be distinguished from those at axon terminals.  Therefore, 
subsequent  experiments  used  ‘reverse  dialysis’  to  determine  the  effects  of 
fluoxetine infused to the frontal cortex and hypothalamus terminal field.
When infused locally, fluoxetine increased  NA efflux in both brain  regions in a 
more consistent way than when given systemically (Chapter 4). Thus, the route 
of administration is critical in determining fluoxetine’s effects on NA efflux. This 
pattern of effects (i.e.  permissive effect at axon terminals,  inhibitory effect at a 
site upstream of the terminals) is entirely consistent with the known  regulatory 
mechanism  of  central  NA  transmission  (i.e.  activation  of  somatodendritic 
a2.adrenoceptors inhibits noradrenergic cell firing and  release of NA;  Mateo et 
al,2 0 0 0 ).
Any effect of fluoxetine on  NA efflux could  be mediated  by the drug elevating 
the concentration of 5-HT in the extracellular space (and subsequent activation 
of excitatory heteroceptors on noradrenergic axon terminals).  However, in rats 
pretreated  with  pCPA,  (which  depleted  tissue  stores  of  5-HT)  fluoxetine 
increased  NA efflux  in  both  brain  regions  at the  highest concentration  tested 
(50pM).  This 5-HT independent effect occurred at a concentration of fluoxetine 
that  is  within  its  range  to  inhibit  NA  reuptake.  This,  along  with  the  5-HT 
independent nature of this  response,  suggests  a direct effect of fluoxetine on 
noradrenergic neurones in vivo.
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In  the  frontal  cortex,  but  not the  hypothalamus,  fluoxetine  also  had  a  5-HT- 
dependent effect on NA efflux. This was abolished by pCPA and was seen with 
a ten-fold  lower concentration of fluoxetine than that required to modulate NA 
efflux directly (see above).  Thus, fluoxetine increases  NA efflux in the frontal 
cortex by two distinct mechanisms: by direct inhibition of NA reuptake and by a 
higher affinity, 5-HT-dependent mechansim.  This 5-HT dependent mechanism 
exhibits  regional  selectivity,  since it was  present  in the frontal  cortex,  but  not 
the hypothalamus.
The 5-HT  dependent effect of fluoxetine  is  not due to  increased  extracellular 
concentration of 5-HT alone.  Thus, citalopram, (a more potent inhibitor of the 
5-HT transporter than fluoxetine) had no effect on NA efflux even at the highest 
concentration tested.  This suggests that an  additional  property of fluoxetine, 
not shared  by citalopram,  (and  so  not obviously  related  to  inhibition  of 5-HT 
uptake),  contributes  to  its  effects  on  NA  in  the frontal  cortex.  Thus,  at  low 
concentrations, fluoxetine has effects on  NA efflux that are not fully explained 
by inhibition of either NA or 5-HT reuptake.
It  is  known  that  both  NA  and  5-HT  transmission  modulate  the  behaviour  of 
rodents in the light/dark exploration box.  Effects of fluoxetine were seen in this 
test that were consistent with an action on NA transmission, while other effects 
were  suggestive  of  an  action  on  5-HT  transmission  (Chapter  5).  Thus, 
although  a  DSP-4-induced  lesion  of  NA  axon  terminals  had  no  effect  on 
behaviour,  when  fluoxetine  was  administered  to  DSP-4  pretreated  rats, 
locomotor activity in the light compartment was decreased.  This combination of 
DSP-4  and  fluoxetine  also  decreased  NA  efflux  in  the  frontal  cortex  and 
hypothalamus  (Chapter 3),  demonstrating  a  parallel  change  in  NA efflux  and 
locomotor activity in the light compartment of this test.  Parallel changes in NA 
transmission  and  locomotor  activity  have  been  described  before,  (Mason  & 
Fibiger,  1977;  Mason  et  al,  1998;  Stone  et  al,  1999)  suggesting  that  the 
decrease  in  locomotor activity seen  in  DSP-4 pretreated  rats  given  fluoxetine 
could be due to the diminished NA efflux resulting from this treatment (Chapter 
3).
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Since  locomotor  activity  in  the  light  compartment  was  unaffected  by  pCPA 
pretreatment, the reduction in this behaviour seen with fluoxetine is unlikely to 
be  related  to effect on  5-HT.  Time of day-dependent effects were seen with 
fluoxetine  (e.g.  decreased  locomotor  activity  in  the  dark  compartment)  that 
were  abolished  or  reversed  by pCPA  pretreatment  and  therefore,  consistent 
with effects on 5-HT-mediated regulation of circadian rhythms.
To  investigate  the  effect of  NK1  receptor  ablation  on  NA transmission,  NK1 
receptor  knockout  mice  were  used  as  a  model  of  life  long  inhibition  of this 
receptor.  Compared  to  wild  type  mice,  knockout  mice  had  abnormal  NA 
transmission: spontaneous NA efflux was approximately two-fold greater in the 
knockouts  (Chapter  6 ).  Subsequent  studies  from  this  laboratory  have 
confirmed this elevated NA efflux in NK1  receptor knockout mice (Fisher et al, 
2004;  Herpfer  et  al,  2005).  This  increase  was  not  due  to  decreased  NA 
reuptake,  since  the  reuptake  inhibitor,  desipramine,  was  equally  effective  at 
increasing NA efflux in both groups of mice, when infused to the frontal cortex. 
NA  efflux was  unaffected  by the  a2-adrenoceptor antagonist,  atipamezole,  in 
either  group  of  mice.  This  was  surprising  in  the  knockout  mice,  since  the 
increased extracellular concentration of NA efflux would be expected to activate 
a2-adrenoceptors and  diminish noradrenergic cell firing and  release rate. That 
atipamezole had no effect on NA efflux in knockout mice could be due to a lack 
of  tonic  activation  of  0 2-adrenoceptor  or  some  deficit  in  their  function. 
Behavioural  experiments explored  this further by testing the  response of NK1 
receptor knockout and wild type mice to a2-adrenoceptor antagonist drugs.
The light/dark exploration  box revealed  NA-related  behaviours in  mice.  Thus, 
two  0 2-adrenoceptor  antagonists  (atipamezole  and  yohimbine)  increased 
locomotor  activity  in  the  light  compartment  and  reduced  the  time  to  return, 
demonstrating that these behaviours  are sensitive to drugs that modulate NA 
transmission.  Subsequent  experiments  from  this  laboratory  confirmed  these 
effects  using  a  third  0 2-adrenoceptor  antagonist,  RX821002  (Fisher  et  al, 
2004).  By demonstrating  reproducible  effects  of  0 2-adrenoceptor antagonists, 
behaviour in the light/dark exploration box was used to demonstrate NA-related 
effects of NK1  receptor ablation.
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NK1  receptor  ablation  produced  the  same  changes  in  behavioural  that were 
common to both a2-adrenoceptor antagonists (i.e.  increased  locomotor activity 
in the light compartment,  reduced  the time to return:  Chapter 7).  Subsequent 
experiments  have  confirmed  both  these  behavioural  effects  of  NK1  receptor 
ablation (Herpfer et al,  2005).  Since the same changes were seen with  both 
0 2-adrenoceptor antagonists, the behaviour of NK1  receptor knockout mice is 
consistent with elevated  NA transmission.  This is in  agreement with elevated 
spontaneous  NA  efflux  in  the  knockout  mice  (Chapter  6 )  and  previous 
experiments  reporting  increased  LC  firing  rate  and  NA  efflux  after 
administration  of  NK1  receptor  antagonist  (Maubach  et al,  2002;  Haddjeri  & 
Blier, 2000).
Neither  a2-adrenoceptor  antagonist  modulated  behaviour  of  NK1  receptor 
knockout  mice.  Although  this  could  be  due  to  a  deficit  in  a2-adrenoceptor 
function  in  the  knockout  mice,  floor and  ceiling  effects  on  behaviour (time to 
return,  locomotor  activity  in  light)  could  have  prevented  the  effects  of these 
drugs  being  seen  in  knockout  mice.  Thus,  although  the  microdialysis  and 
behavioural experiments are suggestive of a deficit in a2-adrenoceptor function 
in NK1  knockout mice, further experiments are required to establish this.
8.2.  Implications of this work
8.2.1.  Modulation of central noradrenergic transmission by fluoxetine
The  experiments  in  freely-moving  rats  demonstrate  that  fluoxetine  has  an 
unpredictable effect on NA efflux in the frontal cortex and hypothalamus, when 
administered systemically.  This is strikingly similar to the effects of SSRIs on 
5-HT efflux, where both increased and no change in efflux have been reported 
after their acute, systemic administration.  An important difference with studies 
of 5-HT efflux and those of NA efflux is that a lack of effect of acute, systemic 
SSRIs on 5-HT efflux is not interpreted as an lack of effect of the drug. On the 
contrary, this is explained by the influence of additional mechanisms (feedback 
inhibition  of 5-HT  release  via activation  of 5-HTiA   receptors).  This  additional 
level of scrutiny is rarely extended to the study of SSRI effects on NA efflux.
It is concluded that microdialysis studies that report no effect of acute, systemic 
SSRIs on NA efflux in forebrain regions should not be interpreted as a lack of
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effect of these drugs.  Just as  has  been the case for microdialysis studies  of 
5-HT,  additional  manipulations  (e.g.  inhibition  of  a2-adrenoceptors)  may  be 
necessary  to  demonstrate  acute  effects  of  SSRIs  on  NA  efflux  in  vivo.  In 
support of this,  the increase in  NA efflux by systemic fluoxetine is augmented 
by a2-adrenoceptor antagonism  (Gobert  et al,  1999).  It could  be  argued  that 
this treatment should be used routinely to determine the in vivo effects of acute, 
systemic administration of other SSRIs on NA efflux.
Inhibition of noradrenergic cell firing and release due to increased activation of 
inhibitory a2-autoreceptors could  explain  how acute,  systemic SSRIs  have  no 
effect on  monoamine efflux,  but not  how their effects  are  inconsistent across 
experiments.  How is it that sometimes fluoxetine elevates NA and 5-HT efflux 
and  not  others?  How  does  activation  of  somatodendritic  autoreceptors 
diminish the increase in NA and 5-HT efflux sometimes, but not others?  Unlike 
releasing agents such as amphetamine or fenfluramine, reuptake inhibitors do 
not  have  intrinsic  effects  on  synaptic  transmission.  Rather,  they  prolong 
ongoing  synaptic transmission  by  reducing  clearance  of released  transmitter. 
Therefore, SSRIs might only augment NA efflux if NA release rate is high. The 
effect of  uptake  inhibitors  would  depend  on  the  neurochemical  status  of the 
animal  at  the  time  of administration.  This  could  explain  how  the  effects  of 
antidepressants  vary  across  individuals  (i.e.  patients  that  respond  to 
antidepressant therapy compared with patients who do not).
Experiments  here  demonstrate  that  changes  in  locomotor  activity  in  a  light, 
novel environment are paralleled  by changes in  NA efflux in the frontal  cortex 
and  hypothalamus.  Thus,  fluoxetine  administration  to  DSP-4  pretreated  rats 
decreased NA efflux and  decreased locomotor activity.  In  mice,  interventions 
that increase NA transmission (a2-adrenoceptor antagonists and  NK1  receptor 
ablation)  increased  locomotor  activity.  Although  a  causative  relationship 
cannot  be  certain,  this  bi-directional,  cross-species  association  between  NA 
efflux and locomotor activity in the light compartment of the exploration box is 
striking and supports the use of this behavioural parameter as a measure of NA 
transmission in rats and mice.
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8.2.2.  Impact of NK1 receptor ablation on central NA transmission
Life-long  inhibition  of  the  NK1  receptor  leads  to  changes  in  central  NA 
transmission similar to those reported after chronic treatment with conventional 
antidepressants of different classes.  This demonstrates two points: firstly, this 
adds to the growing body of evidence that NK1  receptor antagonists are not a 
novel  antidepressant  strategy,  acting  independently  from  any  effects  on 
monoamine  transmission,  as  originally  proposed  (Kramer  et  al,  1998). 
Secondly, that modulation of central NA transmission is a feature common to all 
antidepressant classes, regardless of the molecular drug target.
8.3  Future work
Future experiments could test the hypothesis that the effects of SSRIs on  NA 
efflux  are  offset  by  activation  of  a2-adrenoceptors.  Co-administration  of 
atipamezole  with  fluoxetine  augments  its  effects  on  NA  efflux  in  the  frontal 
cortex  (Gobert  et  al,  1997).  If  co-administration  of  other  SSRIs  with  an 
0 2-ad renoceptor  antagonist  discloses  effects  on  NA  efflux  not  otherwise 
apparent,  this would  demonstrate a lack of selectivity of these drugs for 5-HT 
transmission in vivo.  Given that this selectivity is the defining feature of SSRIs, 
demonstration  that these drugs  also  modulate  NA transmission  in  vivo (as  is 
the  case  for  fluoxetine),  would  challenge  this  definition.  This  would  also 
highlight the difficulty when drawing conclusions about a drug’s effects in vivo, 
based on data from experiments performed in vitro.
Experiments using DSP-4 and fluoxetine demonstrated a decrease in NA efflux 
in the frontal  cortex  and  hypothalamus.  The  most simple  explanation  for this 
finding  is  that  fluoxetine  preferentially  increases  NA  efflux  at  the 
somatodendritic  region,  thereby diminishing  cell  firing  and  NA  release.  This 
could be tested directly,  by administering fluoxetine,  by reverse dialysis, to the 
LC and LTA.  If the above hypothesis is correct, a decrease in NA efflux will be 
observed in the frontal cortex and hypothalamus, respectively.  This effect has 
been demonstrated  by local infusion of the SSRI citalopram to the LC, (Mateo 
et al, 2000), but no other SSRI, thus far.
The  ability  of  SSRIs  to  augment  NA  transmission  depends  on  the 
neurochemical  status  of  the  animal.  This  hypothesis  could  be  tested  by
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comparing the effects of systemic fluoxetine on NA efflux in the homecage with 
those in light compartment of the light/dark exploration  box.  Exposure to novel 
environments  increase  NA  efflux,  (Dailey  &  Stanford,  1995;  McQuade  et al, 
1999).  If the hypothesis that the effect of SSRIs on NA efflux depends on the 
ongoing activity of noradrenergic transmission, then fluoxetine should  produce 
a  more consistent effect on  NA efflux,  thereby demonstrating directly that the 
neurochemical effect of SSRIs depend on the ongoing activity of the transmitter 
systems they target.
The  finding  that  fluoxetine  increases  NA  efflux  in  the  frontal  cortex  at  low 
concentration by a mechanism not explained by inhibition 5-HT or NA uptake is 
striking. The nature of this mechanism is unknown.  Future experiments could 
determine  if  any  of  fluoxetine’s  non-specific  effects  mediate  this  property. 
Thus, if co-administration of citalopram with a 5-HT2c receptor antagonist (e.g. 
SB242,084)  or  a  GABAa  receptor  antagonist  (e.g.  bicuculline),  resulted  in  a 
5-HT-dependent elevation of NA efflux in the frontal cortex, this would confirm 
that fluoxetine has effects on NA transmission in addition its established effect 
as an uptake inhibitor.
The  possibility  of  down-regulation  of  a2-adrenoceptors  in  NK1  receptor 
knockout mice could  be tested  by comparing the responses to ligands at this 
receptor  in  these  mice.  a2-Adrenoceptor  agonists  (e.g.  clonidine)  would  be 
preferable  to  antagonists,  since  their effects  do  not  require  there  to  be tonic 
activation  of  the  receptor.  Some  simple  behavioural  models  have  been 
developed  in mice such (e.g.  locomotor sedation,  Heal  et al,  1989) that could 
be  used  to  overcome  the  potential  floor  and  ceiling  effects  that  were 
problematic in experiments using a2-adrenoceptor antagonists in Chapter 7.
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